# International Nonproprietary Names for Pharmaceutical Substances (INN)

## RECOMMENDED International Nonproprietary Names: List 77

Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [*Off. Rec. Wld Health Org.*, 1955, **60**, 3 (Resolution EB15.R7); 1969, **173**, 10 (Resolution EB43.R9); Resolution EB115.R4 (EB115/2005/REC/1)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.
Lists of Proposed (1–113) and Recommended (1–74) International Nonproprietary Names can be found in *Cumulative List No. 16, 2015* (available in CD-ROM only).

# Dénominations communes internationales des Substances pharmaceutiques (DCI)

## Dénominations communes internationales RECOMMANDÉES: Liste 77

Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [*Actes off. Org. mond. Santé*, 1955, **60**, 3 (résolution EB15.R7); 1969, **173**, 10 (résolution EB43.R9); résolution EB115.R4 (EB115/2005/REC/1)] les dénominations ci-dessous sont choisies par l'Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L'inclusion d'une dénomination dans les listes de DCI recommandées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.
On trouvera d'autres listes de Dénominations communes internationales proposées (1–113) et recommandées (1–74) dans la *Liste récapitulative No. 16, 2015* (disponible sur CD-ROM seulement).

# Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

## Denominaciones Comunes Internacionales RECOMENDADAS: Lista 77

De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [*Act. Of. Mund. Salud*, 1955, **60**, 3 (Resolución EB15.R7); 1969, **173**, 10 (Resolución EB43.R9); Résolution EB115.R4 (EB115/2005/REC/1) EB115.R4 (EB115/2005/REC/1)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.
Las listas de Denominaciones Comunes Internacionales Propuestas (1–113) y Recomendadas (1–74) se encuentran reunidas en *Cumulative List No. 16, 2015* (disponible sólo en CD-ROM).

| **Latin**, English, French, Spanish: *Recommended INN* | *Chemical name or description; Molecular formula; Graphic formula* |
|---|---|
| *DCI Recommandée* | *Nom chimique ou description; Formule brute; Formule développée* |
| *DCI Recomendada* | *Nombre químico o descripción; Fórmula molecular; Fórmula desarrollada* |

**adegramotidum**

adegramotide — human Wilms tumor protein (WT33)-(34-51)-peptide

adégramotide — protéine tumorale de Wilms humaine (WT33)-(34-51)-peptide

adegramotida — proteína tumoral de Wilms humana (WT33)-(34-51)-péptido

$C_{87}H_{123}N_{19}O_{24}$

H—Trp—Ala—Pro—Val—Leu—Asp—Phe—Ala—Pro—
—Pro—Gly—Ala—Ser—Ala—Tyr—Gly—Ser—Leu—OH
10 18

**adomeglivantum**

adomeglivant — 3-(4-{(1*S*)-1-[(4'-*tert*-butyl-2,6-dimethyl[1,1'-biphenyl]-4-yl)oxy]-4,4,4-trifluorobutyl}benzamido)propanoic acid

adoméglivant — acide 3-(4-{(1*S*)-1-[(4'-*tert*-butyl-2,6-diméthyl[1,1'-biphényl]-4-yl)oxy]-4,4,4-trifluorobutyl}benzamido)propanoïque

adomeglivant — ácido 3-(4-{(1*S*)-1-[(4'-*terc*-butil-2,6-dimetil[1,1'-bifenil]-4-il)oxi]-4,4,4-trifluorobutil}benzamido)propanoico

$C_{32}H_{36}F_3NO_4$




**afabicinum**

afabicin — {6-[(1*E*)-3-{methyl[(3-methyl-1-benzofuran-2-yl)methyl]amino}-3-oxoprop-1-en-1-yl]-2-oxo-3,4-dihydro-1,8-naphthyridin-1(2*H*)-yl}methyl dihydrogen phosphate

afabicine — dihydrogénophosphate de {6-[(1*E*)-3-{méthyl[(3-méthyl-1-benzofuran-2-yl)méthyl]amino}-3-oxoprop-1-én-1-yl]-2-oxo-3,4-dihydro-1,8-naphtyridin-1(2*H*)-yl}méthyle

afabicina

dihidrogenofosfato de {6-[(1*E*)-3-{metil[(3-metil-1-benzofuran-2-il)metil]amino}-3-oxoprop-1-en-1-il]-2-oxo-3,4-dihidro-1,8-naftiridin-1(2*H*)-il}metilo

$C_{23}H_{24}N_3O_7P$



**alicapistatum**

alicapistat

(2*R*)-1-benzyl-*N*-[(2*RS*)-4-(cyclopropylamino)-3,4-dioxo-1-phenylbutan-2-yl]-5-oxopyrrolidine-2-carboxamide

alicapistat

(2*R*)-1-benzyl-*N*-[(2*RS*)-4-(cyclopropylamino)-3,4-dioxo-1-phénylbutan-2-yl]-5-oxopyrrolidine-2-carboxamide

alicapistat

(2*R*)-1-bencil-*N*-[(2*RS*)-4-(ciclopropilamino)-1-fenil-3,4-dioxobutan-2-il]-5-oxopirrolidina-2-carboxamida

$C_{25}H_{27}N_3O_4$



and epimer at C*
et l'épimère en C*
y el epímero al C*

**alidornasum alfa #**

alidornase alfa

*N*$^{2.1}$-glycyl-deoxyribonuclease I (DNase I), human, produced in *Nicotiana tabacum* cell culture, glycoform alfa, chemically amidated by condensation of an average of about 10-12 molecules of ethane-1,2-diamine per enzyme molecule with free carboxy groups to give *N*-(2-aminoethyl) carboxamide groups (about 7 per molecule on average) and intramolecularly *N*,*N*'-(ethane-1,2-diyl)-bridged pairs of carboxamide groups

alidornase alfa

*N*$^{2.1}$-glycyl-déoxyribonucléase I (DNase I), humaine, produite par cultures de cellules de *Nicotiana tabacum*, glycoforme alfa, formant des fonctions amides par condensation chimique d'en moyenne environ 10-12 molécules d'éthane-1,2-diamine par molécule d'enzyme avec des groupes carboxy libres pour donner des groupes *N*-(2-aminoéthyl) carboxamide (environ 7 par molécule en moyenne) et des ponts intramoléculaires de groupes *N*,*N*'-(éthane-1,2-diyl) entre des paires de groupes carboxamides

alidornasa alfa

$N^{2.1}$-glicil-desoxiribonucleasa I (DNasa I), humana, producida en cultivos de células de *Nicotiana tabacum*, glicoforma alfa, glicoforma alfa, formadora de funciones amidas por condensación química por término medio de 10-12 moléculas de etano-1,2-diamina por molécula de enzima con grupos carboxi libres para proporcionar grupos *N*-(2-aminoetil) carboxamida (aproximadamente 7 por molécula por término medio) y los puentes intramoleculares de grupos *N,N'*-(etano-1,2-diil) entre pares de grupos carboxamidas

```
GLKIAAFNIQ TFGETKMSNA TLVSYIVQIL SRYDIALVQE VRDSHLTAVG 50
KLLDNLNQDA PDTYHYVVSE PLGRNSYKER YLFVYRPDQV SAVDSYYYDD 100
GCEPCGNDTF NREPAIVRFF SRFTEVREFA IVPLHAAPGD AVAEIDALYD 150
VYLDVQEKWG LEDVMLMGDF NAGCSYVRPS QWSSIRLWTS PTFQWLIPDS 200
ADTTATPTHC AYDRIVVAGM LLRGAVVPDS ALPFNFQAAY GLSDQLAQAI 250
SDHYPVEVML K                                          261
```

Disulfide bridges location / position des ponts disulfure / posiciones de los puentes disulfuro
102-105, 174-210
N-glycosylation sites / sites de N-glycosylation / sitios de N-glicosilación
Asn 19, Asn 107
Ethane-1,2-diamine modification sites: Asp and Glu residues and C-terminal

**andecaliximabum #**

andecaliximab

immunoglobulin G4-kappa, anti-[*Homo sapiens* MMP9 (matrix metallopeptidase 9, gelatinase B)], chimeric monoclonal antibody;
gamma4 heavy chain (1-442) [chimeric VH (*Mus musculus* IGHV2-9*02 -(IGHD) -*Homo sapiens* IGHJ4*01) [8.7.9] (1-115), *Homo sapiens* IGHG4*01 (CH1 (116-213), hinge S10>P (223) (214-225), CH2 (226-335), CH3 (336-440), CHS (441-442)) (116-442)], (129-214')-disulfide with kappa light chain (1'-214') [chimeric V-KAPPA (*Mus musculus* IGKV6-17 -*Homo sapiens* IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimer (221-221":224-224")-bisdisulfide

andécaliximab

immunoglobuline G4-kappa, anti-[*Homo sapiens* MMP9 (matrice métallopeptidase 9, gélatinase B)], anticorps monoclonal chimérique;
chaîne lourde gamma4 (1-440) [VH chimérique (*Mus musculus* IGHV2-9*02 -(IGHD) -*Homo sapiens* IGHJ4*01) [8.7.9] (1-115), *Homo sapiens* IGHG4*01 (CH1 (116-213), charnière S10>P (223) (214-225), CH2 (226-335), CH3 (336-440), CHS (441-442)) (116-442)], (129-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA chimérique (*Mus musculus* IGKV6-17 -*Homo sapiens* IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimère (221-221":224-224")-bisdisulfure

andecaliximab

inmunoglobulina G4-kappa, anti-[*Homo sapiens* MMP9 (matriz metalopeptidasa 9, gelatinasa B)], anticuerpo monoclonal quimérico;
cadena pesada gamma4 (1-440) [VH quimérico (*Mus musculus* IGHV2-9*02 -(IGHD) -*Homo sapiens* IGHJ4*01) [8.7.9] (1-115), *Homo sapiens* IGHG4*01 (CH1 (116-213), bisagra S10>P (223) (214-225), CH2 (226-335), CH3 (336-440), CHS (441-442)) (116-442)], (129-214')-disulfuro con

la cadena ligera kappa (1'-214') [V-KAPPA quimérico (*Mus musculus* IGKV6-17 -*Homo sapiens* IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dímero (221-221":224-224")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLQESGPG LVKPSETLSL TCTVSGFSLL SYGVHWVRQP PGKGLEWLGV  50
IWTGGTTNYN SALMSRFTIS KDDSKNTVYL KMNSLKTEDT AIYYCARYYY 100
GMDYWGQGTL VTVSSASTKG PSVFPLAPCS RSTSESTAAL GCLVKDYFPE 150
PVTVSWNSGA LTSGVHTFPA VLQSSGLYSL SSVVTVPSSS LGTKTYTCNV 200
DHKPSNTKVD KRVESKYGPP CPPCPAPEFL GGPSVFLFPP KPKDTLMISR 250
TPEVTCVVVD VSQEDPEVQF NWYVDGVEVH NAKTKPREEQ FNSTYRVVSV 300
LTVLHQDWLN GKEYKCKVSN KGLPSSIEKT ISKAKGQPRE PQVYTLPPSQ 350
EEMTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTP PVLDSDGSFF 400
LYSRLTVDKS RWQEGNVFSC SVMHEALHNH YTQKSLSLSL GK         442
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVT ITCKASQDVR NTVAWYQQKP GKAPKLLIYS  50
SSYRNTGVPD RFSGSGSGTD FTLTISSLQA EDVAVYYCQQ HYITPYTFGG 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-95 142-198 256-316 362-420
22"-95" 142"-198" 256"-316" 362"-420"
Intra-L (C23-C104) 23'-88' 134'-194'
23'"-88'" 134'"-194'"
Inter-H-L (CH1 10-CL 126) 129-214' 129"-214"'
Inter-H-H (h 8, h 11) 221-221" 224-224"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
292, 292"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

**apararenonum**
apararenone — *N*-[4-(4-fluorophenyl)-2,2-dimethyl-3-oxo-3,4-dihydro-2*H*-1,4-benzoxazin-7-yl]methanesulfonamide

apararénone — *N*-[4-(4-fluorophényl)-2,2-diméthyl-3-oxo-3,4-dihydro-2*H*-1,4-benzoxazin-7-yl]méthanesulfonamide

apararenona — *N*-[4-(4-fluorofenil)-2,2-dimetil-3-oxo-3,4-dihidro-2*H*-1,4-benzoxazin-7-il]metanosulfonamida

$C_{17}H_{17}FN_2O_4S$



**apimostinelum**
apimostinel — L-threonyl-L-prolyl-2-benzyl-L-prolyl-L-threoninamide

apimostinel — L-thréonyl-L-prolyl-2-benzyl-L-prolyl-L-thréoninamide

apimostinel — L-treonil-L-prolil-2-bencil-L-prolil-L-treoninamida

$C_{25}H_{37}N_5O_6$



**aprutumabum #**

| | |
|---|---|
| aprutumab | immunoglobulin G1-lambda1, anti-[*Homo sapiens* FGFR2 (fibroblast growth factor receptor 2, keratinocyte growth factor receptor, KGFR, CD332)], *Homo sapiens* monoclonal antibody; gamma1 heavy chain (1-451) [*Homo sapiens* VH (IGHV3-23*01 (98.00%) -(IGHD) -IGHJ5*02) [8.8.15](1-122) -IGHG1*01, Gm17,1 (CH1 (123-220), hinge (221-235), CH2 (236-345), CH3 (346-450),CHS K>del (451)) (123-451)], (225-215')-disulfide with lambda1 light chain (1'-216') [*Homo sapiens* V-LAMBDA (IGLV1-47*01 (90.70%) -IGLJ3*02) [8.3.11] (1'-110') -IGLC2*01 (111'-216')]; dimer (231-231'':234-234'')-bisdisulfide |
| aprutumab | immunoglobuline G1-lambda1, anti-[*Homo sapiens* FGFR2 (récepteur 2 du facteur de croissance des fibroblastes, récepteur du facteur de croissance des kératinocytes, KGFR, CD332)], *Homo sapiens* anticorps monoclonal; chaîne lourde gamma1 (1-451) [*Homo sapiens* VH (IGHV3-23*01 (98.00%) -(IGHD) -IGHJ5*02) [8.8.15](1-122) -IGHG1*01, Gm17,1 (CH1 (123-220), charnière (236-345), CH2 (236-345), CH3 (346-450), CHS K>del (451)) (123-451)], (225-215')-disulfure avec la chaîne légère lambda1 (1'-216') [*Homo sapiens* V-LAMBDA (IGLV1-47*01 (90.70%) -IGLJ3*02) [8.3.11] (1'-110') -IGLC2*01 (111'-216')]; dimère (231-231'':234-234'')-bisdisulfure |
| aprutumab | inmunoglobulina G1-lambda1, anti-[*Homo sapiens* FGFR2 (receptor 2 del factor de crecimiento de los fibroblastos, receptor del factor de crecimiento de los queratinocitos, KGFR, CD332)], *Homo sapiens* anticuerpo monoclonal; cadena pesada gamma1 (1-451) [*Homo sapiens* VH (IGHV3-23*01 (98.00%) -(IGHD) -IGHJ5*02) [8.8.15](1-122) -IGHG1*01, Gm17,1 (CH1 (123-220), bisagra (236-345), CH2 (236-345), CH3 (346-450), CHS K>del (451)) (123-451)], (225-215')-disulfuro con la cadena ligera lambda1 (1'-216') [*Homo sapiens* V-LAMBDA (IGLV1-47*01 (90.70%) -IGLJ3*02) [8.3.11] (1'-110') -IGLC2*01 (111'-216')]; dímero (231-231'':234-234'')-bisdisulfuro |

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLLESGGG LVQPGGSLRL SCAASGFTFS SYAMSWVRQA PGKGLEWVSA  50
ISGSGTSTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARVR 100
YNWNHGDWFD PWGQGTLVTV SSASTKGPSV FPLAPSSKST SGGTAALGCL 150
VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV VTVPSSSLGT 200
QTYICNVNHK PSNTKVDKKV EPKSCDKTHT CPPCPAPELL GGPSVFLFPP 250
KPKDTLMISR TPEVTCVVVD VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ 300
YNSTYRVVSV LTVLHQDWLN GKEYKCKVSN KALPAPIEKT ISKAKGQPRE 350
PQVYTLPPSR DELTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTP 400
PVLDSDGSFF LYSKLTVDKS RWQQGNVFSC SVMHEALHNH YTQKSLSLSP 450
G                                                       451
```

Light chain / Chaîne légère / Cadena ligera

```
QSVLTQPPSA SGTPGQRVTI SCSGSSSNIG NNYVSWYQQL PGTAPKLLIY  50
ENYNRPAGVP DRFSGSKSGT SASLAISGLR SEDEADYYCS SWDDSLNYWV 100
FGGGTKLTVL GQPKAAPSVT LFPPSSEELQ ANKATLVCLI SDFYPGAVTV 150
AWKADSSPVK AGVETTTPSK QSNNKYAASS YLSLTPEQWK SHRSYSCQVT 200
HEGSTVEKTV APTECS                                       216
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 149-205 266-326 372-430
22"-96" 149"-205" 266"-326" 372"-430"
Intra-L (C23-C104) 22'-89' 138'-197'
22'"-89'" 138'"-197'"
Inter-H-L (h 5-CL 126) 225-215' 225"-215"
Inter-H-H (h 11, h 14) 231-231' 234-234"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
302, 302"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

**aprutumabum ixadotinum #**

aprutumab ixadotin

immunoglobulin G1-lambda1, anti-[*Homo sapiens* FGFR2 (fibroblast growth factor receptor 2, keratinocyte growth factor receptor, KGFR, CD332)], *Homo sapiens* monoclonal antibody conjugated to an auristatin W derivative;
gamma1 heavy chain (1-451) [*Homo sapiens* VH (IGHV3-23*01 (98.00%) -(IGHD) -IGHJ5*02) [8.8.15](1-122) -IGHG1*01, Gm17,1 (CH1 (123-220), hinge (221-235), CH2 (236-345), CH3 (346-450),CHS K>del (451)) (123-451)], (225-215')-disulfide with lambda1 light chain (1'-216') [*Homo sapiens* V-LAMBDA (IGLV1-47*01 (90.70%) -IGLJ3*02) [8.3.11] (1'-110') -IGLC2*01 (111'-216')]; dimer (231-231":234-234")-bisdisulfide; conjugated, on an average of 4 lysyl, to *N*-(5-carboxypentyl)-*N*-demethyl-auristatin W (AW) $C^{1.5}$-(1,2-oxazinan-2-yl) derivative

aprutumab ixadotine

immunoglobuline G1-lambda1, anti-[*Homo sapiens* FGFR2 (récepteur 2 du facteur de croissance des fibroblastes, récepteur du facteur de croissance des kératinocytes, KGFR, CD332)], *Homo sapiens* anticorps monoclonal conjugué à un dérivé de l'auristatine W;
chaîne lourde gamma1 (1-451) [*Homo sapiens* VH (IGHV3-23*01 (98.00%) -(IGHD) -IGHJ5*02) [8.8.15](1-122) -IGHG1*01, Gm17,1 (CH1 (123-220), charnière (236-345), CH2 (236-345), CH3 (346-450), CHS K>del (451)) (123-451)], (225-215')-disulfure avec la chaîne légère lambda1 (1'-216') [*Homo sapiens* V-LAMBDA (IGLV1-47*01 (90.70%) -IGLJ3*02) [8.3.11] (1'-110') -IGLC2*01 (111'-216')]; dimère (231-231":234-234")-bisdisulfure; conjugué, sur 4 lysyl en moyenne, au dérivé $C^{1.5}$-(1,2-oxazinan-2-yle) de *N*-(5-carboxypentyl)-*N*-desméthyl-auristatine W (AW)

aprutumab ixadotina

inmunoglobulina G1-lambda1, anti-[*Homo sapiens* FGFR2 (receptor 2 del factor de crecimiento de los fibroblastos, receptor del factor de crecimiento de los queratinocitos, KGFR, CD332)], *Homo sapiens* anticuerpo monoclonal conjugado a un derivado de la auristatina W; cadena pesada gamma1 (1-451) [*Homo sapiens* VH (IGHV3-23*01 (98.00%) -(IGHD) -IGHJ5*02) [8.8.15](1-122) -IGHG1*01, Gm17,1 (CH1 (123-220), bisagra (236-345), CH2 (236-345), CH3 (346-450), CHS K>del (451)) (123-451)], (225-215')-disulfuro con la cadena ligero lambda1 (1'-216') [*Homo sapiens* V-LAMBDA (IGLV1-47*01 (90.70%) -IGLJ3*02) [8.3.11] (1'-110') -IGLC2*01 (111'-216')]; dímero (231-231":234-234")-bisdisulfuro; conjugado, en 4 grupos lisil por término medio, con el derivado $C^{1.5}$-(1,2-oxazinan-2-ilo) de *N*-(5-carboxipentil)-*N*-desmetil-auristatina W (AW)

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLLESGGG LVQPGGSLRL SCAASGFTFS SYAMSWVRQA PGKGLEWVSA  50
ISGSGTSTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARVR 100
YNWNHGDWFD PWGQGTLVTV SSASTKGPSV FPLAPSSKST SGGTAALGCL 150
VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV VTVPSSSLGT 200
QTYICNVNHK PSNTKVDKKV EPKSCDKTHT CPPCPAPELL GGPSVFLFPP 250
KPKDTLMISR TPEVTCVVVD VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ 300
YNSTYRVVSV LTVLHQDWLN GKEYKCKVSN KALPAPIEKT ISKAKGQPRE 350
PQVYTLPPSR DELTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTP 400
PVLDSDGSFF LYSKLTVDKS RWQQGNVFSC SVMHEALHNH YTQKSLSLSP 450
G                                                       451
```

Light chain / Chaîne légère / Cadena ligera

```
QSVLTQPPSA SGTPGQRVTI SCSGSSSNIG NNYVSWYQQL PGTAPKLLIY  50
ENYNRPAGVP DRFSGSKSGT SASLAISGLR SEDEADYYCS SWDDSLNYWV 100
FGGGTKLTVL GQPKAAPSVT LFPPSSEELQ ANKATLVCLI SDFYPGAVTV 150
AWKADSSPVK AGVETTTPSK QSNNKYAASS YLSLTPEQWK SHRSYSCQVT 200
HEGSTVEKTV APTECS                                      216
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

| | | | | |
|---|---|---|---|---|
| Intra-H (C23-C104) | 22-96 | 149-205 | 266-326 | 372-430 |
| | 22"-96" | 149"-205" | 266"-326" | 372"-430" |
| Intra-L (C23-C104) | 22'-89' | 138'-197' | | |
| | 22'"-89'" | 138'"-197'" | | |
| Inter-H-L (h 5-CL 126) | 225-215' | 225"-215'" | | |
| Inter-H-H (h 11, h 14) | 231-231' | 234-234" | | |

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
302, 302"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

Potential modified residues / résidus modifiés potentiels / restos modificados potenciales
An average of 4 lysyl are substituted
4 lysyls sont substitués en moyenne.
4 lisils estan sustituidos pro término medio.



**asciminibum**

asciminib — *N*-[4-(chlorodifluoromethoxy)phenyl]-6-[(3*R*)-3-hydroxypyrrolidin-1-yl]-5-(1*H*-pyrazol-3-yl)pyridine-3-carboxamide

asciminib — *N*-[4-(chlorodifluorométhoxy)phényl]-6-[(3*R*)-3-hydroxypyrrolidin-1-yl]-5-(1*H*-pyrazol-3-yl)pyridine-3-carboxamide

asciminib — *N*-[4-(clorodifluorometoxi)fenil]-6-[(3*R*)-3-hidroxipirrolidin-1-il]-5-(1*H*-pirazol-3-il)piridina-3-carboxamida

$C_{20}H_{18}ClF_2N_5O_3$



**atuveciclibum**

atuveciclib — (+)-[(3-{[4-(4-fluoro-2-methoxyphenyl)-1,3,5-triazin-2-yl]amino}phenyl)methyl](imino)(methyl)-$\lambda^6$-sulfanone

atuvéciclib — (+)-[(3-{[4-(4-fluoro-2-méthoxyphényl)-1,3,5-triazin-2-yl]amino}phényl)méthyl](imino)(méthyl)-$\lambda^6$-sulfanone

atuveciclib — (+)-[(3-{[4-(4-fluoro-2-metoxifenil)-1,3,5-triazin-2-il]amino}fenil)metil](imino)(metil)-$\lambda^6$-sulfanona

$C_{18}H_{18}FN_5O_2S$



or enantiomer
ou énantiomère
o enantiómero

**audencelum**

audencel — autologous interleukin (IL)-12-secreting dendritic cells (DCs), loaded with autologous tumour lysate, comprising >70% of total immune cells. The cells are differentiated from autologous monocytes by culturing in the presence of interleukin (IL)-4 and GM-CSF (granulocyte-macrophage colony-stimulating factor), following which they are exposed to the patient's tumor protein/tumor-associated antigen (TAA), and subsequently to lipopolysaccharide (LPS) in the presence of interferon gamma (IFN-γ) to enable IL-12 secretion.

| | |
|---|---|
| audencel | cellules dendritiques autologues secrétant de l'interleukine-12 (IL-12), chargées avec un lysat de tumeur autologue, comprenant plus de 70% du total des cellules immunitaires. Les cellules sont différenciées à partir de monocytes autologues par une culture en présence d'interleukine-4 (IL-4) et de facteur de stimulation des colonies de granulocytes et de macrophages (GM-CSF), ensuite elles sont exposées à la protéine tumorale/antigène associé à la tumeur du patient, puis au lipopolysaccharide (LPS) en présence d'interféron gamma (IFN- γ) afin de permettre la sécrétion d'IL-12. |
| audencel | células dendríticas autólogas que secretan la interleukina-12 (IL-12), cargadas con un lisado de tumor autólogo, que comprende más del 70% del total de células inmunitarias. Las células se diferencian a partir de monocitos autólogos a través de un cultivo en presencia de interleukina-4 (IL-4) y del factor de estimulación de las colonias de granulocitos y de macrófagos (GM-CSF), a continuación ellas se exponen a la proteína tumoral/antigénica asociada al tumor del paciente (TAA), y después al lipopolisacárido (LPS) en presencia del interferón gamma (IFN-γ) para permitir la secreción de la IL-12. |

**birabresibum**

| | |
|---|---|
| birabresib | 2-[(6*S*)-4-(4-chlorophenyl)-2,3,9-trimethyl-6*H*-thieno[3,2-*f*][1,2,4]triazolo[4,3-*a*][1,4]diazepin-6-yl]-*N*-(4-hydroxyphenyl)acetamide |
| birabrésib | 2-[(6*S*)-4-(4-chlorophényl)-2,3,9-triméthyl-6*H*-thiéno[3,2-*f*][1,2,4]triazolo[4,3-*a*][1,4]diazépin-6-yl]-*N*-(4-hydroxyphényl)acétamide |
| birabresib | 2-[(6*S*)-4-(4-clorofenil)-2,3,9-trimetil-6*H*-tieno[3,2-*f*][1,2,4]triazolo[4,3-*a*][1,4]diazepin-6-il]-*N*-(4-hidroxifenil)acetamida |

$C_{25}H_{22}ClN_5O_2S$




**branaplamum**

| | |
|---|---|
| branaplam | 5-(1*H*-pyrazol-4-yl)-2-{6-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]pyridazin-3-yl}phenol |
| branaplam | 5-(1*H*-pyrazol-4-yl)-2-{6-[(2,2,6,6-tétraméthylpipéridin-4-yl)oxy]pyridazin-3-yl}phenol |

branaplam

5-(1*H*-pirazol-4-il)-2-{6-[(2,2,6,6-tetrametilpiperidin-4-il)oxi]piridazin-3-il}fenol

$C_{22}H_{27}N_5O_2$



**brazikumabum #**

brazikumab

immunoglobulin G2-lambda, anti-[*Homo sapiens* IL23A (interleukin 23 subunit alpha, IL-23A, IL-23 subunit p19, IL23p19)], *Homo sapiens* monoclonal antibody; gamma2 heavy chain (1-450) [*Homo sapiens* VH (IGHV3-33*01 (99.00%) -(IGHD)-IGHJ3*02) [8.8.17] (1-124) -IGHG2*01, G2m.. (CH1 (125-222), hinge (223-234), CH2 (235-343), CH3 (344-448), CHS (449-450)) (125-450)], (138-216')-disulfide with lambda light chain (1'-217') [*Homo sapiens* V-LAMBDA (IGLV1-40*01 (96.00%) -IGLJ3*02) [9.3.11] (1'-111') -IGLC2*01 (112'-217')]; dimer (226-226'':227-227'':230-230'':233-233'')-tetrakisdisulfide

brazikumab

immunoglobuline G2-lambda, anti-[*Homo sapiens* IL23A (interleukine 23 sous-unité alpha, IL-23A, IL-23 sous-unité p19, IL23p19)], *Homo sapiens* anticorps monoclonal; chaîne lourde gamma2 (1-450) [*Homo sapiens* VH (IGHV3-33*01 (99.00%) -(IGHD)-IGHJ3*02) [8.8.17] (1-124) -IGHG2*01, G2m.. (CH1 (125-222), charnière (223-234), CH2 (235-343), CH3 (344-448), CHS (449-450)) (125-450)], (138-216')-disulfure avec la chaîne légère lambda (1'-217') [*Homo sapiens* V-LAMBDA (IGLV1-40*01 (96.00%) -IGLJ3*02) [9.3.11] (1'-111') -IGLC2*01 (112'-217')]; dimère (226-226'':227-227'':230-230'':233-233'')-tétrakisdisulfure

brazikumab

inmunoglobulina G2-lambda, anti-[*Homo sapiens* IL23A (interleukina 23 subunidad alfa, IL-23A, IL-23 subunidad p19, IL23p19)], *Homo sapiens* anticuerpo monoclonal; cadena pesada gamma2 (1-450) [*Homo sapiens* VH (IGHV3-33*01 (99.00%) -(IGHD)-IGHJ3*02) [8.8.17] (1-124) -IGHG2*01, G2m.. (CH1 (125-222), bisagra (223-234), CH2 (235-343), CH3 (344-448), CHS (449-450)) (125-450)], (138-216')-disulfuro con la cadena ligera lambda (1'-217') [*Homo sapiens* V-LAMBDA (IGLV1-40*01 (96.00%) -IGLJ3*02) [9.3.11] (1'-111') -IGLC2*01 (112'-217')]; dímero (226-226'':227-227'':230-230'':233-233'')-tetrakisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVESGGG VVQPGRSLRL SCAASGFTFS SYGMHWVRQA PGKGLEWVAV  50
IWYDGSNEYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARDR 100
GYTSSWYPDA FDIWGQGTMV TVSSASTKGP SVFPLAPCSR STSESTAALG 150
CLVKDYFPEP VTVSWNSGAL TSGVHTFPAV LQSSGLYSLS SVVTVPSSNF 200
GTQTYTCNVD HKPSNTKVDK TVERKCCVEC PPCPAPPVAG PSVFLFPPKP 250
KDTLMISRTP EVTCVVVDVS HEDPEVQFNW YVDGVEVHNA KTKPREEQFN 300
STFRVVSVLT VVHQDWLNGK EYKCKVSNKG LPAPIEKTIS KTKGQPREPQ 350
VYTLPPSREE MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPM 400
LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPGK 450
```

Light chain / Chaîne légère / Cadena ligera

```
QSVLTQPPSV SGAPGQRVTI SCTGSSSNTG AGYDVHWYQQ VPGTAPKLLI  50
YGSGNRPSGV PDRFSGSKSG TSASLAITGL QAEDEADYYC QSYDSSLSGW 100
VFGGGTRLTV LGQPKAAPSV TLFPPSSEEL QANKATLVCL ISDFYPGAVT 150
VAWKADSSPV KAGVETTTPS KQSNNKYAAS SYLSLTPEQW KSHRSYSCQV 200
THEGSTVEKT VAPTECS                                     217
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

| | | | | |
|---|---|---|---|---|
| Intra-H (C23-C104) | 22-96 | 151-207 | 264-324 | 370-428 |
| | 22"-96" | 151"-207" | 264"-324" | 370"-428" |
| Intra-L (C23-C104) | 22'-90' | 139'-198' | | |
| | 22'"-90'" | 139'"-198'" | | |
| Inter-H-L (CH1 10-CL 126) | 138-216' | 138"-216'" | | |
| Inter-H-H (h 4, h 5, h 8, h 11) | 226-226" | 227-227" | 230-230" | 233-233" |

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
300, 300"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés

**brilanestrantum**

brilanestrant — (2*E*)-3-{4-[(1*E*)-2-(2-chloro-4-fluorophenyl)-1-(1*H*-indazol-5-yl)but-1-en-1-yl]phenyl}prop-2-enoic acid

brilanestrant — acide (2*E*)-3-{4-[(1*E*)-2-(2-chloro-4-fluorophényl)-1-(1*H*-indazol-5-yl)but-1-én-1-yl]phényl}prop-2-énoïque

brilanestrant — ácido (2*E*)-3-{4-[(1*E*)-2-(2-cloro-4-fluorofenil)-1-(1*H*-indazol-5-il)but-1-en-1-il]fenil}prop-2-enoico

$C_{26}H_{20}ClFN_2O_2$




**burosumabum #**

burosumab — immunoglobulin G1-kappa, anti-[*Homo sapiens* FGF23 (fibroblast growth factor 23)], *Homo sapiens* monoclonal antibody;

gamma1 heavy chain (1-447) [*Homo sapiens* VH (IGHV1-46*01 (94.90%) -(IGHD) -IGHJ3*02) [8.8.10] (1-117) -IGHG1*01, Gm17,1 (CH1 (118-215), hinge (216-230), CH2 (231-340), CH3 (341-445), CHS (446-447))(118-447)], (220-213')-disulfide with kappa light chain (1'-213') [*Homo sapiens* V-KAPPA (IGKVD1-13*01 (97.90%) -IGKJ3*01) [6.3.8] (1'-106') -IGKC*01, Km3 (107'-213')]; dimer (226-226'':229-229'')-bisdisulfide

burosumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* FGF23 (facteur de croissance des fibroblastes 23)], *Homo sapiens* anticorps monoclonal;
chaîne lourde gamma1 (1-447) [*Homo sapiens* VH (IGHV1-46*01 (94.90%) -(IGHD) -IGHJ3*02) [8.8.10] (1-117) -IGHG1*01, Gm17,1 (CH1 (118-215), charnière (216-230), CH2 (231-340), CH3 (341-445), CHS (446-447)) (118-447)], (220-213')-disulfure avec la chaîne légère kappa (1'-213') [*Homo sapiens* V-KAPPA (IGKV1-13*02 (97.90%) -IGKJ3*01) [6.3.8] (1'-107') -IGKC*01, Km3 (107'-213')]; (226-226'':229-229'')-bisdisulfure

burosumab

immunoglobulina G1-kappa, anti-[*Homo sapiens* FGF23 (factor de crecimiento de los fibroblastos 23)], *Homo sapiens* anticuerpo monoclonal;
cadena pesada gamma1 (1-447) [*Homo sapiens* VH (IGHV1-46*01 (94.90%) -(IGHD) -IGHJ3*02) [8.8.10] (1-117) -IGHG1*01, Gm17,1 (CH1 (118-215), bisagra (216-230), CH2 (231-340), CH3 (341-445), CHS (446-447)) (118-447)], (220-213')-disulfuro con la cadena ligera kappa (1'-213') [*Homo sapiens* V-KAPPA (IGKV1-13*02 (97.90%) -IGKJ3*01) [6.3.8] (1'-107') -IGKC*01, Km3 (107'-213')]; (226-226'':229-229'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VKKPGASVKV SCKASGYTFT NHYMHWVRQA PGQGLEWMGI  50
INPISGSTSN AQKFQGRVTM TRDTSTSTVY MELSSLRSED TAVYYCARDI 100
VDAFDFWGQG TMVTVSSAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF 150
PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC 200
NVNHKPSNTK VDKKVEPKSC DKTHTCPPCP APELLGGPSV FLFPPKPKDT 250
LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY 300
RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT 350
LPPSRDELTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS 400
DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPGK    447
```

Light chain / Chaîne légère / Cadena ligera

```
AIQLTQSPSS LSASVGDRVT ITCRASQGIS SALVWYQQKP GKAPKLLIYD  50
ASSLESGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ FNDYFTFGPG 100
TKVDIKRTVA APSVFIFPPS DEQLKSGTAS VVCLLNNFYP REAKVQWKVD 150
NALQSGNSQE SVTEQDSKDS TYSLSSTLTL SKADYEKHKV YACEVTHQGL 200
SSPVTKSFNR GEC                                         213
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H (C23-C104) 22-96 144-200 261-321 367-425
22"-96" 144"-200" 261'-321' 367"-425'
Intra-L (C23-C104) 23'-88' 133'-193'
23"'-88"' 133"'-193"'
Inter-H-L (h 5-CL 126) 220-213' 220"-213"'
Inter-H-H (h 11, h 14) 226-226" 229-229"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
297, 297"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

**camrelizumabum #**

| | |
|---|---|
| camrelizumab | immunoglobulin G4-kappa, anti-[*Homo sapiens* PDCD1 (programmed cell death 1, PD-1, PD1, CD279)], humanized monoclonal antibody;<br>gamma4 heavy chain (1-443) [humanized VH (*Homo sapiens* IGHV3-7*01 (90.80%) -(IGHD) -IGHJ4*01) [8.8.9] (1-116) -IGHG4*01 (CH1 (117-214), hinge S10>P (224) (215-226), CH2 (227-336), CH3 (337-441), CHS (442-443)) (117-443)], (130-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens* IGKV1-39*01 (87.40%) -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimer (222-222":225-225")-bisdisulfide |
| camrélizumab | immunoglobuline G4-kappa, anti-[*Homo sapiens* PDCD1 (protéine 1 de mort cellulaire programmée, PD-1, PD1, CD279)], anticorps monoclonal humanisé;<br>chaîne lourde gamma4 (1-443) [VH humanisé (*Homo sapiens* IGHV3-7*01 (90.80%) -(IGHD) -IGHJ4*01) [8.8.9] (1-116) -IGHG4*01 (CH1 (117-214), charnière S10>P (224) (215-226), CH2 (227-336), CH3 (337-441), CHS (442-443)) (117-443)], (130-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (*Homo sapiens* IGKV1-39*01 (87.40%) -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimère (222-222":225-225")-bisdisulfure |
| camrelizumab | inmunoglobulina G4-kappa, anti-[*Homo sapiens* PDCD1 (proteína 1 de muerte celular programada, PD-1, PD1, CD279)], anticuerpo monoclonal humanizado;<br>cadena pesada gamma4 (1-443) [VH humanizado (*Homo sapiens* IGHV3-7*01 (90.80%) -(IGHD) -IGHJ4*01) [8.8.9] (1-116) -IGHG4*01 (CH1 (117-214), bisagra S10>P (224) (215-226), CH2 (227-336), CH3 (337-441), CHS (442-443)) (117-443)], (130-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizado (*Homo sapiens* IGKV1-39*01 (87.40%) -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dímero (222-222":225-225")-bisdisulfuro |

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG LVQPGGSLRL SCAASGFTFS SYMMSWVRQA PGKGLEWVAT 50
ISGGGANTYY PDSVKGRFTI SRDNAKNSLY LQMNSLRAED TAVYYCARQL 100
YYFDYWGQGT TVTVSSASTK GPSVFPLAPC SRSTSESTAA LGCLVKDYFP 150
EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS LSSVVTVPSS SLGTKTYTCN 200
VDHKPSNTKV DKRVESKYGP PCPPCPAPEF LGGPSVFLFP PKPKDTLMIS 250
RTPEVTCVVV DVSQEDPEVQ FNWYVDGVEV HNAKTKPREE QFNSTYRVVS 300
VLTVLHQDWL NGKEYKCKVS NKGLPSSIEK TISKAKGQPR EPQVYTLPPS 350
QEEMTKNQVS LTCLVKGFYP SDIAVEWESN GQPENNYKTT PPVLDSDGSF 400
FLYSRLTVDK SRWQEGNVFS CSVMHEALHN HYTQKSLSLS LGK        443
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVT ITCLASQTIG TWLTWYQQKP GKAPKLLIYT 50
ATSLADGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ VYSIPWTFGG 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                       214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

| | | | | |
|---|---|---|---|---|
| Intra-H (C23-C104) | 22-96 | 143-199 | 257-317 | 363-421 |
| | 22"-96" | 143"-199" | 257"-317" | 363"-421" |
| Intra-L (C23-C104) | 23'-88' | 134'-194' | | |
| | 23'"-88'" | 134'"-194'" | | |
| Inter-H-L (CH1 10-CL 126) | 130-214' | 130"-214'" | | |
| Inter-H-H (h 8, h 11) | 222-222" | 225-225" | | |

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
293, 293"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

Other post-translational modifications / Autres modifications post-traductionnelles / Otras modificaciones post-traduccionales

H CHS K2 C-terminal lysine clipping:
443, 443"

**cannabidiolum**

cannabidiol — 2-[(1*R*,6*R*)-3-methyl-6-(prop-1-en-2-yl)cyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol

cannabidiol — 2-[(1*R*,6*R*)-3-méthyl-6-(prop-1-én-2-yl)cyclohex-2-én-1-yl]-5-pentylbenzène-1,3-diol

cannabidiol — 2-[(1*R*,6*R*)-3-metil-6-(prop-1-en-2-il)ciclohex-2-en-1-il]-5-pentilbenceno-1,3-diol

$C_{21}H_{30}O_2$




**casimersenum**

casimersen — *all-P-ambo*-[2',3'-azanediyl-*P*-(dimethylamino)-*P*,2',3'-trideoxy-2',3'-seco](2'-*N*→5')(C-A-A-T-G-C-C-A-T-C-C-T-G-G-A-G-T-T-C-C-T-G) 5'-{*P*-[4-({2-[2-(2-hydroxyethoxy)ethoxy]ethoxy}carbonyl)piperazin-1-yl]-*N*,*N*-dimethylphosphonamidate}

casimersen — 5'-{*P*-[4-({2-[2-(2-hydroxyéthoxy)éthoxy]éthoxy}carbonyl)pipérazin-1-yl]-*N*,*N*-diméthylphosphonamidate} de *tout-P-ambo*-[2',3'-azanediyl-*P*-(diméthylamino)-*P*,2',3'-tridéoxy-2',3'-séco](2'-*N*→5')(C-A-A-T-G-C-C-A-T-C-C-T-G-G-A-G-T-T-C-C-T-G)

casimersén

5'-{*P*-[4-({2-[2-(2-hidroxietoxi)etoxi]etoxi}carbonil)piperazin-1-il]-*N*,*N*-dimetilfosfonamidato} de *todo*-*P*-*ambo*-[2',3'-azanediil-*P*-(dimetilamino)-*P*,2',3'-tridesoxi-2',3'-seco](2'-*N*→5')(C-A-A-T-G-C-C-A-T-C-C-T-G-G-A-G-T-T-C-C-T-G)

$C_{268}H_{424}N_{124}O_{95}P_{22}$




**cenegerminum #**

cenegermin

human beta-nerve growth factor (beta-NGF)-(1-118)-peptide (non-covalent dimer) produced in *Escherichia coli*

cénégermine

facteur de croissance bêta des cellules nerveuses (beta-NGF)-(1-118)-peptide, humain, produit par *Escherichia coli*

cenegermina

factor de crecimiento beta de las células nerviosas (beta-NGF)-(1-118)-péptido humano (dímero no covalente), producido por *Escherichia coli*

$C_{583}H_{902}N_{166}O_{173}S_8$

```
SSSHPIFHRG EFSVCDSVSV WVGDKTTATD IKGKEVMVLG EVNINNSVFK  50
QYFFETKCRD PNPVDSGCRG IDSKHWNSYC TTTHTFVKAL TMDGKQAAWR 100
FIRIDTACVC VLSRKAVR                                    118
```

Disulfide bridges position / Position des ponts disulfure / Posiciones de los puentes disulfuro
15-80 58-108 68-110

**cenplacelum**

cenplacel

Human placenta-derived adherent (PDA) cells that are culture-expanded, undifferentiated mesenchymal-like cells derived from full-term placental tissue of a human donor.
Cellular identity: Mesenchymal-like stromal cell: $CD34^-$, $CD10^+$, $CD105^+$, and $CD200^+$.
Cells lack the human leukocyte antigen (HLA) and costimulatory molecules on their membrane surface.

cenplacel

Cellules humaines adhérentes dérivées du placenta, en culture d'expansion, cellules semblables aux cellules mésenchymateuses non-différenciées dérivées de tissu placentaire à terme de donneur humain.
identité des cellules: cellules stromales semblables aux cellules mésenchymateuses: $CD34^-$, $CD10^+$, $CD105^+$, and $CD200^+$.
Les cellules sont dépourvues de l'antigène leucocytaire humain (HLA) et des molécules co-stimulantes à la surface de la membrane.

| | |
|---|---|
| cenplacel | Células humanas adherentes derivadas de la placenta (PDA) expandidas por cultivo, células semejantes a las células mesenquimales no diferenciadas derivadas del tejido placentario a término.<br>Identificación de las células: células estromales semejantes a las células mesenquimales: $CD34^-$, $CD10^+$, $CD105^+$, et $CD200^+$.<br>Las células están desprovistas del antígeno leucocitario humano (HLA) y de las moléculas coestimulantes de la superficie de la membrana |
| **cibinetidum** | |
| cibinetide | 5-oxo-L-prolyl-L-α-glutamyl-L-glutaminyl-L-leucyl-L-α-glutamyl-L-arginyl-L-alanyl-L-leucyl-L-asparaginyl-L-seryl-L-serine |
| cibinétide | 5-oxo-L-prolyl-L-α-glutamyl-L-glutaminyl-L-leucyl-L-α-glutamyl-L-arginyl-L-alanyl-L-leucyl-L-asparaginyl-L-séryl-L-sérine |
| cibinetida | 5-oxo-L-prolil-L-α-glutamil-L-glutaminil-L-leucil-L-α-glutamil-L-arginyl-L-alanil-L-leucil-L-asparaginil-L-seril-L-serina |
| | $C_{51}H_{84}N_{16}O_{21}$ |
| |  |
| **crizanlizumabum #** | |
| crizanlizumab | immunoglobulin G2-kappa, anti-[*Homo sapiens* SELP (selectin P, CD62)], humanized monoclonal antibody; gamma2 heavy chain (1-448) [humanized VH (*Homo sapiens* IGHV1-8*01 (81.60%) -(IGHD) -IGHJ4*01) [8.8.15] (1-122) -*Homo sapiens* IGHG2*02 (CH1 (123-220), hinge (221-232), CH2 K105>A (323) (233-341), CH3 (342-446), CHS (447-448)) (123-448)], (136-218')-disulfide with kappa light chain (1'-218') [humanized V-KAPPA (*Homo sapiens* IGKV1-39*01 (86.90%) -IGKJ4*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01, Km3 (112'-218')]; dimer (224-224":225-225":228-228":231-231")-tetrakisdisulfide |
| crizanlizumab | immunoglobuline G2-kappa, anti-[*Homo sapiens* SELP (sélectine P, CD62)], anticorps monoclonal humanisé; chaîne lourde gamma2 (1-448) [VH humanisé (*Homo sapiens* IGHV1-8*01 (81.60%) -(IGHD) -IGHJ4*01) [8.8.15] (1-122) -*Homo sapiens* IGHG2*02 (CH1 (123-220), charnière (221-232), CH2 K105>A (323) (233-341), CH3 (342-446), CHS (447-448)) (123-448)], (136-218')-disulfure avec la chaîne légère kappa (1'-218') [V-KAPPA humanisé (*Homo sapiens* IGKV1-39*01 (86.90%) -IGKJ4*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01, Km3 (112'-218')]; dimère (224-224":225-225":228-228":231-231")-tétrakisdisulfure |

crizanlizumab

inmunoglobulina G2-kappa, anti-[*Homo sapiens* SELP (selectina P, CD62)], anticuerpo monoclonal humanizado; cadena pesada gamma2 (1-448) [VH humanizado (*Homo sapiens* IGHV1-8*01 (81.60%) -(IGHD) -IGHJ4*01) [8.8.15] (1-122) -*Homo sapiens* IGHG2*02 (CH1 (123-220), bisagra (221-232), CH2 K105>A (323) (233-341), CH3 (342-446), CHS (447-448)) (123-448)], (136-218')-disulfuro con la cadena ligera kappa (1'-218') [V-KAPPA humanizado (*Homo sapiens* IGKV1-39*01 (86.90%) -IGKJ4*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01, Km3 (112'-218')]; dímero (224-224":225-225":228-228":231-231")-tetrakisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VKKPGASVKV SCKVSGYTFT SYDINWVRQA PGKGLEWMGW  50
IYPGDGSIKY NEKFKGRVTM TVDKSTDTAY MELSSLRSED TAVYYCARRG 100
EYGNYEGAMD YWGQGTLVTV SSASTKGPSV FPLAPCSRST SESTAALGCL 150
VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV VTVTSSNFGT 200
QTYTCNVDHK PSNTKVDKTV ERKCCVECPP CPAPPVAGPS VFLFPPKPKD 250
TLMISRTPEV TCVVVDVSHE DPEVQFNWYV DGMEVHNAKT KPREEQFNST 300
FRVVSVLTVV HQDWLNGKEY KCAVSNKGLP APIEKTISKT KGQPREPQVY 350
TLPPSREEMT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPMLD 400
SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPGK   448
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVT ITCKASQSVD YDGHSYMNWY QQKPGKAPKL  50
LIYAASNLES GVPSRFSGSG SGTDFTLTIS SLQPEDFATY YCQQSDENPL 100
TFGGGTKVEI KRTVAAPSVF IFPPSDEQLK SGTASVVCLL NNFYPREAKV 150
QWKVDNALQS GNSQESVTEQ DSKDSTYSLS STLTLSKADY EKHKVYACEV 200
THQGLSSPVT KSFNRGEC                                    218
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 149-205 262-322 368-426
22"-96" 149"-205" 262"-322" 368"-426"

Intra-L (C23-C104) 23'-92' 138'-198'
23'"-92'" 138'"-198'"

Inter-H-L (CH1 10-CL 126) 136-218' 136"-218'"

Inter-H-H (h 4, h 5, h 8, h 11) 224-224" 225-225" 228-228" 231-231"

*In addition to the isoform A, isoform A/B characterized by an inter-H-H (h 4 - CH1 10) 224-136' and an inter-H-L (h4-CL 126) 224'-218", instead of the inter-H-H (h 4 - h 4) 224-224" and of one of the two inter-H-L (CH1 10-CL 126) 136'-218".

*En plus del'isoforme A, isoforme A/B caractérisée par un inter-H-H (h 4 - CH1 10) 224-136' et un inter-H-L (h 4- CL 126) 224'-218", au lieu de l'inter-H-H (h4 - h 4) 224-224" et del'un des deux inter-H-L (CH1 10-CL 126) 136'-218".

*Además de la isoforma A, isoforma A/B caracterizado por un inter-H-H (h 4 - CH1 10) 224-116" y un inter-H-L (h 4- CL 126) 224'-218", en lugar del inter-H-H (h 4 - h 4) 224-224" y uno delos dos inter-H-L (CH1 10-CL 126) 136'-218".

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
HCH2N84.4:
298, 298"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

**cupabimodum**
cupabimod

*all-P-ambo*-2'-deoxy-*P*-thiocytidylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-2'-deoxy-*P*-thioadenylyl-(3'→5')-2'-deoxy-*P*-thioadenylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-2'-deoxy-*P*-thioadenylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-2'-deoxycytidine duplex with *all-P-ambo*-2'-deoxy-*P*-thioguanylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-2'-deoxy-*P*-thioadenylyl-(3'→5')-2'-deoxy-*P*-thioadenylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-2'-deoxy-*P*-thiocytidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thioadenylyl-(3'→5')-2'-deoxy-*P*-thioadenylyl-(3'→5')-2'-deoxy-*P*-thioadenylyl-(3'→5')-2'-

deoxy-*P*-thioguanylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-2'-deoxy-*P*-thioadenylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-2'-deoxyguanosine

cupabimod

duplex de *tout-P-ambo*-2'-déoxy-*P*-thiocytidylyl-(3'→5')-2'-déoxy-*P*-thiocytidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-déoxy-*P*-thioguanylyl-(3'→5')-2'-déoxy-*P*-thioadénylyl-(3'→5')-2'-déoxy-*P*-thioadénylyl-(3'→5')-2'-déoxy-*P*-thioguanylyl-(3'→5')-2'-déoxy-*P*-thioguanylyl-(3'→5')-2'-déoxy-*P*-thioguanylyl-(3'→5')-2'-déoxy-*P*-thioadénylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-déoxy-*P*-thiocytidylyl-(3'→5')-2'-déoxy-*P*-thiocytidylyl-(3'→5')-2'-déoxy-*P*-thiocytidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-déoxy-*P*-thiocytidylyl-(3'→5')-2'-déoxycytidine avec *tout-P-ambo*-2'-déoxy-*P*-thioguanylyl-(3'→5')-2'-déoxy-*P*-thioguanylyl-(3'→5')-2'-déoxy-*P*-thioadénylyl-(3'→5')-2'-déoxy-*P*-thioadénylyl-(3'→5')-2'-déoxy-*P*-thiocytidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-déoxy-*P*-thiocytidylyl-(3'→5')-2'-déoxy-*P*-thiocytidylyl-(3'→5')-2'-déoxy-*P*-thiocytidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-déoxy-*P*-thioadénylyl-(3'→5')-2'-déoxy-*P*-thioadénylyl-(3'→5')-2'-déoxy-*P*-thioadénylyl-(3'→5')-2'-déoxy-*P*-thioguanylyl-(3'→5')-2'-déoxy-*P*-thioguanylyl-(3'→5')-2'-déoxy-*P*-thioguanylyl-(3'→5')-2'-déoxy-*P*-thioadénylyl-(3'→5')-2'-désoxy-*P*-thioguanylyl-(3'→5')-2'-déoxyguanosine

cupabimod

duplex de *todo-P-ambo*-2'-desoxi-*P*-tiocitidilil-(3'→5')-2'-desoxi-*P*-tiocitidilil-(3'→5')-*P*-tiotimidilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-2'-desoxi-*P*-tioadenilil-(3'→5')-2'-desoxi-*P*-tioadenilil-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-2'-desoxi-*P*-tioadenilil-(3'→5')-*P*-tiotimidilil-(3'→5')-*P*-tiotimidilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-desoxi-*P*-tiocitidilil-(3'→5')-2'-desoxi-*P*-tiocitidilil-(3'→5')-2'-desoxi-*P*-tiocitidilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-desoxi-*P*-tiocitidilil-(3'→5')-2'-desoxicitidina con *todo-P-ambo*-2'-desoxi-*P*-tioguanilil-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-2'-desoxi-*P*-tioadenilil-(3'→5')-2'-desoxi-*P*-tioadenilil-(3'→5')-2'-desoxi-*P*-tiocitidilil-(3'→5')-*P*-tiotimidilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-desoxi-*P*-tiocitidilil-(3'→5')-2'-desoxi-*P*-tiocitidilil-(3'→5')-2'-desoxi-*P*-tiocitidilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-desoxi-*P*-tioadenilil-(3'→5')-2'-desoxi-*P*-tioadenilil-(3'→5')-2'-desoxi-*P*-tioadenilil-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-2'-desoxi-*P*-tioadenilil-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-2'-desoxiguanosina

$C_{389}H_{491}N_{151}O_{198}P_{38}S_{38}$

(3'-5')d(*P*-thio) (C-C-T-T-G-A-A-G-G-G-A-T-T-T-C-C-C-T-C-C)

(5'-3')d(*P*-thio) (G-G-A-A-C-T-T-C-C-C-T-A-A-A-G-G-G-A-G-G)

**daclizumabum beta #**
daclizumab beta

immunoglobulin G1-kappa, anti-[*Homo sapiens* IL2RA (interleukin 2 receptor alpha subunit, IL-2RA, TAC, p55, CD25)], humanized monoclonal antibody;

| | |
|---|---|
| | gamma1 heavy chain (1-446) [humanized VH (*Homo sapiens* IGHV1-46*01 (82.70%) -(IGHD)-IGHJ4*01) [8.8.9] (1-116) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 (117-214), hinge (215-229), CH2 (230-339), CH3 (340-444), CHS (445-446)) (117-446)], (219-213')-disulfide with kappa light chain (1'-213') [humanized V-KAPPA (*Homo sapiens* IGKV1-5*01 (84.00%) -IGKJ1*01) [5.3.9] (1'-106') -*Homo sapiens* IGKC*01, Km3 (107'-213')]; dimer (225-225":228-228")-bisdisulfide |
| daclizumab bêta | immunoglobuline G1-kappa, anti-[*Homo sapiens* IL2RA (sous-unité alpha du récepteur de l'interleukine 2, IL-2RA, TAC, p55, CD25)], anticorps monoclonal humanisé; chaîne lourde gamma1 (1-446) [VH humanisé (*Homo sapiens* IGHV1-46*01 (82.70%) -(IGHD)-IGHJ4*01) [8.8.9] (1-116) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 (117-214), charnière (215-229), CH2 (230-339), CH3 (340-444), CHS (445-446)) (117-446)], (219-213')-disulfure avec la chaîne légère kappa (1'-213') [V-KAPPA humanisé (*Homo sapiens* IGKV1-5*01 (84.00%) -IGKJ1*01) [5.3.9] (1'-106') -*Homo sapiens* IGKC*01, Km3 (107'-213')]; dimère (225-225":228-228")-bisdisulfure |
| daclizumab beta | inmunoglobulina G1-kappa, anti-[*Homo sapiens* IL2RA (subunidad alfa del receptor de la interleukina 2, IL-2RA, TAC, p55, CD25)], anticuerpo monoclonal humanizado; cadena pesada gamma1 (1-446) [VH humanizado (*Homo sapiens* IGHV1-46*01 (82.70%) -(IGHD)-IGHJ4*01) [8.8.9] (1-116) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 (117-214), bisagra (215-229), CH2 (230-339), CH3 (340-444), CHS (445-446)) (117-446)], (219-213')-disulfuro con la cadena ligera kappa (1'-213') [V-KAPPA humanizado (*Homo sapiens* IGKV1-5*01 (84.00%) -IGKJ1*01) [5.3.9] (1'-106') -*Homo sapiens* IGKC*01, Km3 (107'-213')]; dímero (225-225":228-228")-bisdisulfuro |

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VKKPGSSVKV SCKASGYTFT SYRMHWVRQA PGQGLEWIGY  50
INPSTGYTEY NQKFKDKATI TADESTNTAY MELSSLRSED TAVYYCARGG 100
GVFDYWGQGT LVTVSSASTK GPSVFPLAPS SKSTSGGTAA LGCLVKDYFP 150
EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS LSSVVTVPSS SLGTQTYICN 200
VNHKPSNTKV DKKVEPKSCD KTHTCPPCPA PELLGGPSVF LFPPKPKDTL 250
MISRTPEVTC VVVDVSHEDP EVKFNWYVDG VEVHNAKTKP REEQYNSTYR 300
VVSVLTVLHQ DWLNGKEYKC KVSNKALPAP IEKTISKAKG QPREPQVYTL 350
PPSRDELTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD 400
GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA LHNHYTQKSL SLSPGK     446
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPST LSASVGDRVT ITCSASSSIS YMHWYQQKPG KAPKLLIYTT  50
SNLASGVPAR FSGSGSGTEF TLTISSLQPD DFATYYCHQR STYPLTFGQG 100
TKVEVKRTVA APSVFIFPPS DEQLKSGTAS VVCLLNNFYP REAKVQWKVD 150
NALQSGNSQE SVTEQDSKDS TYSLSSTLTL SKADYEKHKV YACEVTHQGL 200
SSPVTKSFNR GEC                                         213
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

| | | | | |
|---|---|---|---|---|
| Intra-H (C23-C104) | 22-96 | 143-199 | 260-320 | 366-424 |
| | 22"-96" | 143"-199" | 260"-320" | 366"-424" |
| Intra-L (C23-C104) | 23'-87' | 133'-193' | | |
| | 23'"-87'" | 133'"-193" | | |
| Inter-H-L (h 5-CL 126) | 219-213' | 219"-213'" | | |
| Inter-H-H (h 11, h 14) | 225-225" | 228-228" | | |

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
296, 296"
Fucosylated complex bi-antennary NS0-type glycans with low level of high mannose glycans (sum of Man5, Man6 and Man7 <1%) / glycanes de type NS0 bi-antennaires complexes fucosylés avec un taux bas de glycanes riches en mannose (total of Man5, Man6 et Man7 <1%) / glicanos de tipo NS0 biantenarios complejos fucosilados con una baja tasa de altas glicanos manosa (total de Man5, Man6 et Man7 <1%)

**darolutamidum**

darolutamide — *N*-{(2*S*)-1-[3-(3-chloro-4-cyanophenyl)-1*H*-pyrazol-1-yl]propan-2-yl}-5-[(1*RS*)-1-hydroxyethyl]-1*H*-pyrazole-3-carboxamide

darolutamide — *N*-{(2*S*)-1-[3-(3-chloro-4-cyanophényl)-1*H*-pyrazol-1-yl]propan-2-yl}-5-[(1*RS*)-1-hydroxyéthyl]-1*H*-pyrazole-3-carboxamide

darolutamida — *N*-{(2*S*)-1-[3-(4-ciano-3-clorofenil)-1*H*-pirazol-1-il]propan-2-il}-5-[(1*RS*)-1-hidroxietil]-1*H*-pirazol-3-carboxamida

$C_{19}H_{19}ClN_6O_2$




and epimer at C*
et l'épimère en C*
y el epímero al C*

**depatuxizumabum #**

depatuxizumab — immunoglobulin G1-kappa, anti-[*Homo sapiens* EGFR (epidermal growth factor receptor, receptor tyrosine-protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB)], humanized and chimeric monoclonal antibody;
gamma1 heavy chain humanized (1-446) [humanized VH (*Homo sapiens* IGHV4-30-4*01 (84.50%) -(IGHD)-IGHJ4*01) [9.7.9] (1-116) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 (117-214), hinge (215-229),CH2 (230-339), CH3 (340-444), CHS (445-446)) (117-446)], (219-214')-disulfide with kappa light chain chimeric (1'-214') [*Mus musculus* V-KAPPA (*Mus musculus* IGKV14-100*01 -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimer (225-225":228-228")-bisdisulfide

dépatuxizumab — immunoglobuline G1-kappa, anti-[*Homo sapiens* EGFR (Récepteur du facteur de croissance épidermique, récepteur tyrosine-protéine kinase erb-1, ERBB1, HER1, HER-1, ERBB)], anticorps monoclonal humanisé et chimérique;
chaîne lourde gamma1 humanisée (1-446) [VH humanisé (*Homo sapiens* IGHV4-30-4*01 (84.50%) -(IGHD)-IGHJ4*01) [9.7.9] (1-116) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 (117-214), charnière (215-229),CH2 (230-339), CH3 (340-444), CHS (445-446)) (117-446)], (219-214')-disulfure avec la chaîne légère kappa chimérique (1'-214') [*Mus musculus* V-KAPPA (*Mus musculus* IGKV14-100*01 -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimère (225-225":228-228")-bisdisulfure

depatuxizumab — inmunoglobulina G1-kappa, anti-[*Homo sapiens* EGFR (Receptor del factor de crecimiento epidérmico, receptor tirosina-proteína kinasa erb-1, ERBB1, HER1, HER-1, ERBB)], anticuerpo monoclonal humanizado y quimérico;

cadena pesada gamma1 humanizada (1-446) [VH humanizado (*Homo sapiens* IGHV4-30-4*01 (84.50%) -(IGHD)-IGHJ4*01) [9.7.9] (1-116) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 (117-214), bisagra (215-229),CH2 (230-339), CH3 (340-444), CHS (445-446)) (117-446)], (219-214')-disulfuro con la cadena ligera kappa quimérica (1'-214') [*Mus musculus* V-KAPPA (*Mus musculus* IGKV14-100*01 -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dímero (225-225":228-228")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLQESGPG LVKPSQTLSL TCTVSGYSIS SDFAWNWIRQ PPGKGLEWMG  50
YISYSGNTRY QPSLKSRITI SRDTSKNQFF LKLNSVTAAD TATYYCVTAG 100
RGFPYWGQGT LVTVSSASTK GPSVFPLAPS SKSTSGGTAA LGCLVKDYFP 150
EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS LSSVVTVPSS SLGTQTYICN 200
VNHKPSNTKV DKKVEPKSCD KTHTCPPCPA PELLGGPSVF LFPPKPKDTL 250
MISRTPEVTC VVVDVSHEDP EVKFNWYVDG VEVHNAKTKP REEQYNSTYR 300
VVSVLTVLHQ DWLNGKEYKC KVSNKALPAP IEKTISKAKG QPREPQVYTL 350
PPSRDELTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD 400
GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA LHNHYTQKSL SLSPGK     446
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS MSVSVGDRVT ITCHSSQDIN SNIGWLQQKP GKSFKGLIYH  50
GTNLDDGVPS RFSGSGSGTD YTLTISSLQP EDFATYYCVQ YAQFPWTFGG 100
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

| | | | | |
|---|---|---|---|---|
| Intra-H (C23-C104) | 22-96 | 143-199 | 260-320 | 366-424 |
| | 22"-96" | 143"-199" | 260"-320" | 366"-424" |
| Intra-L (C23-C104) | 23'-88' | 134'-194' | | |
| | 23'"-88'" | 134'"-194'" | | |
| Inter-H-L (h 5-CL 126) | 219-214' | 219"-214'" | | |
| Inter-H-H (h 11, h 14) | 225-225" | 228-228" | | |

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
296, 296"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

**depatuxizumabum mafodotinum #**

depatuxizumab mafodotin

immunoglobulin G1-kappa, anti-[*Homo sapiens* EGFR (epidermal growth factor receptor, receptor tyrosine-protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB)], humanized and chimeric monoclonal antibody conjugated to auristatin F;
gamma1 heavy chain humanized (1-446) [humanized VH (*Homo sapiens* IGHV4-30-4*01 (84.50%) -(IGHD)-IGHJ4*01) [9.7.9] (1-116) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 (117-214), hinge (215-229), CH2 (230-339), CH3 (340-444), CHS (445-446)) (117-446)], (219-214')-disulfide with kappa light chain chimeric (1'-214') [*Mus musculus* V-KAPPA (*Mus musculus* IGKV14-100*01 -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimer (225-225":228-228")-bisdisulfide; conjugated, on an average of 4 cysteinyl, to monomethylauristatin F (MMAF), via a noncleavable maleimidocaproyl (mc) linker
For the *mafodotin* part, please refer to the document *"INN for pharmaceutical substances: Names for radicals, groups and others"*.*

dépatuxizumab mafodotine

immunoglobuline G1-kappa, anti-[*Homo sapiens* EGFR (Récepteur du facteur de croissance épidermique, récepteur tyrosine-protéine kinase erb-1, ERBB1, HER1, HER-1, ERBB)], anticorps monoclonal humanisé et chimérique conjugué à l'auristatine F;

chaîne lourde gamma1 humanisée (1-446) [VH humanisé (*Homo sapiens* IGHV4-30-4*01 (84.50%) -(IGHD)-IGHJ4*01) [9.7.9] (1-116) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 (117-214), charnière (215-229),CH2 (230-339), CH3 (340-444), CHS (445-446)) (117-446)], (219-214')-disulfure avec la chaîne légère kappa chimérique (1'-214') [*Mus musculus* V-KAPPA (*Mus musculus* IGKV14-100*01 -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimère (225-225":228-228")-bisdisulfure; conjugué, sur 4 cystéinyl en moyenne, au monométhylauristatine F (MMAF), via un linker maléimidocaproyl (mc) non clivable

Pour la partie *mafodotine*, veuillez-vous référer au document *"INN for pharmaceutical substances: Names for radicals, groups and others"*.*

depatuxizumab mafodotina

inmunoglobulina G1-kappa, anti-[*Homo sapiens* EGFR (Receptor del factor de crecimiento epidérmico, receptor tirosina-proteína kinasa erb-1, ERBB1, HER1, HER-1, ERBB)], anticuerpo monoclonal humanizado y quimérico conjugado con la auristatina F;
cadena pesada gamma1 humanizada (1-446) [VH humanizado (*Homo sapiens* IGHV4-30-4*01 (84.50%) -(IGHD)-IGHJ4*01) [9.7.9] (1-116) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 (117-214), bisagra (215-229),CH2 (230-339), CH3 (340-444), CHS (445-446)) (117-446)], (219-214')-disulfuro con la cadena ligera kappa quimérica (1'-214') [*Mus musculus* V-KAPPA (*Mus musculus* IGKV14-100*01 -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dímero (225-225":228-228")-bisdisulfuro; conjugado, en 4 grupos cisteinil por término medio, con monometilauristatina F (MMAF), mediante un conector no escindible de tipo maleimidocaproil (mc)

Por la parte *mafodotina*, por favor vaya al documento *"INN for pharmaceutical substances: Names for radicals, groups and others"*.*

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLQESGPG LVKPSQTLSL TCTVSGYSIS SDFAWNWIRQ PPGKGLEWMG  50
YISYSGNTRY QPSLKSRITI SRDTSKNQFF LKLNSVTAAD TATYYCVTAG 100
RGFPYWGQGT LVTVSSASTK GPSVFPLAPS SKSTSGGTAA LGCLVKDYFP 150
EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS LSSVVTVPSS SLGTQTYICN 200
VNHKPSNTKV DKKVEPKSCD KTHTCPPCPA PELLGGPSVF LFPPKPKDTL 250
MISRTPEVTC VVVDVSHEDP EVKFNWYVDG VEVHNAKTKP REEQYNSTYR 300
VVSVLTVLHQ DWLNGKEYKC KVSNKALPAP IEKTISKAKG QPREPQVYTL 350
PPSRDELTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD 400
GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA LHNHYTQKSL SLSPGK     446
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS MSVSVGDRVT ITCHSSQDIN SNIGWLQQKP GKSFKGLIYH  50
GTNLDDGVPS RFSGSGSGTD YTLTISSLQP EDFATYYCVQ YAQFPWTFGG 100
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

| | | | | |
|---|---|---|---|---|
| Intra-H (C23-C104) | 22-96 | 143-199 | 260-320 | 366-424 |
| | 22"-96" | 143"-199" | 260"-320" | 366"-424" |
| Intra-L (C23-C104) | 23'-88' | 134'-194' | | |
| | 23'"-88'" | 134'"-194'" | | |
| Inter-H-L (h 5-CL 126)* | 219-214' | 219"-214'" | | |
| Inter-H-H (h 11, h 14)* | 225-225" | 228-228" | | |

*Two or three of the inter-chain disulfide bridges are not present, an average of 4 cysteinyl being conjugated each via a thioether bond to a drug linker.

*Deux ou trois des ponts disulfures inter-chaînes ne sont pas présents, 4 cystéinyl en moyenne étant chacun conjugué via une liaison thioéther à un linker-principe actif.

*Faltan dos o tres puentes disulfuro inter-catenarios, una media de 4 cisteinil está conjugada a conectores de principio activo.

**dexisometheptenum**

dexisometheptene (2*R*)-*N*,6-dimethylhept-5-en-2-amine

dexisométhéptène (2*R*)-*N*,6-diméthylhept-5-én-2-amine

dexisometepteno (2*R*)-*N*,6-dimetilhept-5-en-2-amina

$C_9H_{19}N$



**dezamizumabum #**

dezamizumab immunoglobulin G1-kappa, anti-[*Homo sapiens* APCS (amyloid P component serum, serum amyloid P component, SAP, pentraxin-2, PTX2)], humanized monoclonal antibody;
gamma1 heavy chain (1-452) [humanized VH (*Homo sapiens* IGHV1-69*02 (85.70%) -(IGHD)-IGHJ5*01) [8.8.15] (1-122) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 (123-220), hinge (221-235),CH2 (236-345), CH3 (346-450), CHS (451-452)) (123-452)], (225-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens* IGKV1-39*01 (85.30%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimer (231-231":234-234")-bisdisulfide

dézamizumab immunoglobuline G1-kappa, anti-[*Homo sapiens* APCS (composant amyloïde P du sérum, composant amyloïde P sérique, APS, pentraxine-2, PTX2)], anticorps monoclonal humanisé;
chaîne lourde gamma1 (1-452) [VH humanisé (*Homo sapiens* IGHV1-69*02 (85.70%) -(IGHD)-IGHJ5*01) [8.8.15] (1-122) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 (123-220), charnière (221-235),CH2 (236-345), CH3 (346-450), CHS (451-452)) (123-452)], (225-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (*Homo sapiens* IGKV1-39*01 (85.30%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimère (231-231":234-234")-bisdisulfure

dezamizumab inmunoglobulina G1-kappa, anti-[*Homo sapiens* APCS (componente amiloide P del suero, componente amiloide P serico, APS, pentraxina-2, PTX2)], anticuerpo monoclonal humanizado;
cadena pesada gamma1 (1-452) [VH humanizado (*Homo sapiens* IGHV1-69*02 (85.70%) -(IGHD)-IGHJ5*01) [8.8.15] (1-122) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 (123-220), bisagra (221-235),CH2 (236-345), CH3 (346-450), CHS (451-452)) (123-452)], (225-214')-disulfuro con la cadena lígera kappa (1'-214') [V-KAPPA humanizado (*Homo sapiens* IGKV1-39*01 (85.30%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dímero (231-231":234-234")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VKKPGSSVKV SCKASGFTFA TYNMHWVRQA PGQGLEWMGY  50
IYPGDGNANY NQQFKGRVTI TADKSTSTAY MELSSLRSED TAVYYCARGD 100
FDYDGGYYFD SWGQGTLVTV SSASTKGPSV FPLAPSSKST SGGTAALGCL 150
VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV VTVPSSSLGT 200
QTYICNVNHK PSNTKVDKKV EPKSCDKTHT CPPCPAPELL GGPSVFLFPP 250
KPKDTLMISR TPEVTCVVVD VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ 300
YNSTYRVVSV LTVLHQDWLN GKEYKCKVSN KALPAPIEKT ISKAKGQPRE 350
PQVYTLPPSR DELTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTP 400
PVLDSDGSFF LYSKLTVDKS RWQQGNVFSC SVMHEALHNH YTQKSLSLSP 450
GK                                                      452
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVT ITCRASENIY SYLAWYQQKP GKAPKLLIHN  50
AKTLAEGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQH HYGAPLTFGQ 100
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 149-205 266-326 372-430
22"-96" 149"-205" 266"-326" 372"-430"
Intra-L (C23-C104) 23'-88' 134'-194'
23"'-88"' 134"'-194"'
Inter-H-L (h 5-CL 126) 225-214' 225"-214"'
Inter-H-H (h 11, h 14) 231-231" 234-234"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
302, 302"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

**dinutuximabum beta #**

dinutuximab beta

immunoglobulin G1-kappa, anti-[*Homo sapiens* ganglioside GD2 (disialoganglioside GD2)], chimeric monoclonal antibody;
gamma1 heavy chain (1-443) [*Mus musculus* VH (IGHV1S135*01 -(IGHD)-IGHJ4*01) [8.8.6] (1-113) -*Homo sapiens* IGHG1*03, G1m3 (CH1 (114-211), hinge (212-226), CH2 (227-336), CH3 (337-441), CHS (442-443)) (114-443)], (216-220')-disulfide with kappa light chain (1'-220') [*Mus musculus* V-KAPPA (IGKV1-110*01 -IGKJ5*01) [11.3.10] (1'-113') -*Homo sapiens* IGKC*01, Km3 (114'-220')]; dimer (222-222":225-225")-bisdisulfide

dinutuximab bêta

immunoglobuline G1-kappa, anti-[*Homo sapiens* ganglioside GD2 (disialoganglioside GD2)], anticorps monoclonal chimérique;
chaîne lourde gamma1 (1-443) [*Mus musculus* VH (IGHV1S135*01 -(IGHD)-IGHJ4*01) [8.8.6] (1-113) -*Homo sapiens* IGHG1*03, G1m3 (CH1 (114-211), charnière (212-226), CH2 (227-336), CH3 (337-441), CHS (442-443)) (114-443)], (216-220')-disulfure avec la chaîne légère kappa (1'-220') [*Mus musculus* V-KAPPA (IGKV1-110*01 -IGKJ5*01) [11.3.10] (1'-113') -*Homo sapiens* IGKC*01, Km3 (114'-220')]; dimère (222-222":225-225")-bisdisulfure

dinutuximab beta

inmunoglobulina G1-kappa, anti-[*Homo sapiens* ganglió sido GD2 (disialoganglió sido GD2)], anticuerpo monoclonal quimérico;

| | |
|---|---|
| | gamma1 heavy chain (1-443) [*Mus musculus* VH (IGHV1S135*01 -(IGHD)-IGHJ4*01) [8.8.6] (1-113) -*Homo sapiens* IGHG1*03, G1m3 (CH1 (114-211), hinge (212-226), CH2 (227-336), CH3 (337-441), CHS (442-443)) (114-443)], (216-220')-disulfide with kappa light chain (1'-220') [*Mus musculus* V-KAPPA (IGKV1-110*01 -IGKJ5*01) [11.3.10] (1'-113') -*Homo sapiens* IGKC*01, Km3 (114'-220')]; dimer (222-222":225-225")-bisdisulfide |
| dinutuximab bêta | immunoglobuline G1-kappa, anti-[*Homo sapiens* ganglioside GD2 (disialoganglioside GD2)], anticorps monoclonal chimérique;<br>chaîne lourde gamma1 (1-443) [*Mus musculus* VH (IGHV1S135*01 -(IGHD)-IGHJ4*01) [8.8.6] (1-113) -*Homo sapiens* IGHG1*03, G1m3 (CH1 (114-211), charnière (212-226), CH2 (227-336), CH3 (337-441), CHS (442-443)) (114-443)], (216-220')-disulfure avec la chaîne légère kappa (1'-220') [*Mus musculus* V-KAPPA (IGKV1-110*01 -IGKJ5*01) [11.3.10] (1'-113') -*Homo sapiens* IGKC*01, Km3 (114'-220')]; dimère (222-222":225-225")-bisdisulfure |
| dinutuximab beta | inmunoglobulina G1-kappa, anti-[*Homo sapiens* gangliósido GD2 (disialogangliósido GD2)], anticuerpo monoclonal quimérico;<br>cadena pesada gamma1 (1-443) [*Mus musculus* VH (IGHV1S135*01 -(IGHD)-IGHJ4*01) [8.8.6] (1-113) -*Homo sapiens* IGHG1*03, G1m3 (CH1 (114-211), bisagra (212-226), CH2 (227-336), CH3 (337-441), CHS (442-443)) (114-443)], (216-220')-disulfuro con la cadena ligera kappa (1'-220') [*Mus musculus* V-KAPPA (IGKV1-110*01 -IGKJ5*01) [11.3.10] (1'-113') -*Homo sapiens* IGKC*01, Km3 (114'-220')]; dímero (222-222":225-225")-bisdisulfuro |

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLLQSGPE LEKPGASVMI SCKASGSSFT GYNMNWVRQN IGKSLEWIGA  50
IDPYYGGTSY NQKFKGRATL TVDKSSSTAY MHLKSLTSED SAVYYCVSGM 100
EYWGQGTSVT VSSASTKGPS VFPLAPSSKS TSGGTAALGC LVKDYFPEPV 150
TVSWNSGALT SGVHTFPAVL QSSGLYSLSS VVTVPSSSLG TQTYICNVNH 200
KPSNTKVDKR VEPKSCDKTH TCPPCPAPEL LGGPSVFLFP PKPKDTLMIS 250
RTPEVTCVVV DVSHEDPEVK FNWYVDGVEV HNAKTKPREE QYNSTYRVVS 300
VLTVLHQDWL NGKEYKCKVS NKALPAPIEK TISKAKGQPR EPQVYTLPPS 350
REEMTKNQVS LTCLVKGFYP SDIAVEWESN GQPENNYKTT PPVLDSDGSF 400
FLYSKLTVDK SRWQQGNVFS CSVMHEALHN HYTQKSLSLS PGK        443
```

Light chain / Chaîne légère / Cadena ligera

```
EIVMTQSPAT LSVSPGERAT LSCRSSQSLV HRNGNTYLHW YLQKPGQSPK  50
LLIHKVSNRF SGVPDRFSGS GSGTDFTLKI SRVEAEDLGV YFCSQSTHVP 100
PLTFGAGTKL ELKRTVAAPS VFIFPPSDEQ LKSGTASVVC LLNNFYPREA 150
KVQWKVDNAL QSGNSQESVT EQDSKDSTYS LSSTLTLSKA DYEKHKVYAC 200
EVTHQGLSSP VTKSFNRGEC                                  220
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```
Intra-H (C23-C104)  22-96    140-196     257-317   363-421
                    22"-96"  140"-196"   257"-317" 363"-421"
Intra-L (C23-C104)  23'-93'  140'-200'
                    23'"-93'" 140'"-200'"
Inter-H-L (h 5-CL 126)  216-220'  216"-220'"
Inter-H-H (h 11, h 14)  222-222"  225-225"
```

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
293, 293"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

| | |
|---|---|
| **diroximeli fumaras**<br>diroximel fumarate | 2-(2,5-dioxopyrrolidin-1-yl)ethyl methyl (2*E*)-but-2-enedioate |

fumarate de diroximel

(2*E*)-but-2-ènedioate de 2-(2,5-dioxopyrrolidin-1-yl)éthyle et de méthyle

fumarato de diroximel

(2*E*)-but-2-enodioato de 2-(2,5-dioxopirrolidin-1-il)etilo y de metilo

$C_{11}H_{13}NO_6$



**elacestrantum**

elacestrant

(6*R*)-6-{2-[ethyl({4-[2-(ethylamino)ethyl]phenyl}methyl)amino]-4-methoxyphenyl}-5,6,7,8-tetrahydronaphthalen-2-ol

élacestrant

(6*R*)-6-{2-[éthyl({4-[2-(éthylamino)éthyl]phényl}méthyl)amino]-4-méthoxyphényl}-5,6,7,8-tétrahydronaphtalén-2-ol

elacestrant

(6*R*)-6-{2-[etil({4-[2-(etilamino)etil]fenil}metil)amino]-4-metoxifenil}-5,6,7,8-tetrahidronaftalen-2-ol

$C_{30}H_{38}N_2O_2$



**elapegademasum #**

elapegademase

[Cys$^{74}$>Ser,Ala$^{245}$>Thr]adenosine deaminase (*Bos taurus*, bovine)-(1-356)-peptide, produced in *Escherichia coli*, substituted on $N^2$ of the *N*-terminal alanyl residue ($A^1$) and on $N^6$ of lysyl residues (K) with an average of approximately 13 ω-methoxypoly(oxyethylene)-α-carbonyl groups (~5 kDa each)

élapégadémase

[Cys$^{74}$>Ser,Ala$^{245}$>Thr]adénosine déaminase (*Bos taurus*, bovine)-(1-356)-peptide, produit par *Escherichia coli*, substitué sur les $N^2$ du résidu alanyl *N*-terminal ($A^1$) et sur les $N^6$ des résidus lysyl (K) avec en en moyenne 13 groupes ω-métoxipoli(oxietileno)-α-carbonyle (~5 kDa chacun) approximativement

elapegademasa

[Cys$^{74}$>Ser,Ala$^{245}$>Thr]adenosina deaminasa (*Bos taurus*, bovino)-(1-356)-péptido, producido por *Escherichia coli*, sustituido en los $N^2$ del resto alanil*N*-terminal ($A^1$) y en los $N^6$ de los restos lisil (K) con una media de 13 grupos ω-metoxipoli(oxietileno)-α-carbonilo (~5 kDa cada uno de ellos) de forma aproximada

Sequence / Séquence / Secuencia

```
AQTPAFNKPK VELHVHLDGA IKPETILYYG RKRGIALPAD TPEELQNIIG  50
MDKPLSLPEF LAKFDYYMPA IAGSREAVKR IAYEFVEMKA KDGVVYVEVR 100
YSPHLLANSK VEPIPWNQAE GDLTPDEVVS LVNQGLQEGE RDFGVKVRSI 150
LCCMRHQPSW SSEVVELCKK YREQTVVAID LAGDETIEGS SLFPGHVKAY 200
AEAVKSGVHR TVHAGEVGSA NVVKEAVDTL KTERLGHGYH TLEDTTLYNR 250
LRQENMHFEV CPWSSYLTGA WKPDTEHPVV RFKNDQVNYS LNTDDPLIFK 300
STLDTDYQMT KNEMGFTEEE FKRLNINAAK SSFLPEDEKK ELLDLLYKAY 350
GMPSPA                                                 356
```

Potential pegylated residues / Résidus pégylés potentiels / Restos pegilados potenciales




**elezanumabum #**

elezanumab

immunoglobulin G1-lambda1, anti-[*Homo sapiens* RGMA (repulsive guidance molecule family member a, repulsive guidance molecule A, RGMa)], *Homo sapiens* monoclonal antibody;
gamma1 heavy chain (1-450) [*Homo sapiens* VH (IGHV1-18*01 (92.90%) -(IGHD) -IGHJ6*03) [8.8.13](1-120) -IGHG1*01, Gm17,1 (CH1 (121-218), hinge (219-233), CH2 L1.2>A (238), L1.3>A (237), T14>Q (253) (234-343), CH3 M107>L (431) (344-448),CHS (449-450)) (121-450)], (223-214')-disulfide with lambda1 light chain (1'-215') [*Homo sapiens* V-LAMBDA (IGLV2-11*01 (89.90%) -IGLJ2*01) [9.3.9] (1'-109') -IGLC2*01 (110'-215')]; dimer (229-229'':232-232'')-bisdisulfide

élézanumab

immunoglobuline G1-lambda1, anti-[*Homo sapiens* RGMA (membre a de la famille de molécules d'orientation répulsive, molécule d'orientation répulsive A, RGMa)], *Homo sapiens* anticorps monoclonal;
chaîne lourde gamma1 (1-450) [*Homo sapiens* VH (IGHV1-18*01 (92.90%) -(IGHD) -IGHJ6*03) [8.8.13] (1-120) -IGHG1*01, Gm17,1 (CH1 (121-218), charnière (219-233),CH2 L1.2>A (238), L1.3>A (237), T14>Q (253) (234-343), CH3 M107>L (431) (344-448), CHS (449-450)) (121-450)], (223-214')-disulfure avec la chaîne légère lambda1 (1'-215') [*Homo sapiens* V-LAMBDA (IGLV2-11*01 (89.90%) -IGLJ2*01) [9.3.9] (1'-109') -IGLC2*01 (110'-215')]; dimère (229-229'':232-232'')-bisdisulfure

elezanumab

inmunoglobulina G1-lambda1, anti-[*Homo sapiens* RGMA (miembro de la familia de moléculas de orientación repulsiva, molécula de orientación repulsiva A, RGMa)], *Homo sapiens* anticuerpo monoclonal;

cadena pesada gamma1 (1-450) [*Homo sapiens* VH (IGHV1-18*01 (92.90%) -(IGHD) -IGHJ6*03) [8.8.13] (1-120) -IGHG1*01, Gm17,1 (CH1 (121-218), bisagra (219-233),CH2 L1.2>A (238), L1.3>A (237), T14>Q (253) (234-343), CH3 M107>L (431) (344-448), CHS (449-450)) (121-450)], (223-214')-disulfuro con la cadena ligera lambda1 (1'-215') [*Homo sapiens* V-LAMBDA (IGLV2-11*01 (89.90%) -IGLJ2*01) [9.3.9] (1'-109') -IGLC2*01 (110'-215')]; dímero (229-229'':232-232'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVQSGAE VKKPGASVKV SCKASGYTFT SHGISWVRQA PGQGLDWMGW  50
ISPYSGNTNY AQKLQGRVTM TTDTSTSTAY MELSSLRSED TAVYYCARVG 100
SGPYYYMDVW GQGTLVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK 150
DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT 200
YICNVNHKPS NTKVDKKVEP KSCDKTHTCP PCPAPEAAGG PSVFLFPPKP 250
KDQLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN 300
STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ 350
VYTLPPSREE MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV 400
LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV LHEALHNHYT QKSLSLSPGK 450
```

Light chain / Chaîne légère / Cadena ligera

```
QSALTQPRSV SGSPGQSVTI SCTGTSSSVG DSIYVSWYQQ HPGKAPKLML  50
YDVTKRPSGV PDRFSGSKSG NTASLTISGL QAEDEADYYC YSYAGTDTLF 100
GGGTKVTVLG QPKAAPSVTL FPPSSEELQA NKATLVCLIS DFYPGAVTVA 150
WKADSSPVKA GVETTTPSKQ SNNKYAASSY LSLTPEQWKS HRSYSCQVTH 200
EGSTVEKTVA PTECS                                       215
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

| | | | | |
|---|---|---|---|---|
| Intra-H (C23-C104) | 22-96 | 147-203 | 264-324 | 370-428 |
| | 22''-96'' | 147''-203'' | 264''-324'' | 370''-428'' |
| Intra-L (C23-C104) | 22'-90' | 137'-196' | | |
| | 22'''-90''' | 137'''-196''' | | |
| Inter-H-L (h 5-CL 126) | 223-214' | 223''-214''' | | |
| Inter-H-H (h 11, h 14) | 229-229' | 232-232'' | | |

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
300, 300''
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

**elivaldogenum tavalentivecum #**
elivaldogene tavalentivec

A VSV-G*-pseudotyped self-inactivating HIV-1-derived lentiviral vector (pLBP100 hALD) encoding human adrenoleukodystrophy (ALD) protein (ABCD1 gene) under the control of a modified myeloproliferative sarcoma virus promoter (MND**)
* VSV-G = vesicular stomatitis virus G envelope protein
** MND = myeloproliferative sarcoma virus enhancer with negative control region deleted, dl587rev primer-binding site substituted

élivaldogène tavalentivec

vecteur lentiviral dérivé du VIH-1 auto-inactivant (pLBP100 hALD) pseudotypé VSV-G*, codant pour la protéine humaine (gène ABCD1) de l'adrénoleucodystrophie (ALD), sous le contrôle d'un promoteur du virus du sarcome myéloprolifératif modifié (MND**)
* VSV-G = glycoprotéine G de l'enveloppe du virus de la stomatite vésiculaire
** MND = promoteur du virus du sarcome myéloprolifératif dont la région de contrôle négatif a été supprimée, le site de liaison de l'amorce substitué par dl587rev

| | |
|---|---|
| elivaldogén tavalentivec | vector lentiviral derivado del VIH-1 auto-inactivante (pLBP100 hALD) pseudotipo VSV-G*, que codifica para la proteína humana (gen ABCD1) de la adrenoleucodistrofia (ALD), bajo el control de un promotor del virus del sarcoma mieloproliferativo modificado (MND**)<br>* VSV-G = glicoproteína G del virus de la estomatitis vesicular<br>** MND = promotor del virus del sarcoma mieloproliferativo bajo la región de control negativo ha sido suprimido, el sitio de enlace del inicio substituido por dl587rev |
| **eltrapuldencelum** | |
| eltrapuldencel | Autologous dendritic cells loaded with antigen from self-renewing, proliferating autologous irradiated tumour cells, in a solution of granulocyte-macrophage colony stimulating factor (GM-CSF).<br>Patient's monocytes are collected from peripheral blood by leukocyte apheresis, led to differentiate into dendritic cells in culture and incubated with expanded irradiated autologous self-renewing, cancer-initiating cells (CICs). |
| eltrapuldencel | cellules dendritiques autologues chargées avec un antigène de cellules tumorales autologues, auto-renouvellantes, proliférantes et irradiées, dans une solution de facteur de stimulation des colonies de granulocytes et de macrophages (GM-CSF).<br>Les monocytes des patients sont recueillis par leucaphérèse à partir de sang périphérique, conduits à se différencier en cellules dendritiques par culture et incubés avec des cellules initiatrices de cancer (CICs) autologues ayant des propriétés d'auto-renouvellement. |
| eltrapuldencel | células dendríticas autólogas cargadas con un antígeno de células tumorales autólogas, autorenovables, proliferantes e irradiadas, en una solución de factor de estimulación de colonias de granulocitos y de macrófagos (GM-CSF).<br>Los monocitos de los pacientes se recogen por leucoféresis a partir de sangre periférica, conducidos a diferenciarse en células dendríticas para el cultivo e incubados con las células iniciadoras de cáncer (CICs) autólogas con las propiedades de autorenovación. |
| **emapalumabum #** | |
| emapalumab | immunoglobulin G1-lambda1, anti-[*Homo sapiens* IFNG (interferon gamma, IFN gamma)], *Homo sapiens* monoclonal antibody;<br>gamma1 heavy chain (1-453) [*Homo sapiens* VH (IGHV3-23*01 -(IGHD) -IGHJ5*02) [8.8.16] (1-123) -IGHG1*03, Gm17,1 (CH1 (124-221), hinge (222-236), CH2 (237-346), CH3 (347-451), CHS (452-453)) (124-453)], (226-216')-disulfide with lambda1 light chain (1'-217') [*Homo sapiens* V-LAMBDA (IGLV6-57*01 (99.00%) -IGLJ3*02) [8.3.10] (1'-111') -IGLC2*01 (112'-217')]; dimer (232-232":235-235")-bisdisulfide |

émapalumab

immunoglobuline G1-lambda1, anti-[*Homo sapiens* IFNG (interféron gamma, IFN gamma)], *Homo sapiens* anticorps monoclonal;
chaîne lourde gamma1 (1-453) [*Homo sapiens* VH (IGHV3-23*01 -(IGHD) -IGHJ5*02) [8.8.16] (1-123) - IGHG1*03, Gm17,1 (CH1 (124-221), charnière (222-236), CH2 (237-346), CH3 (347-451), CHS (452-453)) (124-453)],(226-216')-disulfure avec la chaîne légère lambda1 (1'-217') [*Homo sapiens* V-LAMBDA (IGLV6-57*01 (99.00%) -IGLJ3*02) [8.3.10] (1'-111') -IGLC2*01 (112'-217')]; dimère (232-232":235-235")-bisdisulfure

emapalumab

inmunoglobulina G1-lambda1, anti-[*Homo sapiens* IFNG (interferón gamma, IFN gamma)], *Homo sapiens* anticuerpo monoclonal;
cadena pesada gamma1 (1-453) [*Homo sapiens* VH (IGHV3-23*01 -(IGHD) -IGHJ5*02) [8.8.16] (1-123) - IGHG1*03, Gm17,1 (CH1 (124-221), bisagra (222-236), CH2 (237-346), CH3 (347-451), CHS (452-453)) (124-453)], (226-216')-disulfuro con la cadena ligera lambda1 (1'-217') [*Homo sapiens* V-LAMBDA (IGLV6-57*01 (99.00%) -IGLJ3*02) [8.3.10] (1'-111') -IGLC2*01 (112'-217')]; dímero (232-232":235-235")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLLESGGG LVQPGGSLRL SCAASGFTFS SYAMSWVRQA PGKGLEWVSA  50
ISGSGGSTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKDG 100
SSGWYVPHWF DPWGQGTLVT VSSASTKGPS VFPLAPSSKS TSGGTAALGC 150
LVKDYFPEPV TVSWNSGALT SGVHTFPAVL QSSGLYSLSS VVTVPSSSLG 200
TQTYICNVNH KPSNTKVDKR VEPKSCDKTH TCPPCPAPEL LGGPSVFLFP 250
PKPKDTLMIS RTPEVTCVVV DVSHEDPEVK FNWYVDGVEV HNAKTKPREE 300
QYNSTYRVVS VLTVLHQDWL NGKEYKCKVS NKALPAPIEK TISKAKGQPR 350
EPQVYTLPPS REEMTKNQVS LTCLVKGFYP SDIAVEWESN GQPENNYKTT 400
PPVLDSDGSF FLYSKLTVDK SRWQQGNVFS CSVMHEALHN HYTQKSLSLS 450
PGK                                                     453
```

Light chain / Chaîne légère / Cadena ligera

```
NFMLTQPHSV SESPGKTVTI SCTRSSGSIA SNYVQWYQQR PGSSPTTVIY  50
EDNQRPSGVP DRFSGSIDSS SNSASLTISG LKTEDEADYY CQSYDGSNRW 100
MFGGGTKLTV LGQPKAAPSV TLFPPSSEEL QANKATLVCL ISDFYPGAVT 150
VAWKADSSPV KAGVETTTPS KQSNNKYAAS SYLSLTPEQW KSHRSYSCQV 200
THEGSTVEKT VAPTECS                                      217
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

| | | | | |
|---|---|---|---|---|
| Intra-H (C23-C104) | 22-96 | 150-206 | 267-327 | 373-431 |
| | 22"-96" | 150"-206" | 267-327" | 373"-431" |
| Intra-L (C23-C104) | 22'-91' | 139'-198' | | |
| | 22'"-91'" | 139'"-198'" | | |
| Inter-H-L (h 5-CL 126) | 226-216' | 226"-216'" | | |
| Inter-H-H (h 11, h 14) | 232-232' | 235-235" | | |

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
303, 303"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

**ensartinibum**

ensartinib

6-amino-5-[(1*R*)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-*N*-{4-[(3*R*,5*S*)-3,5-dimethylpiperazine-1-carbonyl]phenyl}pyridazine-3-carboxamide

ensartinib

6-amino-5-[(1*R*)-1-(2,6-dichloro-3-fluorophényl)éthoxy]-*N*-{4-[(3*R*,5*S*)-3,5-diméthylpiperazine-1-carbonyl]phényl}pyridazine-3-carboxamide

ensartinib

6-amino-5-[(1*R*)-1-(2,6-dicloro-3-fluorofenil)etoxi]-*N*-{4-[(3*R*,5*S*)-3,5-dimetilpiperazina-1-carbonil]fenil}piridazina-3-carboxamida

$C_{26}H_{27}Cl_2FN_6O_3$



**enzaplatovirum**

enzaplatovir — (10a*R*)-1-(3-methyl-1,2-oxazole-4-carbonyl)-10a-(6-methylpyridin-3-yl)-2,3,10,10a-tetrahydro-1*H*,5*H*-imidazo[1,2-*a*]pyrrolo[1,2-*d*]pyrazin-5-one

enzaplatovir — (10a*R*)-1-(3-méthyl-1,2-oxazole-4-carbonyl)-10a-(6-méthylpyridin-3-yl)-2,3,10,10a-tétrahydro-1*H*,5*H*-imidazo[1,2-*a*]pyrrolo[1,2-*d*]pyrazin-5-one

enzaplatovir — (10a*R*)-1-(3-metil-1,2-oxazol-4-carbonil)-10a-(6-metilpiridin-3-il)-2,3,10,10a-tetrahidro-1*H*,5*H*-imidazo[1,2-*a*]pirrolo[1,2-*d*]pirazin-5-ona

$C_{20}H_{19}N_5O_3$



**epertinibum**

epertinib — *N*-{3-chloro-4-[(3-fluorophenyl)methoxy]phenyl}-6-[(1*Z*)-*N*-{[(3*R*)-morpholin-3-yl]methoxy}but-2-ynimidoyl]quinazolin-4-amine

épertinib — *N*-{3-chloro-4-[(3-fluorophényl)méthoxy]phényl}-6-[(1*Z*)-*N*-{[(3*R*)-morpholin-3-yl]méthoxy}but-2-ynimidoyl]quinazolin-4-amine

epertinib — *N*-{3-cloro-4-[(3-fluorofenil)metoxi]fenil}-6-[(1*Z*)-*N*-{[(3*R*)-morfolin-3-il]metoxi}but-2-inimidoil]quinazolin-4-amina

$C_{30}H_{27}ClFN_5O_3$



**eptinezumabum #**

| | |
|---|---|
| eptinezumab | immunoglobulin G1-kappa, anti-[*Homo sapiens* CALCA (calcitonin related polypeptide alpha) calcitonin gene-related peptide 1, CGRP1, 83-119 and *Homo sapiens* CALCB (calcitonin related polypeptide beta) calcitonin gene-related peptide 2, CGRP2, 82-118], humanized monoclonal antibody;<br>gamma1 heavy chain (1-441) [humanized VH (*Homo sapiens* IGHV3-66*01 (81.40%) -(IGHD)-IGHJ3*02) [8.7.5] (1-111) -*Homo sapiens* IGHG1*03 (CH1 K119>A (156) (112-209), hinge (210-224), CH2 N84.4>A (291) (225-334), CH3 (335-439), CHS (440-441)) (112-441)], (214-219')-disulfide with kappa light chain (1'-219') [humanized V-KAPPA (*Homo sapiens* IGKV1-27*01 (86.20%) -IGKJ4*01) [8.3.13] (1'-112') -*Homo sapiens* IGKC*01, Km3 (113'-219')]; dimer (220-220":223-223")-bisdisulfide |
| eptinezumab | immunoglobuline G1-kappa, anti-[*Homo sapiens* CALCA (polypeptide alpha apparenté à la calcitonine) peptide 1 apparenté au gène de la calcitonine, CGRP1, 83-119 et *Homo sapiens* CALCB (polypeptide bêta apparenté à la calcitonine) peptide 2 apparenté au gène de la calcitonine, CGRP2, 82-118], anticorps monoclonal humanisé;<br>chaîne lourde gamma1 (1-441) [VH humanisé (*Homo sapiens* IGHV3-66*01 (81.40%) -(IGHD)-IGHJ3*02) [8.7.5] (1-111) -*Homo sapiens* IGHG1*03 (CH1 K119>A (156) (112-209), charnière (210-224), CH2 N84.4>A (291) (225-334), CH3 (335-439), CHS (440-441)) (112-441)], (214-219')-disulfure avec la chaîne légère kappa (1'-219') [V-KAPPA humanisé (*Homo sapiens* IGKV1-27*01 (86.20%) -IGKJ4*01) [8.3.13] (1'-112') -*Homo sapiens* IGKC*01, Km3 (113'-219')]; dimère (220-220":223-223")-bisdisulfure |
| eptinezumab | inmunoglobulina G1-kappa, anti-[*Homo sapiens* CALCA (polipéptido alfa relacionado con la calcitonina) péptido 1 relacionado con el gen de la calcitonina, CGRP1, 83-119 y *Homo sapiens* CALCB (polipéptido beta relacionado con la calcitonina) péptido 2 relacionado con el gen de la calcitonina, CGRP2, 82-118], anticuerpo monoclonal humanizado;<br>cadena pesada gamma1 (1-441) [VH humanizado (*Homo sapiens* IGHV3-66*01 (81.40%) -(IGHD)-IGHJ3*02) [8.7.5] (1-111) -*Homo sapiens* IGHG1*03 (CH1 K119>A (156) (112-209), bisagra (210-224), CH2 N84.4>A (291) (225-334), CH3 (335-439), CHS (440-441)) (112-441)], (214-219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA humanizado (*Homo sapiens* IGKV1-27*01 (86.20%) -IGKJ4*01) [8.3.13] (1'-112') -*Homo sapiens* IGKC*01, Km3 (113'-219')]; dímero (220-220":223-223")-bisdisulfuro |

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG LVQPGGSLRL SCAVSGIDLS GYYMNWVRQA PGKGLEWVGV  50
IGINGATYYA SWAKGRFTIS RDNSKTTVYL QMNSLRAEDT AVYFCARGDI 100
WGQGTLVTVS SASTKGPSVF PLAPSSKSTS GGTAALGCLV KDYFPEPVTV 150
SWNSGALTSG VHTFPAVLQS SGLYSLSSVV TVPSSSLGTQ TYICNVNHKP 200
SNTKVDARVE PKSCDKTHTC PPCPAPELLG GPSVFLFPPK PKDTLMISRT 250
PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY ASTYRVVSVL 300
TVLHQDWLNG KEYKCKVSNK ALPAPIEKTI SKAKGQPREP QVYTLPPSRE 350
EMTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP VLDSDGSFFL 400
YSKLTVDKSR WQQGNVFSCS VMHEALHNHY TQKSLSLSPG K          441
```

Light chain / Chaîne légère / Cadena ligera

```
QVLTQSPSSL SASVGDRVTI NCQASQSVYH NTYLAWYQQK PGKVPKQLIY  50
DASTLASGVP SRFSGSGSGT DFTLTISSLQ PEDVATYYCL GSYDCTNGDC 100
FVFGGGTKVE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK 150
VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE 200
VTHQGLSSPV TKSFNRGEC                                   219
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

| | | | | |
|---|---|---|---|---|
| Intra-H (C23-C104) | 22-95 | 138-194 | 255-315 | 361-419 |
| | 22"-95" | 138"-194" | 255"-315" | 361"-419" |
| Intra-L (C23-C104) | 22'-89' | 139'-199' | Intra-L | 95'-100' |
| | 22'''-89''' | 139'''-199''' | (C110-C115) | 95'''-100''' |
| Inter-H-L (h 5-CL 126) | 214-219' | 214"-219''' | | |
| Inter-H-H (h 11, h 14) | 220-220" | 223-223" | | |

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4>A (291, 291"):
No N-glycosylation sites / pas de sites de N-glycosylation /ningún posición de N-glicosilación

**erenumabum #**

| | |
|---|---|
| erenumab | immunoglobulin G2-lambda, anti-[*Homo sapiens* CALCRL (calcitonin receptor like receptor, calcitonin gene-related peptide receptor, CGRPR, CGRP-R, CRLR)], *Homo sapiens* monoclonal antibody;<br>gamma2 heavy chain (1-456) [*Homo sapiens* VH (IGHV3-30*03 (93.90%) -(IGHD) -IGHJ6*01) [8.8.23] (1-130) -IGHG2*01, G2m.. (CH1 (131-228), hinge (229-240), CH2 (241-349), CH3 (350-454), CHS (455-456)) (131-456)], (144-215')-disulfide with lambda light chain (1'-216') [*Homo sapiens* V-LAMBDA (IGLV1-51*01 (98.00%) -IGLJ2*01) [8.3.11] (1'-110') -IGLC1*01 (111'-216')]; dimer (232-232":233-233":236-236":239-239")-tetrakisdisulfide |
| érénumab | immunoglobuline G2-lambda, anti-[*Homo sapiens* CALCRL (récepteur analogue au récepteur de la calcitonine, récepteur du peptide apparenté au gène de la calcitonine, CGRPR, CGRP-R, CRLR)], *Homo sapiens* anticorps monoclonal;<br>chaîne lourde gamma2 (1-456) [*Homo sapiens* VH (IGHV3-30*03 (93.90%) -(IGHD) -IGHJ6*01) [8.8.23] (1-130) -IGHG2*01, G2m.. (CH1 (131-228), charnière (229-240), CH2 (241-349), CH3 (350-454), CHS (455-456)) (131-456)], (144-215')-disulfure avec la chaîne légère lambda (1'-216') [*Homo sapiens* V-LAMBDA (IGLV1-51*01 (98.00%) -IGLJ2*01) [8.3.11] (1'-110') -IGLC1*01 (111'-216')]; dimère (232-232":233-233":236-236":239-239")-tétrakisdisulfure |
| erenumab | inmunoglobulina G2-lambda, anti-[*Homo sapiens* CALCRL (receptor análogo del receptor de la calcitonina, receptor del péptido relacionado con el gen de la calcitonina, CGRPR, CGRP-R, CRLR)], *Homo sapiens* anticuerpo monoclonal; |

cadena pesada gamma2 (1-456) [*Homo sapiens* VH (IGHV3-30*03 (93.90%) -(IGHD) -IGHJ6*01) [8.8.23] (1-130) -IGHG2*01, G2m.. (CH1 (131-228), bisagra (229-240), CH2 (241-349), CH3 (350-454), CHS (455-456)) (131-456)], (144-215')-disulfuro con la cadena ligera lambda (1'-216') [*Homo sapiens* V-LAMBDA (IGLV1-51*01 (98.00%) -IGLJ2*01) [8.3.11] (1'-110') -IGLC1*01 (111'-216')]; dímero (232-232'':233-233'':236-236'':239-239'')-tetrakisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVESGGG VVQPGRSLRL SCAASGFTFS SFGMHWVRQA PGKGLEWVAV  50
ISFDGSIKYS VDSVKGRFTI SRDNSKNTLF LQMNSLRAED TAVYYCARDR 100
LNYYDSSGYY HYKYYGMAVW GQGTTVTVSS ASTKGPSVFP LAPCSRSTSE 150
STAALGCLVK DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT 200
VPSSNFGTQT YTCNVDHKPS NTKVDKTVER KCCVECPPCP APPVAGPSVF 250
LFPPKPKDTL MISRTPEVTC VVVDVSHEDP EVQFNWYVDG VEVHNAKTKP 300
REEQFNSTFR VVSVLTVVHQ DWLNGKEYKC KVSNKGLPAP IEKTISKTKG 350
QPREPQVYTL PPSREEMTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY 400
KTTPPMLDSD GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA LHNHYTQKSL 450
SLSPGK                                                  456
```

Light chain / Chaîne légère / Cadena ligera

```
QSVLTQPPSV SAAPGQKVTI SCSGSSSNIG NNYVSWYQQL PGTAPKLLIY  50
DNNKRPSGIP DRFSGSKSGT STTLGITGLQ TGDEADYYCG TWDSRLSAVV 100
FGGGTKLTVL GQPKANPTVT LFPPSSEELQ ANKATLVCLI SDFYPGAVTV 150
AWKADGSPVK AGVETTKPSK QSNNKYAASS YLSLTPEQWK SHRSYSCQVT 200
HEGSTVEKTV APTECS                                       216
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 157-213 270-330 376-434
22"-96" 157"-213" 270"-330" 376"-434"
Intra-L (C23-C104) 22'-89' 138'-197'
22'"-89'" 138'"-197"
Inter-H-L (CH1 10-CL 126) 144-215' 144"-215'"
Inter-H-H (h 4, h 5, h 8, h 11) 232-232" 233-233" 236-236" 239-239"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
306, 306"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

**eretidigenum velentivecum #**
eretidigene velentivec

Recombinant, non-replicating, lentiviral vector w1.6_hWAS_WPREmut6 (VSV-G*) encoding the human Wiskott-Aldrich syndrome (WAS) gene under the control of its native promoter, post-transcriptionally-regulated by a modified WPRE (mut6 WPRE**)
* VSV-G = vesicular stomatitis virus G envelope protein
** WPRE m6 = WPRE mut6 = mut6 = mut6 WPRE: mutated woodchuck hepatitis virus posttranscriptional regulatory element

érétidigène vélentivec

vecteur lentiviral recombinant sans capacité de réplication w1.6_hWAS_WPREmut6 (VSV-G*) contenant le gène humain du syndrome de Wiskott-Aldrich sous le contrôle de son promoteur natif, régulé en post-transcription par WPRE** modifié (mut6 WPRE**)
* VSV-G = glycoprotéine G du virus de la stomatite vésiculaire
**WPRE m6 = WPRE mut6 = mut6 = mut6 WPRE: élément muté de régulation post-transcriptionnelle du virus de l'hépatite de la marmotte d'Amérique

| | |
|---|---|
| eretidigén velentivec | vector lentiviral recombinante no replicativo w1.6_hWAS_WPREmut6 (VSV-G*) que contiene el gen humano del síndrome de Wiskott-Aldrich bajo el control de su promotor nativo, regulado post-transcripcionalmente por WPRE** modificado (mut6 WPRE**)<br>* VSV-G = glicoproteína G del virus de la estomatitis vesicular<br>**WPRE m6 = WPRE mut6 = mut6 = mut6 WPRE: elemento mutado de regulación post-transcriptionnal del virus de la hepatitis de la marmota de América |

**evobrutinibum**

| | |
|---|---|
| evobrutinib | 1-[4-({[6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl]amino}methyl)piperidin-1-yl]prop-2-en-1-one |
| évobrutinib | 1-[4-({[6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl]amino}méthyl)pipéridin-1-yl]prop-2-én-1-one |
| evobrutinib | 1-[4-({[6-amino-5-(4-fenoxifenil)pirimidin-4-il]amino}metil)piperidin-1-il]prop-2-en-1-ona |

$C_{25}H_{27}N_5O_2$



**fezolinetantum**

| | |
|---|---|
| fezolinetant | (4-fluorophenyl)[(8*R*)-8-methyl-3-(3-methyl-1,2,4-thiadiazol-5-yl)-5,6-dihydro-1,2,4-triazolo[4,3-*a*]pyrazin-7(8*H*)-yl]methanone |
| fézolinétant | (4-fluorophényl)[(8*R*)-8-méthyl-3-(3-méthyl-1,2,4-thiadiazol-5-yl)-5,6-dihydro-1,2,4-triazolo[4,3-*a*]pyrazin-7(8*H*)-yl]méthanone |
| fezolinetant | (4-fluorofenil)[(8*R*)-8-metil-3-(3-metil-1,2,4-tiadiazol-5-il)-5,6-dihidro-1,2,4-triazolo[4,3-*a*]pirazin-7(8*H*)-il]metanona |

$C_{16}H_{15}FN_6OS$



**flurdihydroergotaminum**

| | |
|---|---|
| flurdihydroergotamine | 5'α-benzyl-12'-hydroxy-2'-methyl-2-(trifluoromethyl)-(10α)-9,10-dihydroergotaman-3',6',18-trione |

flurdihydroergotamine

5'α-benzyl-12'-hydroxy-2'-méthyl-2-(trifluorométhyl)-(10α)-9,10-dihydroergotamane-3',6',18-trione

flurdihidroergotamina

5'α-bencil-12'-hidroxi-2'-metil-2-(trifluorometil)-(10α)-9,10-dihidroergotaman-3',6',18-triona

$C_{34}H_{36}F_3N_5O_5$



**follitropinum epsilon #**

follitropin epsilon

heterodimer of human glycoprotein hormones alpha chain and follitropin subunit beta (FSH-beta), follicle-stimulating hormone, produced in human chronic myelogenous leukaemia cells, glycoform epsilon

follitropine epsilon

hétérodimère constitué de la chaîne alpha des hormones glycoprotéiques et de la sous-unité bêta de la follitropine (HFS-bêta) humaines, hormone folliculostimulante, produite dans des cellules humaines de leucémie myéloïde chronique, forme glycosylée epsilon

folitropina épsilon

heterodímero constituido por la cadena alfa de las hormonas glicoproteícas y la subunidad beta de la folitropina (HFS-beta) humanas, hormona estimulante del folículo, producida en células humanas de la leucemia mieloide crónica, forma glicosilada épsilon

alpha chain / chaîne alpha / cadena alfa

```
APDVQDCPEC TLQENPFFSQ PGAPILQCMG CCFSRAYPTP LRSKKTMLVQ 50
KNVTSESTCC VAKSYNRVTV MGGFKVENHT ACHCSTCYYH KS         92
```

beta chain / chaîne bêta / cadena beta

```
NSCELTNITI AIEKEECRFC ISINTTWCAG YCYTRDLVYK DPARPKIQKT 50'
CTFKELVYET VRVPGCAHHA DSLYTYPVAT QCHCGKCDSD STDCTVRGLG 100'
PSYCSFGEMK E                                           111'
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

7-31 10-60 28-82 32-84 59-87
3'-51' 17'-66' 20'-104' 28'-82' 32'-84' 87'-94'

Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)

Asn-52 Asn-78 Asn-7' Asn-24'

**fostemsavirum**

fostemsavir

{3-[(4-benzoylpiperazin-1-yl)-oxoacetyl]-4-methoxy-7-(3-methyl-1*H*-1,2,4-triazol-1-yl)-1*H*-pyrrolo[2,3-*c*]pyridin-1-yl}methyl dihydrogen phosphate

fostemsavir

dihydrogénophosphate de {3-[(4-benzoylpipérazin-1-yl)-oxoacétyl]-4-méthoxy-7-(3-méthyl-1*H*-1,2,4-triazol-1-yl)-1*H*-pyrrolo[2,3-*c*]pyridin-1-yl}méthyle

fostemsavir

dihidrogenofosfato de {3-[(4-benzoilpiperazin-1-il)-oxoacetil]-4-metoxi-7-(3-metil-1*H*-1,2,4-triazol-1-il)-1*H*-pirrolo[2,3-*c*]piridin-1-il}metilo

$C_{25}H_{26}N_7O_8P$



**fremanezumabum #**

fremanezumab

immunoglobulin G2-kappa, anti-[*Homo sapiens* CALCA (calcitonin related polypeptide alpha) calcitonin gene-related peptide 1, CGRP1, 83-119 and *Homo sapiens* CALCB (calcitonin related polypeptide beta) calcitonin gene-related peptide 2, CGRP2, 82-118], humanized monoclonal antibody;
gamma2 heavy chain (1-448) [humanized VH (*Homo sapiens* IGHV3-7*01 (85.70%) -(IGHD) -IGHJ4*01) [8.10.13] (1-122) -*Homo sapiens* IGHG2*01, G2m..(CH1 (123-220), hinge (221-232), CH2 A115>S (331), P116>S (332) (233-341), CH3 (342-446), CHS (447-448)) (123-448)], (136-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens* IGKV3-11*01 (85.30%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimer (224-224":225-225":228-228":231-231")-tetrakisdisulfide

frémanezumab

immunoglobuline G2-kappa, anti-[*Homo sapiens* CALCA (polypeptide alpha apparenté à la calcitonine) peptide 1 apparenté au gène de la calcitonine, CGRP1, 83-119 et *Homo sapiens* CALCB (polypeptide bêta apparenté à la calcitonine) peptide 2 apparenté au gène de la calcitonine, CGRP2, 82-118], anticorps monoclonal humanisé;
chaîne lourde gamma2 (1-448) [VH humanisé (*Homo sapiens* IGHV3-7*01 (85.70%) -(IGHD) -IGHJ4*01) [8.10.13] (1-122) -*Homo sapiens* IGHG2*01, G2m..(CH1 (123-220), charnière (221-232), CH2 A115>S (331), P116>S (332) (233-341), CH3 (342-446), CHS (447-448)) (123-448)], (136-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (*Homo sapiens* IGKV3-11*01 (85.30%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimère (224-224":225-225":228-228":231-231")-tétrakisdisulfure

fremanezumab

inmunoglobulina G2-kappa, anti-[*Homo sapiens* CALCA (polipéptido alfa relacionado con la calcitonina) péptido 1 relacionado con el gen de la calcitonina, CGRP1, 83-119 y *Homo sapiens* CALCB (polipéptido beta relacionado con la calcitonina) péptido 2 relacionado con el gen de la calcitonina, CGRP2, 82-118], anticuerpo monoclonal humanizado;

cadena pesada gamma2 (1-448) [VH humanizado (*Homo sapiens* IGHV3-7*01 (85.70%) -(IGHD) -IGHJ4*01) [8.10.13] (1-122) -*Homo sapiens* IGHG2*01, G2m.. (CH1 (123-220), bisagra (221-232), CH2 A115>S (331), P116>S (332) (233-341), CH3 (342-446), CHS (447-448)) (123-448)], (136-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizado (*Homo sapiens* IGKV3-11*01 (85.30%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dímero (224-224":225-225":228-228":231-231")-tetrakisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG LVQPGGSLRL SCAASGFTFS NYWISWVRQA PGKGLEWVAE  50
IRSESDASAT HYAEAVKGRF TISRDNAKNS LYLQMNSLRA EDTAVYYCLA 100
YFDYGLAIQN YWGQGTLVTV SSASTKGPSV FPLAPCSRST SESTAALGCL 150
VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV VTVPSSNFGT 200
QTYTCNVDHK PSNTKVDKTV ERKCCVECPP CPAPPVAGPS VFLFPPKPKD 250
TLMISRTPEV TCVVVDVSHE DPEVQFNWYV DGVEVHNAKT KPREEQFNST 300
FRVVSVLTVV HQDWLNGKEY KCKVSNKGLP SSIEKTISKT KGQPREPQVY 350
TLPPSREEMT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPMLD 400
SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPGK   448
```

Light chain / Chaîne légère / Cadena ligera

```
EIVLTQSPAT LSLSPGERAT LSCKASKRVT TYVSWYQQKP GQAPRLLIYG  50
ASNRYLGIPA RFSGSGSGTD FTLTISSLEP EDFAVYYCSQ SYNYPYTFGQ 100
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

| | | | | |
|---|---|---|---|---|
| Intra-H (C23-C104) | 22-98 | 149-205 | 262-322 | 368-426 |
| | 22"-98" | 149"-205" | 262"-322" | 368"-426" |
| Intra-L (C23-C104) | 23'-88' | 134'-194' | | |
| | 23"'-88"' | 134"'-194"' | | |
| Inter-H-L (CH1 10-CL 126) | 136-214' | 136"-214"' | | |
| Inter-H-H (h 4, h 5, h 8, h 11) | 224-224" | 225-225" | 228-228" | 231-231" |

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
298, 298"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

**gemtuzumabum ozogamicinum #**
gemtuzumab ozogamicin

immunoglobulin G4-kappa, anti-[*Homo sapiens* CD33 (sialic acid binding Ig-like lectin 3, SIGLEC3, SIGLEC-3, gp67, p67)], humanized monoclonal antibody conjugated to *N*-acetyl-gamma calicheamicin;
gamma4 heavy chain (1-443) [humanized VH (*Homo sapiens* IGHV1-3*01 (72.90%) -(IGHD) -IGHJ5*01) [8.8.9] (1-116)), IGHG4*01 (CH1 (117-214), hinge S10>P (224) (215-226), CH2 (227-336), CH3 (337-441), CHS (442-443)) (117-443)], (130-218')-disulfide with kappa light chain (1'-218') [humanized V-KAPPA (*Homo sapiens* IGKV1-5*01 (81.90%) -IGKJ1*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01, Km3 (112'-218')]; dimer (232-232":235-235")-bisdisulfide; conjugated, on an average of 2 or 3 lysyl (0-6), to *N*-acetyl-*S*'-des(methylsulfanyl)-*S*'-(4-hydrazinyl-2-methyl-4-oxobutan-2-yl)calicheamicin $\gamma_1$ via a bifunctional 4-(4-acetylphenoxy)butanoyle (AcBut) linker

gemtuzumab ozogamicine

immunoglobuline G4-kappa, anti-[*Homo sapiens* CD33 (lectine 3 de type Ig-like liant l'acide sialique, SIGLEC3, SIGLEC-3, gp67, p67)], anticorps monoclonal humanisé conjugué à la *N*-acétyl-gamma calichéamicine;
chaîne lourde gamma4 chain (1-443) [VH humanisé (*Homo sapiens* IGHV1-3*01 (72.90%) -(IGHD) -IGHJ5*01) [8.8.9] (1-116)), IGHG4*01 (CH1 (117-214), charnière S10>P (224) (215-226), CH2 (227-336), CH3 (337-441),

CHS (442-443)) (117-443)], (130-218')-disulfure avec la chaîne légère (1'-218') [V-KAPPA humanisé (*Homo sapiens* IGKV1-5*01 (81.90%) - IGKJ1*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01, Km3 (112'-218')]; dimère (232-232":235-235")-bisdisulfure; conjugué, sur 2 ou 3 lysyl en moyenne (0-6), à la *N*-acétyl-*S*'-dés(méthylsulfanyl)-*S*'-(4-hydrazinyl-2-méthyl-4-oxobutan-2-yl)calichéamicine $\gamma_1$ via un linker bifunctionnel 4-(4-acétylphénoxy)butanoyle (AcBut)

gemtuzumab ozogamicina

inmunoglobulina G4-kappa, anti-[*Homo sapiens* CD33 (lectina de tipo inmunoglobulina 3 que se une al ácido siálico, SIGLEC3, SIGLEC-3, gp67, p67)], anticuerpo monoclonal humanizado conjugado con la *N*-acetil-gamma calicheamicina;
cadena pesada gamma4 cadena (1-443) [VH humanizado (*Homo sapiens* IGHV1-3*01 (72.90%) -(IGHD) -IGHJ5*01) [8.8.9] (1-116)), IGHG4*01 (CH1 (117-214), bisagra S10>P (224) (215-226), CH2 (227-336), CH3 (337-441), CHS (442-443)) (117-443)], (130-218')-disulfuro con la cadena ligera (1'-218') [V-KAPPA humanizada (*Homo sapiens* IGKV1-5*01 (81.90%) -IGKJ1*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01, Km3 (112'-218')]; dímero (232-232":235-235")-bisdisulfuro; conjugado, sobre 2 o 3 lisil por término medio (0-6), a la *N*-acetil-*S*'-des(metilsulfanil)-*S*'-(4-hidrazinil-2-metil-4-oxobutan-2-il)calicheamicina $\gamma_1$ mediante un enlace bifuncional 4-(4-acetilfenoxi)butanoil (AcBut)

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVQSGAE VKKPGSSVKV SCKASGYTIT DSNIHWVRQA PGQSLEWIGY  50
IYPYNGGTDY NQKFKNRATL TVDNPTNTAY MELSSLRSED TAFYYCVNGN 100
PWLAYWGQGT LVTVSSASTK GPSVFPLAPC SRSTSESTAA LGCLVKDYFP 150
EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS LSSVVTVPSS SLGTKTYTCN 200
VDHKPSNTKV DKRVESKYGP PCPPCPAPEF LGGPSVFLFP PKPKDTLMIS 250
RTPEVTCVVV DVSQEDPEVQ FNWYVDGVEV HNAKTKPREE QFNSTYRVVS 300
VLTVLHQDWL NGKEYKCKVS NKGLPSSIEK TISKAKGQPR EPQVYTLPPS 350
QEEMTKNQVS LTCLVKGFYP SDIAVEWESN GQPENNYKTT PPVLDSDGSF 400
FLYSRLTVDK SRWQEGNVFS CSVMHEALHN HYTQKSLSLS LGK        443
```

Light chain / Chaîne légère / Cadena ligera

```
DIQLTQSPST LSASVGDRVT ITCRASESLD NYGIRFLTWF QQKPGKAPKL  50
LMYAASNQGS GVPSRFSGSG SGTEFTLTIS SLQPDDFATY YCQQTKEVPW 100
SFGQGTKVEV KRTVAAPSVF IFPPSDEQLK SGTASVVCLL NNFYPREAKV 150
QWKVDNALQS GNSQESVTEQ DSKDSTYSLS STLTLSKADY EKHKVYACEV 200
THQGLSSPVT KSFNRGEC                                    218
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 143-199 257-317 363-421
22"-96" 143"-199" 257"-317" 363"-421"
Intra-L (C23-C104) 23'-92' 138'-198'
23'"-92'" 138'"-198'"
Inter-H-L (CH1 10-CL 126) 130-218' 130"-218'"
Inter-H-H (h 8, h 11) 222-222" 225-225"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
293, 293"
Fucosylated complex bi-antennary NS0-type glycans / glycanes de type NS0 bi-antennaires complexes fucosylés / glicanos de tipo NS0 biantenarios complejos fucosilados
Other post-translational modifications / Autres modifications post-traductionnelles / Otras modificaciones post-traduccionales
H CHS K2 C-terminal lysine clipping:
443, 443"

Potential modified residues / résidus modifiés potentiels / restos modificados potenciales
An average of 2 or 3 lysyl are substituted. 2 ou 3 lysyl sont substitués en moyenne. 2 o 3 lisil estan sustituidos pro término medio.



**golodirsenum**

golodirsen

*all-P-ambo*-[2',3'-azanediyl-*P*-(dimethylamino)-*P*,2',3'-trideoxy-2',3'-seco](2'-*N*→5')(G-T-T-G-C-C-T-C-C-G-G-T-T-C-T-G-A-A-G-G-T-G-T-T-C) 5'-{*P*-[4-({2-[2-(2-hydroxyethoxy)ethoxy]ethoxy}carbonyl)piperazin-1-yl]-*N*,*N*-dimethylphosphonamidate}

golodirsen

*tout-P-ambo*-5'-{*P*-[4-({2-[2-(2-hydroxy-éthoxy)éthoxy]éthoxy}carbonyl)pipérazin-1-yl]-*N*,*N*-diméthylphosphonamidate} de [2',3'-azanediyl-*P*-(diméthylamino)-*P*,2',3'-tridéoxy-2',3'-séco](2'-*N*→5')(G-T-T-G-C-C-T-C-C-G-G-T-T-C-T-G-A-A-G-G-T-G-T-T-C)

golodirsén

*todo-P-ambo*-5'-{*P*-[4-({2-[2-(2-hidroxietoxi)etoxi]etoxi}carbonil)piperazin-1-il]-*N*,*N*-dimetilfosfonamidato} de [2',3'-azanediil-*P*-(dimetilamino)-*P*,2',3'-tridesoxi-2',3'-seco](2'-*N*→5')(G-T-T-G-C-C-T-C-C-G-G-T-T-C-T-G-A-A-G-G-T-G-T-T-C)

$C_{305}H_{481}N_{138}O_{112}P_{25}$




B(1-25):
G-T-T-G-C-C-T-C-C-G-G-T-T-C-T-G-A-A-G-G-T-G-T-T-C

**hemoglobinum betafumarilum (bovinum) #**

hemoglobin betafumaril (bovine)

$S^{3.\beta92}$,$S^{3.\beta'92}$-bis(2-amino-2-oxoethyl)-$N^{6.\beta81}$,$N^{6.\beta'81}$-[(2*E*)-(but-2-enedioyl)]bovine hemoglobin ($\alpha_2\beta_2$ tetramer)

hémoglobine bêtafumaril (bovine)

$S^{3.\beta92}$,$S^{3.\beta'92}$-bis(2-amino-2-oxoéthyl)-$N^{6.\beta81}$,$N^{6.\beta'81}$-[(2*E*)-(but-2-ènedioyl)]hémoglobine bovine (tétramère $\alpha_2\beta_2$)

hemoglobina betafumarilo (bovina)

$S^{3.\beta92}$,$S^{3.\beta'92}$-bis(2-amino-2-oxoetil)-$N^{6.\beta81}$,$N^{6.\beta'81}$-[(2*E*)-(but-2-enedioil)]hemoglobina bovina (tetrámero $\alpha_2\beta_2$)

Alpha chain / Chaîne alpha / Cadena alfa

```
VLSAADKGNV KAAWGKVGGH AAEYGAEALE RMFLSFPTTK TYFPHFDLSH  50
GSAQVKGHGA KVAAALTKAV EHLDDLPGAL SELSDLHAHK LRVDPVNFKL 100
LSHSLLVTLA SHLPSDFTPA VHASLDKFLA NVSTVLTSKY R          141
```

Beta chain / Chaîne bêta / Cadena beta

```
MLTAEEKAAV TAFWGKVKVD EVGGEALGRL LVVYPWTQRF FESFGDLSTA  50
DAVMNNPKVK AHGKKVLDSF SNGMKHLDDL KGTFAALSEL HCDKLHVDPE 100
NFKLLGNVLV VVLARNFGKE FTPVLQADFQ KVVAGVANAL AHRYH       145
```

Modified residues / Résidus modifiés / Restos modificados

C β92, C β'92




K β81-fumaryl- K β'81



**ifabotuzumabum #**

| | |
|---|---|
| ifabotuzumab | immunoglobulin G1-kappa, anti-[*Homo sapiens* EPHA3 (ephrin receptor A3, EPH receptor A3, ephrin type-A receptor 3, tyrosine protein kinase TYR04, tyrosine-protein kinase receptor REK4, ETK, ETK1, HEK, HEK4)], humanized monoclonal antibody;<br>gamma1 heavy chain (1-449) [humanized VH (*Homo sapiens* IGHV1-2*02 (91.80%) -(IGHD)-IGHJ6*01) [8.8.11] (1-118) -*Homo sapiens* IGHG1*03, Gm3 (CH1 (119-216), hinge (217-231), CH2 (232-341), CH3 (342-447), CHS (448-449)) (119-448)], (221-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens* IGKV1D-16*01 (91.60%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; dimer (227-227":230-230")-bisdisulfide |
| ifabotuzumab | immunoglobuline G1-kappa, anti-[*Homo sapiens* EPHA3 (récepteur A3 d'éphrine, récepteur A3 d'EPH, récepteur 3 type-A d'éphrine, protéine tyrosine kinase TYR04, récepteur tyrosine-protéine kinase REK4, ETK, ETK1, HEK, HEK4)], anticorps monoclonal humanisé;<br>chaîne lourde gamma1 (1-449) [VH humanisé (*Homo sapiens* IGHV1-2*02 (91.80%) -(IGHD)-IGHJ6*01) [8.8.11] (1-118) -*Homo sapiens* IGHG1*03, Gm3 (CH1 (119-216), charnière (217-231), CH2 (232-341), CH3 (342-447), CHS (448-449)) (119-448)], (221-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (*Homo sapiens* IGKV1D-16*01 (91.60%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; dimère (227-227":230-230")-bisdisulfure |
| ifabotuzumab | inmunoglobulina G1-kappa, anti-[*Homo sapiens* EPHA3 (receptor A3 de efrina, receptor A3 d'EPH, receptor 3 tipo-A de efrina, tirosina protein kinasa TYR04, receptor tirosina-protein kinasa REK4, ETK, ETK1, HEK, HEK4)], anticuerpo monoclonal humanizado;<br>cadena pesada gamma1 (1-449) [VH humanizado (*Homo sapiens* IGHV1-2*02 (91.80%) -(IGHD)-IGHJ6*01) [8.8.11] (1-118) -*Homo sapiens* IGHG1*03, Gm3 (CH1 (119-216), bisagra (217-231), CH2 (232-341), CH3 (342-447), CHS (448-449)) (119-448)], (221-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizado (*Homo sapiens* IGKV1D-16*01 (91.60%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; dímero (227-227":230-230")-bisdisulfuro |

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VKKPGASVKV SCKASGYTFT GYWMNWVRQA PGQGLEWMGD  50
IYPGSGNTNY DEKFQGRVTM TRDTSISTAY MELSRLRSDD TAVYYCARGG 100
YYEDFDSWGQ GTTVTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY 150
FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI 200
CNVNHKPSNT KVDKRVEPKS CDKTHTCPPC PAPELLGGPS VFLFPPKPKD 250
TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST 300
YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY 350
TLPPSREEMT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD 400
SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPGK   448
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSF LSASVGDRVT ITCRASQGII SYLAWYQQKP EKAPKRLIYA  50
ASSLQSGVPS RFSGSGSGTE FTLTISSLQP EDFATYYCGQ YANYPYTFGQ 100
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 145-201 262-322 368-426
22"-96" 145"-201" 262"-322" 368"-426"
Intra-L (C23-C104) 23'-88' 134'-194'
23'"-88'" 134'"-194'"
Inter-H-L (h 5-CL 126) 221-214' 221"-214'"
Inter-H-H (h 11, h 14) 227-227" 230-230"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
298, 298"
Afucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes afucosylés / glicanos de tipo CHO biantenarios complejos no fucosilados

**ilmetropii iodidum**

ilmetropium iodide

(1*R*,3*r*,5*S*)-3-{[(2*RS*)-2-(hydroxymethyl)-2-phenylbutanoyl]oxy}-8,8-dimethyl-8-azabicyclo[3.2.1]octanium iodide

iodure d'ilmétropium

iodure de (1*R*,3*r*,5*S*)-3-{[(2*RS*)-2-(hydroxyméthyl)-2-phénylbutanoyl]oxy}-8,8-diméthyl-8-azabicyclo[3.2.1]octanium

ioduro de ilmetropio

ioduro de (1*R*,3*r*,5*S*)-3-{[(2*RS*)-2-fenil-2-(hidroximetil)butanoil]oxi}-8,8-dimetil-8-azabiciclo[3.2.1]octanio

$C_{20}H_{30}INO_3$




and enantiomer
et énantiomère
y enantiómero

**imlatoclaxum**

imlatoclax

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-*N*-(4-{[(*trans*-4-hydroxy-4-methylcyclohexyl)methyl]amino}-3-nitrobenzenesulfonyl)-2-[(1*H*-pyrrolo[2,3-*b*]pyridin-5-yl)oxy]benzamide

imlatoclax

4-(4-{[2-(4-clorofenil)-4,4-dimetilciclohex-1-en-1-il]metil}piperazin-1-il)-*N*-(4-{[(*trans*-4-hidroxi-4-metilciclohexil)metil]amino}-3-nitrobencenosulfonil)-2-[(1*H*-pirrolo[2,3-*b*]piridin-5-il)oxi]benzamida

$C_{47}H_{54}ClN_7O_7S$



**inotersenum**

inotersen

*all-P-ambo*-2'-*O*-(2-methoxyethyl)-5-methyl-*P*-thiouridylyl-(3'→5')-2'-*O*-(2-methoxyethyl)-5-methyl-*P*-thiocytidylyl-(3'→5')-2'-*O*-(2-methoxyethyl)-5-methyl-*P*-thiouridylyl-(3'→5')-2'-*O*-(2-methoxyethyl)-5-methyl-*P*-thiouridylyl-(3'→5')-2'-*O*-(2-methoxyethyl)-*P*-thioguanylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thioadenylyl-(3'→5')-2'-deoxy-5-methyl-*P*-thiocytidylyl-(3'→5')-2'-deoxy-*P*-thioadenylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-deoxy-*P*-thioguanylyl-(3'→5')-2'-deoxy-*P*-thioadenylyl-(3'→5')-2'-deoxy-*P*-thioadenylyl-(3'→5')-2'-*O*-(2-methoxyethyl)-*P*-thioadenylyl-(3'→5')-2'-*O*-(2-methoxyethyl)-5-methyl-*P*-thiouridylyl-(3'→5')-2'-*O*-(2-methoxyethyl)-5-methyl-*P*-thiocytidylyl-(3'→5')-2'-*O*-(2-methoxyethyl)-5-methyl-*P*-thiocytidylyl-(3'→5')-2'-*O*-(2-methoxyethyl)-5-methylcytidine

inotersen

*tout-P-ambo*-2'-*O*-(2-méthoxyéthyl)-5-méthyl-*P*-thiouridylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-5-méthyl-*P*-thiocytidylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-5-méthyl-*P*-thiouridylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-5-méthyl-*P*-thiouridylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-*P*-thioguanylyl-(3'→5')-2'-déoxy-*P*-thioguanylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-déoxy-*P*-thioadénylyl-(3'→5')-2'-déoxy-5-méthyl-*P*-thiocytidylyl-(3'→5')-2'-déoxy-*P*-thioadénylyl-(3'→5')-*P*-thiothymidylyl-(3'→5')-2'-déoxy-*P*-thioguanylyl-(3'→5')-2'-déoxy-*P*-thioadénylyl-(3'→5')-2'-déoxy-*P*-thioadénylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-*P*-thioadénylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-5-méthyl-*P*-thiouridylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-5-méthyl-*P*-thiocytidylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-5-méthyl-*P*-thiocytidylyl-(3'→5')-2'-*O*-(2-méthoxyéthyl)-5-méthylcytidine

inotersén

*todo-P-ambo*-5-metil-2'-*O*-(2-metoxietil)-*P*-tiouridilil-(3'→5')-5-metil-2'-*O*-(2-metoxietil)-*P*-tiocitidilil-(3'→5')-5-metil-2'-*O*-(2-metoxietil)-*P*-tiouridilil-(3'→5')-5-metil-2'-*O*-(2-metoxietil)-*P*-tiouridilil-(3'→5')-2'-*O*-(2-metoxietil)-*P*-tioguanilil-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-*P*-tiotimidilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-desoxi-*P*-tioadenilil-(3'→5')-2'-desoxi-5-metil-*P*-tiocitidilil-(3'→5')-2'-desoxi-*P*-tioadenilil-(3'→5')-*P*-tiotimidilil-(3'→5')-2'-desoxi-*P*-tioguanilil-(3'→5')-2'-desoxi-*P*-tioadenilil-(3'→5')-2'-desoxi-*P*-tioadenilil-(3'→5')-2'-*O*-(2-metoxietil)-*P*-tioadenilil-(3'→5')-5-metil-2'-*O*-(2-metoxietil)-*P*-tiouridilil-(3'→5')-5-metil-2'-*O*-(2-metoxietil)-*P*-tiocitidilil-(3'→5')-5-metil-2'-*O*-(2-metoxietil)-*P*-tiocitidilil-(3'→5')-2'-*O*-(2-metoxietil)-5-metilcitidina

$C_{230}H_{318}N_{69}O_{121}P_{19}S_{19}$

(3'-5')(*P*-thio)(mUmoe-mCmoe-mUmoe-mUmoe-Gmoe-dG-dT-dT-dA-mdC--dA-dT-dG-dA-dA-Amoe-mUmoe-mCmoe-mCmoe-mCmoe)




**itacitinibum**

itacitinib — (1-{1-[3-fluoro-2-(trifluoromethyl)pyridine-4-carbonyl]piperidin-4-yl}-3-[4-(7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)-1*H*-pyrazol-1-yl]azetidin-3-yl)acetonitrile

itacitinib — (1-{1-[3-fluoro-2-(trifluorométhyl)pyridine-4-carbonyl]pipéridin-4-yl}-3-[4-(7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)-1*H*-pyrazol-1-yl]azétidin-3-yl)acetonitrile

itacitinib — (1-{1-[3-fluoro-2-(trifluorometil)piridina-4-carbonil]piperidin-4-il}-3-[4-(7*H*-pirrolo[2,3-*d*]pirimidin-4-il)-1*H*-pirazol-1-il]azetidin-3-il)acetonitrile

$C_{26}H_{23}F_4N_9O$



**larotrectinibum**

larotrectinib — (3*S*)-*N*-{5-[(2*R*)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-*a*]pyrimidin-3-yl}-3-hydroxypyrrolidine-1-carboxamide

larotrectinib — (3*S*)-*N*-{5-[(2*R*)-2-(2,5-difluorophényl)pyrrolidin-1-yl]pyrazolo[1,5-*a*]pyrimidin-3-yl}-3-hydroxypyrrolidine-1-carboxamide

larotrectinib

(3*S*)-*N*-{5-[(2*R*)-2-(2,5-difluorofenil)pirrolidin-1-il]pirazolo[1,5-*a*]pirimidin-3-il}-3-hidroxipirrolidina-1-carboxamida

$C_{21}H_{22}F_2N_6O_2$



**lisavanbulinum**

lisavanbulin

(2*S*)-2,6-diamino-*N*-[4-[2-(2-{4-[(2-cyanoethyl)amino]-1,2,5-oxadiazol-3-yl}-1*H*-benzimidazol-1-yl)acetyl]phenyl}hexanamide

lisavanbuline

(2*S*)-2,6-diamino-*N*-[4-[2-(2-{4-[(2-cyanoéthyl)amino]-1,2,5-oxadiazol-3-yl}-1*H*-benzimidazol-1-yl)acétyl]phényl}hexanamide

lisavanbulina

(2*S*)-2,6-diamino-*N*-[4-[2-(2-{4-[(2-cianoetil)amino]-1,2,5-oxadiazol-3-il}-1*H*-benzimidazol-1-il)acetil]fenil}hexanamida

$C_{26}H_{29}N_9O_3$



**lumicitabinum**

lumicitabine

4'-*C*-(chloromethyl)-2'-deoxy-2'-fluorocytidine 3',5'-bis(2-methylpropanoate)

lumicitabine

3',5'-bis(2-méthylpropanoate) de 4'-*C*-(chlorométhyl)-2'-déoxy-2'-fluorocytidine

lumicitabina

3',5'-bis(2-metilpropanoato) de 4'-*C*-(clorometil)-2'-desoxi-2'-fluorocitidina

$C_{18}H_{25}ClFN_3O_6$



**lupartumabum #**

| | |
|---|---|
| lupartumab | immunoglobulin G1-lambda1, anti-[*Homo sapiens* LYPD3 (Ly6/PLAUR domain containing 3, GPI-anchored cell-surface protein C4.4a, C4.4A)], *Homo sapiens* monoclonal antibody;<br>gamma1 heavy chain (1-446) [*Homo sapiens* VH (IGHV3-48*03 (92.90%) -(IGHD) -IGHJ4*01) [8.8.10](1-117) -IGHG1*01, Gm17,1 (CH1 (118-215), hinge (216-230), CH2 (231-340), CH3 (341-445), CHS K>del (446)) (118-446)], (220-216')-disulfide with lambda1 light chain (1'-217') [*Homo sapiens* V-LAMBDA (IGLV1-47*01 (87.90%) -IGLJ2*01) [9.3.11] (1'-111') -IGLC2*01 (112'-217')]; dimer (226-226":229-229")-bisdisulfide |
| lupartumab | immunoglobuline G1-lambda1, anti-[*Homo sapiens* LYPD3 (protéine 3 contenant un domaine Ly6/PLAUR, protéine C4.4a GPI-ancrée à la surface cellulaire, C4.4A)], *Homo sapiens* anticorps monoclonal;<br>chaîne lourde gamma1 (1-446) [*Homo sapiens* VH (IGHV3-48*03 (92.90%) -(IGHD) -IGHJ4*01) [8.8.10](1-117) -IGHG1*01, Gm17,1 (CH1 (118-215), charnière (216-230), CH2 (231-340), CH3 (341-445), CHS K>del (446)) (118-446)], (220-216')-disulfure avec la chaîne légère lambda1 (1'-217') [*Homo sapiens* V-LAMBDA (IGLV1-47*01 (87.90%) -IGLJ2*01) [9.3.11] (1'-111') -IGLC2*01 (112'-217')]; dimère (226-226":229-229")-bisdisulfure |
| lupartumab | inmunoglobulina G1-lambda1, anti-[*Homo sapiens* LYPD3 (proteína 3 que contiene un dominio Ly6/PLAUR, proteína C4.4a GPI-anclada en la superficie celular, C4.4A)], *Homo sapiens* anticuerpo monoclonal;<br>cadena pesada gamma1 (1-446) [*Homo sapiens* VH (IGHV3-48*03 (92.90%) -(IGHD) -IGHJ4*01) [8.8.10](1-117) -IGHG1*01, Gm17,1 (CH1 (118-215), bisagra (216-230), CH2 (231-340), CH3 (341-445), CHS K>del (446)) (118-446)], (220-216')-disulfuro con la cadena ligera lambda1 (1'-217') [*Homo sapiens* V-LAMBDA (IGLV1-47*01 (87.90%) -IGLJ2*01) [9.3.11] (1'-111') -IGLC2*01 (112'-217')]; dímero (226-226":229-229")-bisdisulfuro |

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLLESGGG LVQPGGSLRL SCAASGFTFS NAWMSWVRQA PGKGLEWVSY  50
ISSSGSTIYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAREG 100
LWAFDYWGQG TLVTVSSAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF 150
PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC 200
NVNHKPSNTK VDKKVEPKSC DKTHTCPPCP APELLGGPSV FLFPPKPKDT 250
LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY 300
RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT 350
LPPSRDELTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS 400
DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPG     446
```

Light chain / Chaîne légère / Cadena ligera

```
ESVLTQPPSV SGAPGQRVTI SCTGSSSNIG AGYVVHWYQQ LPGTAPKLLI  50
YDNNKRPSGV PDRFSGSKSG TSASLAISGL RSEDEADYYC AAWDDRLNGP 100
VFGGGTKLTV LGQPKAAPSV TLFPPSSEEL QANKATLVCL ISDFYPGAVT 150
VAWKADSSPV KAGVETTTPS KQSNNKYAAS SYLSLTPEQW KSHRSYSCQV 200
THEGSTVEKT VAPTECS                                     217
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 144-200 261-321 367-425
22"-96" 144"-200" 261"-321" 367"-425"
Intra-L (C23-C104) 22'-90' 139'-198'
22'"-90'" 139'"-198'"
Inter-H-L (h 5-CL 126) 220-216' 220"-216'"
Inter-H-H (h 11, h 14) 226-226' 229-229"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
297, 297"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

**lupartumabum amadotinum #**

lupartumab amadotin

immunoglobulin G1-lambda1, anti-[*Homo sapiens* LYPD3 (Ly6/PLAUR domain containing 3, GPI-anchored cell-surface protein C4.4a, C4.4A)], *Homo sapiens* monoclonal antibody conjugated to an auristatin W derivative; gamma1 heavy chain (1-446) [*Homo sapiens* VH (IGHV3-48*03 (92.90%) -(IGHD) -IGHJ4*01) [8.8.10](1-117) -IGHG1*01, Gm17,1 (CH1 (118-215), hinge (216-230), CH2 (231-340), CH3 (341-445), CHS K>del (446)) (118-446)], (220-216')-disulfide with lambda1 light chain (1'-217') [*Homo sapiens* V-LAMBDA (IGLV1-47*01 (87.90%) -IGLJ2*01) [9.3.11] (1'-111') -IGLC2*01 (112'-217')]; dimer (226-226":229-229")-bisdisulfide; *S*-substituted on an average of 4 reduced cysteinyl by reaction with *N*-demethyl-*N*-[4-(6-maleimidohexanohydrazido)-4-oxobutyl]auristatin W amide

lupartumab amadotine

immunoglobuline G1-lambda1, anti-[*Homo sapiens* LYPD3 (protéine 3 contenant un domaine Ly6/PLAUR, protéine C4.4a GPI-ancrée à la surface cellulaire, C4.4A)], *Homo sapiens* anticorps monoclonal conjugué à un dérivé de l'auristatine W;
chaîne lourde gamma1 (1-446) [*Homo sapiens* VH (IGHV3-48*03 (92.90%) -(IGHD) -IGHJ4*01) [8.8.10](1-117) -IGHG1*01, Gm17,1 (CH1 (118-215), charnière (216-230), CH2 (231-340), CH3 (341-445), CHS K>del (446)) (118-446)], (220-216')-disulfure avec la chaîne légère lambda1 (1'-217') [*Homo sapiens* V-LAMBDA (IGLV1-47*01 (87.90%) -IGLJ2*01) [9.3.11] (1'-111') -IGLC2*01 (112'-217')]; dimère (226-226":229-229")-bisdisulfure; *S*-substitué, sur 4 cystéines réduits en moyenne, par reaction avec *N*-desméthyl-*N*-[4-(6-maléimidohexanohydrazido)-4-oxobutyl]auristatine W amide

lupartumab amadotina

inmunoglobulina G1-lambda1, anti-[*Homo sapiens* LYPD3 (proteína 3 que contiene un dominio Ly6/PLAUR, proteína C4.4a GPI-anclada a la superficie celular, C4.4A)], *Homo sapiens* anticuerpo monoclonal conjugado con un derivado de la auristatina W;
cadena pesada gamma1 (1-446) [*Homo sapiens* VH (IGHV3-48*03 (92.90%) -(IGHD) -IGHJ4*01) [8.8.10](1-117) -IGHG1*01, Gm17,1 (CH1 (118-215), bisagra (216-230), CH2 (231-340), CH3 (341-445), CHS K>del (446)) (118-446)], (220-216')-disulfuro con la cadena ligera lambda1 (1'-217') [*Homo sapiens* V-LAMBDA (IGLV1-47*01 (87.90%) -IGLJ2*01) [9.3.11] (1'-111') -IGLC2*01 (112'-217')]; dímero (226-226":229-229")-bisdisulfuro;
*S*-sustituido, en 4 grupos cisteinil reducidos por término medio, por reacción con *N*-desmetil-*N*-[4-(6-maleimidohexanohidrazido)-4-oxobutil]auristatina W amida

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLLESGGG LVQPGGSLRL SCAASGFTFS NAWMSWVRQA PGKGLEWVSY  50
ISSSGSTIYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAREG 100
LWAFDYWGQG TLVTVSSAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF 150
PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC 200
NVNHKPSNTK VDKKVEPKSC DKTHTCPPCP APELLGGPSV FLFPPKPKDT 250
LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY 300
RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT 350
LPPSRDELTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS 400
DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPG     446
```

Light chain / Chaîne légère / Cadena ligera

```
ESVLTQPPSV SGAPGQRVTI SCTGSSSNIG AGYVVHWYQQ LPGTAPKLLI  50
YDNNKRPSGV PDRFSGSKSG TSASLAISGL RSEDEADYYC AAWDDRLNGP 100
VFGGGTKLTV LGQPKAAPSV TLFPPSSEEL QANKATLVCL ISDFYPGAVT 150
VAWKADSSPV KAGVETTTPS KQSNNKYAAS SYLSLTPEQW KSHRSYSCQV 200
THEGSTVEKT VAPTECS                                     217
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 144-200 261-321 367-425
22"-96" 144"-200" 261"-321" 367"-425"
Intra-L (C23-C104) 22'-90' 139'-198'
22'"-90'" 139'"-198'"
Inter-H-L (h 5-CL 126)* 220-216' 220"-216'"
Inter-H-H (h 11, h 14)* 226-226' 229-229"

*Two or three of the inter-chain disulfide bridges are not present, an average of 4 cysteinyl being conjugated each via a thioether bond to a drug linker.
*Deux ou trois des ponts disulfures inter-chaînes ne sont pas présents, 4 cystéinyl en moyenne étant chacun conjugué via une liaison thioéther à un linker-principe actif.
*Faltan dos o tres puentes disulfuro inter-catenarios, una media de 4 cisteinil está conjugada a conectores de principio activo.

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
297, 297"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

Potential modified residues / résidus modifiés potentiels / restos modificados potenciales



**lutikizumabum #**

| | |
|---|---|
| lutikizumab | immunoglobulin G1-kappa, anti-[*Homo sapiens* IL1A (interleukin 1 alpha) and *Homo sapiens* IL1B (interleukin 1 beta, IL-1B, 1L1F2)], humanized monoclonal antibody, tetravalent bispecific;<br>gamma1 heavy chain (1-577) [humanized VH anti-IL1B (*Homo sapiens* IGHV3-23*04 (80.60%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -6-mer linker (120-125) -*Homo sapiens* VH anti-IL1A (IGHV3-30*03 (88.80%) -(IGHD)-IGHJ1*01) [8.8.15] (126-247) -*Homo sapiens* IGHG1*01 (CH1 (248-345), hinge (346-360), CH2 L1.3>A (364), L1.2>A (365), (361-470), CH3 (471-575), CHS (576-577)) (248-577)], (350-327')-disulfide with kappa light chain (1'-327') [humanized V-KAPPA anti-IL1B (*Homo sapiens* IGKV1-27*01 (82.10%) -IGKJ2*01) [6.3.9] (1'-106') -7-mer linker -*Homo sapiens* V-KAPPA anti-IL1A (IGKV1-12*01 (92.60%) -IGKJ4*01) [6.3.9] (114'-220') -*Homo sapiens* IGKC*01, Km3 (221'-327')]; dimer (356-356":359-359")-bisdisulfide |
| lutikizumab | immunoglobuline G1-kappa, anti-[*Homo sapiens* IL1A (interleukine 1 alpha) et *Homo sapiens* IL1B (interleukine 1 bêta, IL-1B, 1L1F2)], anticorps monoclonal humanisé, tétravalent bispécifique;<br>chaîne lourde gamma1 chaîne (1-577) [VH humanisé anti-IL1B (*Homo sapiens* IGHV3-23*04 (80.60%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -6-mer linker (120-125) -*Homo sapiens* VH anti-IL1A (IGHV3-30*03 (88.80%) -(IGHD)-IGHJ1*01) [8.8.15] (126-247)-*Homo sapiens* IGHG1*01 (CH1 (248-345), charnière (346-360), CH2 L1.3>A (364), L1.2>A (365), (361-470), CH3 (471-575), CHS (576-577)) (248-577)], (350-327')-disulfure avec la chaîne légère (1'-327') [V-KAPPA humanisé anti-IL1B (*Homo sapiens* IGKV1-27*01 (82.10%) -IGKJ2*01) [6.3.9] (1'-106') -7-mer linker -*Homo sapiens* V-KAPPA anti-IL1A (IGKV1-12*01 (92.60%) -IGKJ4*01) [6.3.9] (114'-220') -*Homo sapiens* IGKC*01, Km3 (221'-327')]; dimère (356-356":359-359")-bisdisulfure |
| lutikizumab | immunoglobulina G1-kappa, anti-[*Homo sapiens* IL1A (interleukina 1 alfa) y *Homo sapiens* IL1B (interleukina 1 beta, IL-1B, 1L1F2)], anticuerpo monoclonal humanizado, tetravalente biespecífico;<br>cadena pesada gamma1 cadena (1-577) [VH humanizado anti-IL1B (*Homo sapiens* IGHV3-23*04 (80.60%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -linker 6-mer (120-125) -*Homo sapiens* VH anti-IL1A (IGHV3-30*03 (88.80%) -(IGHD)-IGHJ1*01) [8.8.15] (126-247)-*Homo sapiens* IGHG1*01 (CH1 (248-345), bisagra (346-360), CH2 L1.3>A (364), L1.2>A (365), (361-470), CH3 (471-575), CHS (576-577)) (248-577)], (350-327')-disulfuro con la cadena ligera (1'-327') [V-KAPPA humanizado anti-IL1B (*Homo sapiens* IGKV1-27*01 (82.10%) -IGKJ2*01) [6.3.9] (1'-106') linker 7-mer -*Homo sapiens* V-KAPPA anti-IL1A (IGKV1-12*01 (92.60%) -IGKJ4*01) [6.3.9] (114'-220') -*Homo sapiens* IGKC*01, Km3 (221'-327')]; dímero (356-356":359-359")-bisdisulfuro |

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG VVQPGRSLRL SCSASGFIFS RYDMSWVRQA PGKGLEWVAY  50
ISHGGAGTYY PDSVKGRFTI SRDNSKNTLF LQMDSLRPED TGVYFCARGG 100
VTKGYFDVWG QGTPVTVSSA STKGPQVQLV ESGGGVVQPG RSLRLSCTAS 150
GFTFSMFGVH WVRQAPGKGL EWVAAVSYDG SNKYYAESVK GRFTISRDNS 200
KNILFLQMDS LRLEDTAVYY CARGRPKVVI PAPLAHWGQG TLVTFSSAST 250
KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF PEPVTVSWNS GALTSGVHTF 300
PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC NVNHKPSNTK VDKKVEPKSC 350
DKTHTCPPCP APEAAGGPSV FLFPPKPKDT LMISRTPEVT CVVVDVSHED 400
PEVKFNWYVD GVEVHNAKTK PREEQYNSTY RVVSVLTVLH QDWLNGKEYK 450
CKVSNKALPA PIEKTISKAK GQPREPQVYT LPPSREEMTK NQVSLTCLVK 500
GFYPSDIAVE WESNGQPENN YKTTPPVLDS DGSFFLYSKL TVDKSRWQQG 550
NVFSCSVMHE ALHNHYTQKS LSLSPGK                         577
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVT ITCRASGNIH NYLTWYQQTP GKAPKLLIYN  50
AKTLADGVPS RFSGSGSGTD YTFTISSLQP EDIATYYCQH FWSIPYTFGQ 100
GTKLQITRTV AAPDIQMTQS PSSVSASVGD RVTITCRASQ GISSWLAWYQ 150
QKPGKAPKLL IYEASNLETG VPSRFSGSGS GSDFTLTISS LQPEDFATYY 200
CQQTSSFLLS FGGGTKVEHK RTVAAPSVFI FPPSDEQLKS GTASVVCLLN 250
NFYPREAKVQ WKVDNALQSG NSQESVTEQD SKDSTYSLSS TLTLSKADYE 300
KHKVYACEVT HQGLSSPVTK SFNRGEC                         327
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

| | | | | | |
|---|---|---|---|---|---|
| Intra-H (C23-C104) | 22-96 | 147-221 | 274-330 | 391-451 | 497-555 |
| | 22"-96" | 147"-221" | 274"-330" | 391"-451" | 497"-555" |
| Intra-L (C23-C104) | 23'-88' | 136'-201' | 247'-307' | | |
| | 23'"-88'" | 136'"-201'" | 247'"-307'" | | |
| Inter-H-L (h 5-CL 126) | 350-327' | 350"-327'" | | | |
| Inter-H-H (h 11, h 14) | 356-356" | 359-359" | | | |

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
427, 427"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

**miridesapum**
miridesap — 1,1'-hexanedioyldi-D-proline

miridésap — 1,1'-hexanedioyldi-D-proline

miridesap — 1,1'-hexanodioildi-D-prolina

$C_{16}H_{24}N_2O_6$




**mivebresibum**
mivebresib — *N*-[4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1*H*-pyrrolo[2,3-*c*]pyridin-4-yl)phenyl]ethanesulfonamide

mivébrésib — *N*-[4-(2,4-difluorophénoxy)-3-(6-méthyl-7-oxo-6,7-dihydro-1*H*-pyrrolo[2,3-*c*]pyridin-4-yl)phényl]éthanesulfonamide

mivebresib — *N*-[4-(2,4-difluorofenoxi)-3-(6-metil-7-oxo-6,7-dihidro-1*H*-pirrolo[2,3-*c*]piridin-4-il)fenil]etanosulfonamida

$C_{22}H_{19}F_2N_3O_4S$



**nacubactamum**

nacubactam — (1*R*,2*S*,5*R*)-2-[(2-aminoethoxy)carbamoyl]-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl hydrogen sulfate

nacubactam — hydrogénosulfate de (1*R*,2*S*,5*R*)-2-[(2-aminoéthoxy)carbamoyl]-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yle

nacubactam — hidrogenosulfato de (1*R*,2*S*,5*R*)-2-[(2-aminoetoxi)carbamoil]-7-oxo-1,6-diazabiciclo[3.2.1]octan-6-ilo

$C_9H_{16}N_4O_7S$



**naquotinibum**

naquotinib — 6-ethyl-3-{4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino}-5-{[(3*R*)-1-(prop-2-enoyl)pyrrolidin-3-yl]oxy}pyrazine-2-carboxamide

naquotinib — 6-éthyl-3-{4-[4-(4-méthylpipérazin-1-yl)pipéridin-1-yl]anilino}-5-{[(3*R*)-1-(prop-2-énoyl)pyrrolidin-3-yl]oxy}pyrazine-2-carboxamide

naquotinib — 6-etil-3-{4-[4-(4-metilpiperazin-1-il)piperidin-1-il]anilino}-5-{[(3*R*)-1-(prop-2-enoil)pirrolidin-3-il]oxi}pirazina-2-carboxamida

$C_{30}H_{42}N_8O_3$



**navoximodum**

navoximod — *trans*-4-{(1*R*)-2-[(5*S*)-6-fluoro-5*H*-imidazo[5,1-*a*]isoindol-5-yl]-1-hydroxyethyl}cyclohexan-1-ol

navoximod — *trans*-4-{(1*R*)-2-[(5*S*)-6-fluoro-5*H*-imidazo[5,1-*a*]isoindol-5-yl]-1-hydroxyéthyl}cyclohexan-1-ol

navoximod — *trans*-4-{(1*R*)-2-[(5*S*)-6-fluoro-5*H*-imidazo[5,1-*a*]isoindol-5-il]-1-hidroxietil}ciclohexan-1-ol

$C_{18}H_{21}FN_2O_2$




**nelatimotidum**

nelatimotide — L-cysteinyl[human Wilms tumor protein (WT33)-(126-134)-peptide] (1-10) and [236-L-tyrosine(M>Y)]human Wilms tumor protein (WT33)-(235-243)-peptide (1'-9'), (1-1')-disulfide

nélatimotide — (1-1')-disulfure entre le L-cystéinyl-[protéine tumorale de Wilms humaine (WT33)-(126-133)-peptide] (1-10) et le [236-L-tyrosine(M>Y)]protéine tumorale de Wilms humaine (WT33)-(235-243)-peptide (1'-9')

nelatimotida — (1-1')-disulfuro entre la L-cisteinil[proteína tumoral de Wilms humana (WT33)-(126-134)-péptido] (1-10) y la [236-L-tirosina(M>Y)]proteína tumoral de Wilms humana (WT33)-(235-243)-péptido (1'-9')

$C_{106}H_{153}N_{27}O_{28}S_4$

H−Cys−Arg−Met−Phe−Pro−Asn−Ala−Pro−Tyr−Leu−OH
1 10
H−Cys−Tyr−Thr−Trp−Asn−Gln−Met−Asn−Leu−OH
1' 9'

**nirogacestatum**

nirogacestat — (2*S*)-2-{[(2*S*)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl]amino}-*N*-(1-{1-[(2,2-dimethylpropyl)amino]-2-methylpropan-2-yl}-1*H*-imidazol-4-yl)pentanamide

nirogacéstat — (2*S*)-2-{[(2*S*)-6,8-difluoro-1,2,3,4-tétrahydronaphtalén-2-yl]amino}-*N*-(1-{1-[(2,2-diméthylpropyl)amino]-2-méthylpropan-2-yl}-1*H*-imidazol-4-yl)pentanamide

nirogacestat — (2*S*)-2-{[(2*S*)-6,8-difluoro-1,2,3,4-tetrahidronaftalen-2-il]amino}-*N*-(1-{1-[(2,2-dimetilpropil)amino]-2-metilpropan-2-il}-1*H*-imidazol-4-il)pentanamida

$C_{27}H_{41}F_2N_5O$



**obicetrapibum**

| | |
|---|---|
| obicetrapib | 4-{[2-({[3,5-bis(trifluoromethyl)phenyl]methyl}[(2*R*,4*S*)-1-(ethoxycarbonyl)-2-ethyl-6-(trifluoromethyl)-1,2,3,4-tetrahydroquinolin-4-yl]amino)pyrimidin-5-yl]oxy}butanoic acid |
| obicétrapib | acide 4-{[2-({[3,5-bis(trifluorométhyl)phényl]méthyl}[(2*R*,4*S*)-1-(éthoxycarbonyl)-2-éthyl-6-(trifluorométhyl)-1,2,3,4-tétrahydroquinoléin-4-yl]amino)pyrimidin-5-yl]oxy}butanoïque |
| obicetrapib | ácido 4-{[2-({[3,5-bis(trifluorometil)fenil]metil}[(2*R*,4*S*)-2-etil-1-(etoxicarbonil)-6-(trifluorometil)-1,2,3,4-tetrahidroquinolein-4-il]amino)pirimidin-5-il]oxi}butanoico |

$C_{32}H_{31}F_9N_4O_5$



**ofranergenum obadenovecum #**

| | |
|---|---|
| ofranergene obadenovec | A recombinant non-replicating adenovirus type 5 vector carrying a fas-chimera transgene consisting of fas and human tumour necrosis factor receptor 1 (TNFR1), under transcriptional control of a murine pre-proendothelin promoter (PPE-1-3X*)<br>*PPE-1-3X = modified PPE-1 promoter that contains three copies of the endothelial cells (EC)-positive regulatory elements. |
| ofranergéne obadénovec | vecteur adenoviral 5 recombinant sans capacité de réplication, contenant un transgène chimérique-fas constitué du fas et du récepteur 1 du facteur de nécrose tumorale humain (TNFR1), sous le contrôle transcriptionnel d'un promoteur pré-pro-endothéline murin (PPE-1-3X*)<br>*PPE-1-3X = promoteur pré-pro-endothéline modifié contenant trois copies d'éléments de régulation positive provenant des cellules endothéliales |

| | |
|---|---|
| ofranergén obadenovec | vector adenoviral 5 recombinante no replicante, que contiene un transgec quimérico-fas constituido del fas y del receptor 1 del factor de necrosis tumoral humano (TNFR1), bajo el control transcripcional de un promotor pre-pro-endotelina murino (PPE-1-3X*)<br>*PPE-1-3X = promotor pre-pro-endotelina modificado que contiene tres copias de elementos de regulación positiva que proviene de las células endoteliales |
| **padsevonilum** | |
| padsevonil | (4*R*)-4-(2-chloro-2,2-difluoroethyl)-1-{[2-(methoxymethyl)-6-(trifluoromethyl)imidazo[2,1-*b*][1,3,4]thiadiazol-5-yl]methyl}pyrrolidin-2-one |
| padsévonil | (4*R*)-4-(2-chloro-2,2-difluoroéthyl)-1-{[2-(méthoxyméthyl)-6-(trifluorométhyl)imidazo[2,1-*b*][1,3,4]thiadiazol-5-yl]méthyl}pyrrolidin-2-one |
| padsevonil | (4*R*)-4-(2-cloro-2,2-difluoroetil)-1-{[2-(metoximetil)-6-(trifluorometil)imidazo[2,1-*b*][1,3,4]tiadiazol-5-il]metil}pirrolidin-2-ona |
| | $C_{14}H_{14}ClF_5N_4O_2S$ |
| |  |
| **palucorcelum** | |
| palucorcel | allogeneic human umbilical tissue derived cells (hUTC) obtained by enzymatic digestion of post-partum blood-free umbilical cord tissue and *ex vivo* expansion. Cells secrete trophic factors and do not express markers of endothelial cells (CD31), cord blood cells (CD45), epithelial cells (E-cadherin) and fibroblasts (FSP-1). |
| palucorcel | cellules humaines allogéniques dérivées de tissu ombilical (hUTC) obtenues par réactions enzymatiques de tissu de cordon ombilical post-partum exsangue et par expansion *ex vivo*. Les cellules secrètent des facteurs trophiques et n'expriment pas les marqueurs des cellules endothéliales (CD31), des cellules sanguines du cordon (CD45), des célulles épithéliales (cadhérine E) ni des fibroblastes (FSP-1). |
| palucorcel | células humanas alogénicas derivadas de tejido umbilical (hUTC) obtenidas por reacciones enzimáticas de tejido de cordón umbilical posparto libre de sangre y por expansión *ex vivo*. Las células secretan los factores tróficos y no expresan los marcadores de las células endoteliales (CD31), las células sanguíneas del cordón (CD45), las células epiteliales (cadherina E) y los fibroblastos (FSP-1). |

**pegunigalsidasum alfa #**

pegunigalsidase alfa

glycyl-human α-galactosidasyl-L-seryl-L-α-glutamyl-L-lysyl-L-α-aspartyl-L-α-glutamyl-L-leucine, non-covalent dimer, glycosylated with plant glycans, produced in *Nicotiana tabacum* cells, substituted with an average of eight 4-({α-[2-(3-carboxypropanamido)ethyl]poly(oxyethylene)-ω-yl}amino)-4-oxobutanoyl groups (2 kDa each) and cross-linking (polyethylene glycol-*O*,*O*'-diyl)bis[ethane-2,1-diylazanediyl(1,4-dioxobutane-4,1-diyl)] bridges (2 kDa each) per dimeric protein on Gly$^{1}$-*N* and Lys-*N*$^{6}$ sites

pégunigalsidase alfa

glycyl-α-galactosidasyl humain-L-séryl-L-α-glutamyl-L-lysyl-L-α-aspartyl-L-α-glutamyl-L-leucine, dimère non covalent, glycosylé avec des glycanes de plantes, produit par des cellules de *Nicotiana tabacum*, substitué avec une moyenne de 8 groupes 4-({α-[2-(3-carboxypropanamido)éthyl]poly(oxyéthylène)-ω-yl}amino)-4-oxobutanoyle (2 kDa chacun) et lié par des ponts (polyéthylène glycol-*O*,*O*'-diyl)bis[éthane-2,1-diylazanediyl(1,4-dioxobutane-4,1-diyl)] (2 kDa chacun) par deux monomères sur les sites Gly$^{1}$-*N* et Lys-*N*$^{6}$

pegunigalsidasa alfa

glicil-α-galactosidasil humano-L-seril-L-α-glutamil-L-lisil-L-α-aspartil-L-α-glutamil-L-leucina, dímero no covalente, glicosilado con los glicanos de plantas, producido por las células de *Nicotiana tabacum*, sustituido con una media de 8 grupos 4-({α-[2-(3-carboxipropanamido)etil]poli(oxietileno)-ω-il}amino)-4-oxobutanoilo (2 kDa cada uno de ellos) y unido por los puentes (polietileno glicol-*O*,*O*'-diil)bis[etano-2,1-diilazanediil(1,4-dioxobutano-4,1-diil)] (2 kDa cada uno de ellos) por ambos monómeros sobre los lugares Gly$^{1}$-*N* y Lys-*N*$^{6}$

Monomer / Monomère / Monómero

```
GLDNGLARTP TMGWLHWERF MCNLDCQEEP DSCISEKLFM EMAELMVSEG 50
WKDAGYEYLC IDDCWMAPQR DSEGRLQADP QRFPHGIRQL ANYVHSKGLK 100
LGIYADVGNK TCAGFPGSFG YYDIDAQTFA DWGVDLLKFD GCYCDSLENL 150
ADGYKHMSLA LNRTGRSIVY SCEWPLYMWP FQKPNYTEIR QYCNHWRNFA 200
DIDDSWKSIK SILDWTSFNQ ERIVDVAGPG GWNDPDMLVI GNFGLSWNQQ 250
VTQMALWAIM AAPLFMSNDL RHISPQAKAL LQDKDVIAIN QDPLGKQGYQ 300
LRQGDNFEVW ERPLSGLAWA VAMINRQEIG GPRSYTIAVA SLGKGVACNP 350
ACFITQLLPV KRKLGFYEWT SRLRSHINPT GTVLLQLENT MQMSLKDLLS 400
EKDEL                                                  405
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

22-64 26-33 112-142 172-193 348-352

Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)

Asn-109 Asn-162 Asn-185 Asn-378

Potential *N*-substituted residues with pegylated radical Gly-1 and *N*-6 of lysines

Résidus potentiellement *N*-substitués par le radical pegylé Gly-1 et *N*-6 des lysines

Restos potencialmente *N*-sustituidos por el radical pegilado Gly-1 y *N*-6 de las lisinas

schematic structure
schéma de la structure
esquema de la estructura



**pegvorhyaluronidasum alfa #**

pegvorhyaluronidase alfa

human hyaluronidase PH-20 (hyaluronoglucosaminidase PH-20, sperm adhesion molecule 1, EC 3.2.1.35) precursor-(36-482)-peptide (mature (1-447)-peptide), produced in Chinese hamster ovary (CHO) cells, glycoform alfa, substituted on $N^6$ of an average of 4 to 5 lysyl residues with 4-[ω-methoxypoly(oxyethylene)-α-yl]butanoyl groups (~30 kDa each)

pègvorhyaluronidase alfa

hyaluronidase PH-20 humaine (hyaluronoglucosaminidase PH-20, molécule adhésive 1 du sperme, EC 3.2.1.35) précurseur-(36-482)-peptide (à maturité-(1-447)-peptide), produite par des cellules ovariennes de hamster chinois (CHO), forme glycosylée alfa, substituée sur les $N^6$ de 4 à 5 résidus lysyl en moyenne par des groupes 4-[ω-méthoxypoly(oxyéthylène)-α-yl]butanoyle (~30 kDa chacun)

pegvorhialuronidasa alfa

hialuronidasa PH-20 humana (hialuronoglucosaminidasa PH-20, molécula de adhesión 1 de esperma, EC 3.2.1.35) precursor-(36-482)-péptido (maduro-(1-447)-péptido), producida por células ováricas de hamster chino (CHO), forma glicosilada alfa, sustituída en $N^6$ de 4 a 5 restos lysyl pro termino medio por grupos 4-[ω-metoxipoli(oxietileno)-α-il]butanoilo (~ 30 kDa cada uno)

```
LNFRAPPVIP NVPFLWAWNA PSEFCLGKFD EPLDMSLFSF IGSPRINATG 50
QGVTIFYVDR LGYYPYIDSI TGVTVNGGIP QKISLQDHLD KAKKDITFYM 100
PVDNLGMAVI DWEEWRPTWA RNWKPKDVYK NRSIELVQQQ NVQLSLTEAT 150
EKAKQEFEKA GKDFLVETIK LGKLLRPNHL WGYYLFPDCY NHHYKKPGYN 200
GSCFNVEIKR NDDLSWLWNE STALYPSIYL NTQQSPVAAT LYVRNRVREA 250
IRVSKIPDAK SPLPVFAYTR IVFTDQVLKF LSQDELVYTF GETVALGASG 300
IVIWGTLSIM RSMKSCLLLD NYMETILNPY IINVTLAAKM CSQVLCQEQG 350
VCIRKNWNSS DYLHLNPDNF AIQLEKGGKF TVRGKPTLED LEQFSEKFYC 400
SCYSTLSCKE KADVKDTDAV DVCIADGVCI DAFLKPPMET EEPQIFY 457
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
25-316 189-203 341-352 346-400 402-408 423-429

Pegylated residues / Résidus pégylés / Restos pegilados




Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)
Asn-47 Asn-131 Asn-200 Asn-219 Asn-333 Asn-358

**pimodivirum**

pimodivir

(2*S*,3*S*)-3-{[5-fluoro-2-(5-fluoro-1*H*-pyrrolo[2,3-*b*]pyridin-3-yl)pyrimidin-4-yl]amino}bicyclo[2.2.2]octane-2-carboxylic acid

pimodivir

acide (2*S*,3*S*)-3-{[5-fluoro-2-(5-fluoro-1*H*-pyrrolo[2,3-*b*]pyridin-3-yl)pyrimidin-4-yl]amino}bicyclo[2.2.2]octane-2-carboxylique

pimodivir

ácido (2*S*,3*S*)-3-{[5-fluoro-2-(5-fluoro-1*H*-pirrolo[2,3-*b*]piridin-3-il)pirimidin-4-il]amino}biciclo[2.2.2]octano-2-carboxílico

$C_{20}H_{19}F_2N_5O_2$



**poseltinibum**

poseltinib — *N*-[3-({2-[4-(4-methylpiperazin-1-yl)anilino]furo[3,2-*d*]pyrimidin-4-yl}oxy)phenyl]prop-2-enamide

poseltinib — *N*-[3-({2-[4-(4-méthylpipérazin-1-yl)anilino]furo[3,2-*d*]pyrimidin-4-yl}oxy)phényl]prop-2-énamide

poseltinib — *N*-[3-({2-[4-(4-metilpiperazin-1-il)anilino]furo[3,2-*d*]pirimidin-4-il}oxi)fenil]prop-2-enamida

$C_{26}H_{26}N_6O_3$



**ranevetmabum #**

ranevetmab — immunoglobulin G1-kappa, anti-[*Mus musculus* NGF (nerve growth factor, nerve growth factor beta polypeptide, NGFB, beta-NGF)], caninized monoclonal antibody; gamma1 heavy chain (1-453) [caninizedVH (*Rattus norvegicus* IGHV5S13*01 (71.40%) -(IGHD)-IGHJ4*01) [8.7.16] (1-122) -*Canis lupus familiaris* IGHG1*01 (CH1 (123-219), hinge (220-233), CH2 (234-343), CH3 (344-451), CHS (452-453)) (123-453)], (137-213')-disulfide with kappa light chain (1'-217') [caninizedV-KAPPA (*Rattus norvegicus* IGKV12S34*01 (76.80%) -IGKJ2-3*01) [6.3.9] (1'-107') -*Canis lupus familiaris* IGKC*01 (108'-213') -4-mer (214'-217')]; dimer (224-224'':226-226'':232-232'')-trisdisulfide

ranévetmab — immunoglobuline G2-kappa, anti-[*Mus musculus* NGF (facteur de croissance du nerf, facteur de croissance du nerf polypeptide bêta, NGFB, bêta-NGF)], anticorps monoclonal caninisé;
chaîne lourde gamma2 (1-453) [VH caninisé (*Rattus norvegicus* IGHV5S13*01 (71.40%) -(IGHD)-IGHJ4*01) [8.7.16] (1-122) -*Canis lupus familiaris* IGHG1*01 (CH1 (123-219), charnière (220-233), CH2 (234-343), CH3 (344-451), CHS (452-453)) (123-453)], (137-213')-disulfure avec la chaîne légèrekappa (1'-217') [V-KAPPA caninisé (*Rattus norvegicus* IGKV12S34*01 (76.80%) -IGKJ2-3*01) [6.3.9] (1'-107') -*Canis lupus familiaris* IGKC*01 (108'-213') -4-mer (214'-217')]; dimère (224-224'':226-226'':232-232'')-trisdisulfure

ranevetmab

inmunoglobulina G2-kappa, anti-[*Mus musculus* NGF (factor de crecimiento de los nervios, factor de crecimiento de nervios polipéptido beta, NGFB, beta-NGF)], anticuerpo monoclonal caninizado;
cadena pesada gamma2 (1-453) [VH caninizado (*Rattus norvegicus* IGHV5S13*01 (71.40%) -(IGHD)-IGHJ4*01) [8.7.16] (1-122) -*Canis lupus familiaris* IGHG1*01 (CH1 (123-219), bisagra (220-233), CH2 (234-343), CH3 (344-451), CHS (452-453)) (123-453)], (137-213')-disulfuro con la cadena ligerakappa (1'-217') [V-KAPPA caninizado (*Rattus norvegicus* IGKV12S34*01 (76.80%) -IGKJ2-3*01) [6.3.9] (1'-107') -*Canis lupus familiaris* IGKC*01 (108'-213') -4-mer (214'-217')]; dímero (224-224'':226-226'':232-232'')-trisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG LVQPGGSLRL SCVASGFSLT NNNVNWVRQA PGKGLEWVGG  50
VWAGGATDYN SALKSRFTIS RDNAKNTVFL QMHSLRSEDT AVYYCARDGG 100
YSSSTLYAMD AWGQGTSVTV SSASTTAPSV FPLAPSCGST SGSTVALACL 150
VSGYFPEPVT VSWNSGSLTS GVHTFPSVLQ SSGLHSLSSM VTVPSSRWPS 200
ETFTCNVVHP ASNTKVDKPV FNECRCTDTP PCPVPEPLGG PSVLIFPPKP 250
KDILRITRTP EVTCVVLDLG REDPEVQISW FVDGKEVHTA KTQSREQQFN 300
GTYRVVSVLP IEHQDWLTGK EFKCRVNHID LPSPIERTIS KARGRAHKPS 350
VYVLPPSPKE LSSSDTVSIT CLIKDFYPPD IDVEWQSNGQ QEPERKHRMT 400
PPQLDEDGSY FLYSKLSVDK SRWQQGDPFT CAVMHETLQN HYTDLSLSHS 450
PGK                                                     453
```

Light chain / Chaîne légère / Cadena ligera

```
DIVMTQSPAS LSLSQGETVT ITCRASEDIY NALAWYQQKP GQAPKLLIYN  50
TDTLHTGVPS RFSGSGSGTD FSLTISSLEP EDVAVYYCQH YFHYPRTFGQ 100
GTKVELKRND AQPAVYLFQP SPDQLHTGSA SVVCLLNSFY PKDINVKWKV 150
DGVIQDTGIQ ESVTEQDKDS TYSLSSTLTM SSTEYLSHEL YSCEITHKSL 200
PSTLIKSFQR SECQRVD                                     217
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

| | | | | |
|---|---|---|---|---|
| Intra-H (C23-C104) | 22-95 | 149-205 | 264-324 | 371-431 |
| | 22''-95'' | 149''-205'' | 264''-324'' | 371''-431'' |
| Intra-L (C23-C104) | 23'-88' | 134'-193' | | |
| | 23'''-88''' | 134'''-193''' | | |
| Inter-H-L (CH1 11-CL 126) | 137-213' | 137''-213''' | | |
| Inter-H-H (h 14, h 17) | 224-224'' | 226-226'' | 232-232'' | |

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
300, 300''
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

**ravoxertinibum**

ravoxertinib

1-[(1*S*)-1-(4-chloro-3-fluorophenyl)-2-hydroxyethyl]-4-{2-[(1-methyl-1*H*-pyrazol-5-yl)amino]pyrimidin-4-yl}pyridin-2(1*H*)-one

ravoxertinib

1-[(1*S*)-1-(4-chloro-3-fluorophényl)-2-hydroxyéthyl]-4-{2-[(1-méthyl-1*H*-pyrazol-5-yl)amino]pyrimidin-4-yl}pyridin-2(1*H*)-one

ravoxertinib

1-[(1*S*)-1-(4-cloro-3-fluorofenil)-2-hidroxietil]-4-{2-[(1-metil-1*H*-pirazol-5-il)amino]pirimidin-4-il}piridin-2(1*H*)-ona

$C_{21}H_{18}ClFN_6O_2$



**recanaclotidum**

recanaclotide — *S*$^{1}$,*S*$^{6}$:*S*$^{2}$,*S*$^{10}$:*S*$^{5}$,*S*$^{13}$-tricyclo(L-cysteinyl-L-cysteinyl-*O*-phosphono-L-seryl-L-leucyl-L-cysteinyl-L-cysteinyl-L-asparaginyl-L-prolyl-L-alanyl-L-cysteinyl-L-threonylglycyl-L-cysteine)

récanaclotide — *S*$^{1}$,*S*$^{6}$:*S*$^{2}$,*S*$^{10}$:*S*$^{5}$,*S*$^{13}$-tricyclo(L-cystéinyl-L-cystéinyl-*O*-phosphono-L-séryl-L-leucyl-L-cystéinyl-L-cystéinyl-L-asparaginyl-L-prolyl-L-alanyl-L-cystéinyl-L-thréonylglycyl-L-cystéine)

recanaclotida — *S*$^{1}$,*S*$^{6}$:*S*$^{2}$,*S*$^{10}$:*S*$^{5}$,*S*$^{13}$-triciclo(L-cisteinil-L-cisteinil-*O*-fosfono-L-seril-L-leucil-L-cisteinil-L-cisteinil-L-asparaginil-L-prolil-L-alanil-L-cisteinil-L-treonilglicil-L-cisteína)

$C_{45}H_{71}N_{14}O_{20}PS_6$



**reltecimodum**

reltecimod — D-alanyl-[T-cell-specific surface glycoprotein CD28-(8-15)-peptide]-D-alanine:
D-alanyl-L-seryl-L-prolyl-L-methionyl-L-leucyl-L-valyl-L-alanyl-L-tyrosyl-L-α-aspartyl-D-alanine

reltécimod — D-alanyl-[(8-15)-peptide de glycoprotéine de surface CD28 spécifique des cellules T]-D-alanine:
D-alanyl-L-séryl-L-prolyl-L-méthionyl-L-leucyl-L-valyl-L-alanyl-L-tyrosyl-L-α-aspartyl-D-alanine

reltecimod — D-alanil-[(8-15)-péptido de glicoproteína de superfice CD28 específica de las células T]-D-alanina:
D-alanil-L-seril-L-prolil-L-metionil-L-leucil-L-valil-L-alanil-L-tirosil-L-α-aspartil-D-alanina

$C_{46}H_{72}N_{10}O_{15}S$



**remetinostatum**

remetinostat — methyl 4-{[8-(hydroxyamino)-8-oxooctanoyl]oxy}benzoate

rémétinostat — 4-{[8-(hydroxyamino)-8-oxooctanoyl]oxy}benzoate de méthyle

remetinostat — 4-{[8-(hidroxiamino)-8-oxooctanoil]oxi}benzoato de metilo

$C_{16}H_{21}NO_6$



**remtolumabum #**

remtolumab — immunoglobulin G1-kappa, anti-[*Homo sapiens* IL17A (interleukin 17A, IL-17A) and *Homo sapiens* TNF (tumor necrosis factor (TNF) superfamily member 2, TNFSF2, TNF-alpha, TNFA)], *Homo sapiens* monoclonal antibody, tetravalent bispecific;
gamma1 heavy chain (1-587) [*Homo sapiens* VH anti-TNF (IGHV3-9*01 (93.90%) -(IGHD) -IGHJ4*01) [8.8.14] (1-121) -10-mer bis(tetraglycyl-seryl) linker (122-132) -*Homo sapiens* VH' anti-IL17A (IGHV1-69*01 (85.70%) -(IGHD) -IGHJ6*01) [8.8.19] (132-257) -IGHG1*01, G1m17,1 (CH1 (258-355), hinge (356-370), CH2 (371-480), CH3 (481-585), CHS (586-587)) (258-587)], (360-331')-disulfide with kappa light chain (1'-331') [*Homo sapiens* V-KAPPA anti-TNF (IGKV1-27*01 (95.80%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* V-KAPPA anti-IL17A (IGKV6-21*01 (90.50%) -IGKJ3*01) [6.3.9] (118'-224') -IGKC*01, Km3 (225'-213')]; dimer (366-366'':369-369'')-bisdisulfide

remtolumab — immunoglobuline G1-kappa, anti-[*Homo sapiens* IL17A (interleukine 17A, IL-17A) et *Homo sapiens* TNF (facteur de nécrose tumorale membre 2 de la superfamille du TNF, TNFSF2, TNF-alpha, TNFA)], *Homo sapiens* anticorps monoclonal, tétravalent bispécifique;
chaîne lourde gamma1 (1-587) [*Homo sapiens* VH anti-TNF (IGHV3-9*01 (93.90%) -(IGHD) -IGHJ4*01) [8.8.14] (1-121) -10-mer bis(tétraglycyl-séryl) linker (122-132) -*Homo sapiens* VH' anti-IL17A (IGHV1-69*01 (85.70%) -(IGHD) -IGHJ6*01) [8.8.19] (132-257) -IGHG1*01, G1m17,1 (CH1 (258-355), charnière (356-370), CH2 (371-480), CH3 (481-585), CHS (586-587)) (258-587)], (360-331')-disulfure avec la chaîne légère kappa (1'-331') [*Homo sapiens* V-KAPPA anti-TNF (IGKV1-27*01 (95.80%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* V-KAPPA anti-IL17A (IGKV6-21*01 (90.50%) -IGKJ3*01) [6.3.9] (118'-224') -IGKC*01, Km3 (225'-213')]; dimère (366-366'':369-369'')-bisdisulfure

remtolumab — inmunoglobulina G1-kappa, anti-[*Homo sapiens* IL17A (interleukina 17A, IL-17A) y *Homo sapiens* TNF (factor de necrosis tumoral miembro 2 de la superfamilia del TNF, TNFSF2, TNF-alfa, TNFA)], *Homo sapiens* anticuerpo monoclonal, tetravalente biespecífico;

cadena pesada gamma1 (1-587) [*Homo sapiens* VH anti-TNF (IGHV3-9*01 (93.90%) -(IGHD) -IGHJ4*01) [8.8.14] (1-121) -10-mer bis(tetraglicil-seril) linker (122-132) -*Homo sapiens* VH' anti-IL17A (IGHV1-69*01 (85.70%) -(IGHD) -IGHJ6*01) [8.8.19] (132-257) -IGHG1*01, G1m17,1 (CH1 (258-355), bisagra (356-370), CH2 (371-480), CH3 (481-585), CHS (586-587)) (258-587)], (360-331')-disulfuro con la cadena ligera kappa (1'-331') [*Homo sapiens* V-KAPPA anti-TNF (IGKV1-27*01 (95.80%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* V-KAPPA anti-IL17A (IGKV6-21*01 (90.50%) -IGKJ3*01) [6.3.9] (118'-224') -IGKC*01, Km3 (225'-213')]; dímero (366-366'':369-369'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG LVQPGRSLRL SCAASGFTFD DYAMHWVRQA PGKGLEWVSA  50
ITWNSGHIDY ADSVEGRFTI SRDNAKNSLY LQMNSLRAED TAVYYCAKVS 100
YLSTASSLDY WGQGTLVTVS SGGGGSGGGG SEVQLVQSGA EVKKPGSSVK 150
VSCKASGGSF GGYGIGWVRQ APGQGLEWMG GITPFFGFAD YAQKFQGRVT 200
ITADESTTTA YMELSGLTSD DTAVYYCARD PNEFWNGYYS THDFDSWGQG 250
TTVTVSSAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF PEPVTVSWNS 300
GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC NVNHKPSNTK 350
VDKKVEPKSC DKTHTCPPCP APELLGGPSV FLFPPKPKDT LMISRTPEVT 400
CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY RVVSVLTVLH 450
QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT LPPSRDELTK 500
NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS DGSFFLYSKL 550
TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPGK               587
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVT ITCRASQGIR NYLAWYQQKP GKAPKLLIYA  50
ASTLQSGVPS RFSGSGSGTD FTLTISSLQP EDVATYYCQR YNRAPYTFGQ 100
GTKVEIKRGG SGGGGSGEIV LTQSPDFQSV TPKEKVTITC RASQDIGSEL 150
HWYQQKPDQP PKLLIKYASH STSGVPSRFS GSGSGTDFTL TINGLEAEDA 200
GTYYCHQTDS LPYTFGPGTK VDIKRTVAAP SVFIFPPSDE QLKSGTASVV 250
CLLNNFYPRE AKVQWKVDNA LQSGNSQESV TEQDSKDSTY SLSSTLTLSK 300
ADYEKHKVYA CEVTHQGLSS PVTKSFNRGE C                     331
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 153-227 284-340 401-461 507-565
22''-96'' 153''-227'' 284''-340'' 401''-461'' 507''-565''
Intra-L (C23-C104) 23'-88' 140'-205' 251'-311'
23'''-88''' 140'''-205''' 251'''-311'''
Inter-H-L (h 5-CL 126) 360-331' 360''-331'''
Inter-H-H (h 11, h 14) 366-366'' 369-369''

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
437, 437''
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

**rogaratinibum**

| | |
|---|---|
| rogaratinib | 4-{[4-amino-6-(methoxymethyl)-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo[2,1-*f*][1,2,4]triazin-7-yl]methyl}piperazin-2-one |
| rogaratinib | 4-{[4-amino-6-(méthoxyméthyl)-5-(7-méthoxy-5-méthyl-1-benzothiophén-2-yl)pyrrolo[2,1-*f*][1,2,4]triazin-7-yl]méthyl}pipérazin-2-one |
| rogaratinib | 4-{[4-amino-5-(5-metil-7-metoxi-1-benzotiofen-2-il)-6-(metoximetil)pirrolo[2,1-*f*][1,2,4]triazin-7-il]metil}piperazin-2-ona |

$C_{23}H_{26}N_6O_3S$



**rosiptorum**

| | |
|---|---|
| rosiptor | 7-amino-17-methylidene-6,7-seco-5α-androstane-3β,6-diol |
| rosiptor | 7-amino-17-méthylidène-6,7-séco-5α-androstane-3β,6-diol |
| rosiptor | 7-amino-17-metilideno-6,7-seco-5α-androstano-3β,6-diol |

$C_{20}H_{35}NO_2$



**rosmantuzumabum #**

| | |
|---|---|
| rosmantuzumab | immunoglobulin G1-kappa, anti-[*Homo sapiens* RSPO3 (R-spondin 3, thrombospondin type I (TSP1) domain containing protein 2, THSD2)], humanized monoclonal antibody;<br>gamma1 heavy chain (1-447) [humanized VH (*Homo sapiens* IGHV1-46*01 (84.50%) -(IGHD)-IGHJ4*01) [8.8.10] (1-117) -*Homo sapiens* IGHG1*03, (CH1 (118-215), hinge (216-230), CH2 (231-340), CH3 (341-445), CHS (446-447)) (118-447)], (220-218')-disulfide with kappa light chain (1'-218') [humanized V-KAPPA (*Homo sapiens* IGKV1-39*01 (83.80%) -IGKJ4*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01, Km3 (112'-218')]; dimer (226-226":229-229")-bisdisulfide |
| rosmantuzumab | immunoglobuline G1-kappa, anti-[*Homo sapiens* RSPO3 (R-spondine 3, protéine 2 contenant un domaine thrombospondine de type I (TSP1), THSD2)], anticorps monoclonal humanisé;<br>chaîne lourde gamma1 (1-447) [VH humanisé (*Homo sapiens* IGHV1-46*01 (84.50%) -(IGHD)-IGHJ4*01) [8.8.10] (1-117) -*Homo sapiens* IGHG1*03, (CH1 (118-215), charnière (216-230), ), CH2 (231-340), CH3 (341-445), CHS (446-447)) (118-447)], (220-218')-disulfure avec la chaîne légère (1'-218') [V-KAPPA humanisé (*Homo sapiens* IGKV1-39*01 (83.80%) -IGKJ4*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01, Km3 (112'-218')]; dimère (226-226":229-229")-bisdisulfure |

rosmantuzumab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* RSPO3 (R-espondina 3, proteína 2 que contiene un dominio tromboespondina de tipo I (TSP1), THSD2)], anticuerpo monoclonal humanizado;
cadena pesada gamma1 (1-447) [VH humanizado (*Homo sapiens* IGHV1-46*01 (84.50%) -(IGHD)-IGHJ4*01) [8.8.10] (1-117) -*Homo sapiens* IGHG1*03, (CH1 (118-215), bisagra (216-230), ), CH2 (231-340), CH3 (341-445), CHS (446-447)) (118-447)], (220-218')-disulfuro con la cadena ligera (1'-218') [V-KAPPA humanizado (*Homo sapiens* IGKV1-39*01 (83.80%) -IGKJ4*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01, Km3 (112'-218')]; dímero (226-226":229-229")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VKKPGASVKV SCKASGYTFT DYSIHWVRQA PGQGLEWIGY  50
IYPSNGDSGY NQKFKNRVTM TRDTSTSTAY MELSRLRSED TAVYYCATYF 100
ANNFDYWGQG TTLTVSSAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF 150
PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC 200
NVNHKPSNTK VDKRVEPKSC DKTHTCPPCP APELLGGPSV FLFPPKPKDT 250
LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY 300
RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT 350
LPPSREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS 400
DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPGK    447
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVT ITCKASQSVD YDGDSYMNWY QQKPGKAPKL  50
LIYAASNLES GVPSRFSGSG SGTDFTLTIS PVQAEDFATY YCQQSNEDPL 100
TFGAGTKLEL KRTVAAPSVF IFPPSDEQLK SGTASVVCLL NNFYPREAKV 150
QWKVDNALQS GNSQESVTEQ DSKDSTYSLS STLTLSKADY EKHKVYACEV 200
THQGLSSPVT KSFNRGEC                                    218
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

| | | | | |
|---|---|---|---|---|
| Intra-H (C23-C104) | 22-96 | 144-200 | 261-321 | 367-425 |
| | 22"-96" | 144"-200" | 261"-321" | 367"-425" |
| Intra-L (C23-C104) | 23'-92' | 138'-198' | | |
| | 23'"-92'" | 138'"-198'" | | |
| Inter-H-L (h 5-CL 126) | 220-218' | 220"-218'" | | |
| Inter-H-H (h 11, h 14) | 226-226" | 229-229" | | |

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
297, 297"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

Other post-translational modifications / Autres modifications post-traductionnelles / Otras modificaciones post-traduccionales
H CHS K2 C-terminal lysine clipping:
447, 447"

**rosomidnarum**
rosomidnar

DNA oligonucleotide sequence that is complementary to a region upstream of the B-cell lymphoma (BCL-2) gene: 2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxyguanosine

| | |
|---|---|
| rosomidnar | séquence oligonucléotide d'ADN complémentaire d'une région en amont du gène (BCL-2) lymphome formé de lymphocytes B:<br>2'-déoxycytidylyl-(3'→5')-2'-déoxyadénylyl-(3'→5')-2'-déoxycytidylyl-(3'→5')-2'-déoxyguanylyl-(3'→5')-2'-déoxycytidylyl-(3'→5')-2'-déoxyadénylyl-(3'→5')-2'-déoxycytidylyl-(3'→5')-2'-déoxyguanylyl-(3'→5')-2'-déoxycytidylyl-(3'→5')-2'-déoxyguanylyl-(3'→5')-2'-déoxycytidylyl-(3'→5')-2'-déoxyadénylyl-(3'→5')-thymidylyl-(3'→5')-2'-déoxycytidylyl-(3'→5')-2'-déoxycytidylyl-(3'→5')-2'-déoxycytidylyl-(3'→5')-2'-déoxycytidylyl-(3'→5')-2'-déoxyguanylyl-(3'→5')-2'-déoxycytidylyl-(3'→5')-2'-déoxycytidylyl-(3'→5')-2'-déoxycytidylyl-(3'→5')-2'-déoxyguanylyl-(3'→5')-thymidylyl-(3'→5')-2'-déoxyguanosine |
| rosomidnar | secuencia de oligonucleótidos de ADN complementaria de una región ascendente del gen (BCL-2) de linfomas de células B:<br>2'-desoxicitidilil-(3'→5')-2'-desoxiadenilil-(3'→5')-2'-desoxicitidilil-(3'→5')-2'-desoxiguanilil-(3'→5')-2'-desoxicitidilil-(3'→5')-2'-desoxiadenilil-(3'→5')-2'-desoxicitidilil-(3'→5')-2'-desoxiguanilil-(3'→5')-2'-desoxicytidilil-(3'→5')-2'-desoxiguanilil-(3'→5')-2'-desoxicitidilil-(3'→5')-2'-desoxiadenilil-(3'→5')-timidilil-(3'→5')-2'-desoxicitidilil-(3'→5')-2'-desoxicitidilil-(3'→5')-2'-desoxicitidilil-(3'→5')-2'-desoxicitidilil-(3'→5')-2'-desoxiguanilil-(3'→5')-2'-desoxicitidilil-(3'→5')-2'-desoxicitidilil-(3'→5')-2'-desoxiguanilil-(3'→5')-timidilil-(3'→5')-2'-desoxiguanosina<br><br>$C_{227}H_{291}N_{88}O_{141}P_{23}$<br><br>(3'-5')d(C-A-C-G-C-A-C-G-C-G-C-A-T-C-C-C-C-G-C-C-C-G-T-G) |

**rozanolixizumabum #**

| | |
|---|---|
| rozanolixizumab | immunoglobulin G4-kappa, anti-[*Homo sapiens* FCGRT (Fc fragment of IgG receptor and transporter, neonatal Fc receptor, FcRn, transmembrane alpha chain of the neonatal receptor)], humanized and chimeric monoclonal antibody;<br>gamma4 heavy chain (1-444) humanized [humanized VH (*Homo sapiens* IGHV3-7*01 (86.50%) -(IGHD) -IGHJ4*01) [8.8.10] (1-117)), *Homo sapiens* IGHG4*01 (CH1 (118-215), hinge S10>P (225) (216-227),CH2 (228-337), CH3 (338-442), CHS (443-444)) (118-444)], (131-219')-disulfide with kappa light chain chimeric (1'-219') [synthetic V-KAPPA (*Homo sapiens* IGKV1-9*01 (76.00%) -*Homo sapiens* IGKJ2*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01, Km3 (113'-219')]; dimer (223-223":226-226")-bisdisulfide |

rozanolixizumab

immunoglobuline G4-kappa, anti-[*Homo sapiens* FCGRT (récepteur du fragment Fc des IgG et transporteur, récepteur Fc néonatal, FcRn, chaîne alpha transmembranaire du récepteur néonatal)], anticorps monoclonal humanisé et chimérique;
chaîne lourde gamma4 humanisée (1-444) [VH humanisé (*Homo sapiens* IGHV3-7*01 (86.50%) -(IGHD) -IGHJ4*01) [8.8.10] (1-117)), *Homo sapiens* IGHG4*01 (CH1 (118-215), charnière S10>P (225) (216-227), CH2 (228-337), CH3 (338-442), CHS (443-444)) (118-444)], (131-219')-disulfure avec la chaîne légère kappa chimérique (1'-219') [V-KAPPA synthétique (*Homo sapiens*IGKV1-9*01 (76.00%) -*Homo sapiens* IGKJ2*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01, Km3 (113'-219')]; dimère (223-223":226-226")-bisdisulfure

rozanolixizumab

inmunoglobulina G4-kappa, anti-[*Homo sapiens* FCGRT (receptor del fragmento Fc de las IgG y transportador, receptor Fc neonatal, FcRn, cadena alfa transmembranaria del receptor neonatal)], anticuerpo monoclonal humanizado y quimérico;
cadena pesada gamma4 humanizada (1-444) [VH humanizado (*Homo sapiens* IGHV3-7*01 (86.50%) -(IGHD) -IGHJ4*01) [8.8.10] (1-117)), *Homo sapiens* IGHG4*01 (CH1 (118-215), bisagra S10>P (225) (216-227), CH2 (228-337), CH3 (338-442), CHS (443-444)) (118-444)], (131-219')-disulfuro con la cadena ligera kappa quimérica (1'-219') [V-KAPPA sintético (*Homo sapiens*IGKV1-9*01 (76.00%) -*Homo sapiens* IGKJ2*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01, Km3 (113'-219')]; dímero (223-223":226-226")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVPLVESGGG LVQPGGSLRL SCAVSGFTFS NYGMVWVRQA PGKGLEWVAY  50
IDSDGDNTYY RDSVKGRFTI SRDNAKSSLY LQMNSLRAED TAVYYCTTGI 100
VRPFLYWGQG TLVTVSSAST KGPSVFPLAP CSRSTSESTA ALGCLVKDYF 150
PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTKTYTC 200
NVDHKPSNTK VDKRVESKYG PPCPPCPAPE FLGGPSVFLF PPKPKDTLMI 250
SRTPEVTCVV VDVSQEDPEV QFNWYVDGVE VHNAKTKPRE EQFNSTYRVV 300
SVLTVLHQDW LNGKEYKCKV SNKGLPSSIE KTISKAKGQP REPQVYTLPP 350
SQEEMTKNQV SLTCLVKGFY PSDIAVEWES NGQPENNYKT TPPVLDSDGS 400
FFLYSRLTVD KSRWQEGNVF SCSVMHEALH NHYTQKSLSL SLGK       444
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVT ITCKSSQSLV GASGKTYLYW LFQKPGKAPK  50
RLIYLVSTLD SGIPSRFSGS GSGTEFTLTI SSLQPEDFAT YYCLQGTHFP 100
HTFGQGTKLE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK 150
VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE 200
VTHQGLSSPV TKSFNRGEC                                   219
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

| | | | | |
|---|---|---|---|---|
| Intra-H (C23-C104) | 22-96 | 144-200 | 258-318 | 364-422 |
| | 22"-96" | 144"-200" | 258"-318" | 364"-422" |
| Intra-L (C23-C104) | 23'-93' | 139'-199' | | |
| | 23'"-93'" | 139'"-199'" | | |
| Inter-H-L (CH1 10-CL 126) | 131-219' | 131"-219'" | | |
| Inter-H-H (h 8, h 11) | 223-223" | 226-226" | | |

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
294, 294"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

| | |
|---|---|
| **sacituzumabum #** | |
| sacituzumab | immunoglobulin G1-kappa, anti-[*Homo sapiens* TACSTD2 (tumor-associated calcium signal transducer 2, membrane component chromosome 1 surface marker 1, M1S1, gastrointestinal tumor-associated antigen GA7331, pancreatic carcinoma marker protein GA733-1, epithelial glycoprotein-1, EGP-1, trophoblast antigen-2, cell surface glycoprotein Trop-2, TROP2)], humanized monoclonal antibody;<br>gamma1 heavy chain (1-451) [humanized VH (*Homo sapiens* IGHV7-4-1*02 (85.70%) -(IGHD)-IGHJ2*01) [8.8.14] (1-121) -*Homo sapiens* IGHG1*03, G1m3 (CH1 (122-219), hinge (220-234), CH2 (235-344), CH3 (345-449), CHS (450-451)) (122-451)], (224-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens* IGKV1-9*01 (82.20%) -IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimer (230-230":233-233")-bisdisulfide |
| sacituzumab | immunoglobuline G1-kappa, anti-[*Homo sapiens* TACSTD2 (transducteur 2 de signaux calciques associé aux tumeurs, composant membranaire du chromosome 1 marqueur de surface 1, M1S1, antigène GA7331 associé aux tumeurs gastrointestinales, protéine GA733-1 marqueur de carcinomes pancréatiques, glycoprotéine épithéliale 1, EGP-1, antigène 2 du trophoblaste, glycoprotéine Trop-2 à la surface des cellules, TROP2)], anticorps monoclonal humanisé;<br>chaîne lourde gamma1 (1-451) [VH humanisé (*Homo sapiens* IGHV7-4-1*02 (85.70%) -(IGHD)-IGHJ2*01) [8.8.14] (1-121) -*Homo sapiens* IGHG1*03, G1m3 (CH1 (122-219), charnière (220-234), CH2 (235-344), CH3 (345-449), CHS (450-451)) (122-451)], (224-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (*Homo sapiens* IGKV1-9*01 (82.20%) -IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimère (230-230":233-233")-bisdisulfure |
| sacituzumab | inmunoglobulina G1-kappa, anti-[*Homo sapiens* TACSTD2 (transductor 2 de señales cálcicas asociado a los tumores, componente membranario del cromosoma 1 marcador de superficie 1, M1S1, antígeno GA7331 asociado a todos los tumores gastrointestinales, proteína GA733-1 marcador de carcinomas pancreáticos, glicoproteína epitelial 1, EGP-1, antígeno 2 de trofoblasto, glicoproteína Trop-2 de la superficie de las células, TROP2)], anticuerpo monoclonal humanizado;<br>cadena pesada gamma1 (1-451) [VH humanizado (*Homo sapiens* IGHV7-4-1*02 (85.70%) -(IGHD)-IGHJ2*01) [8.8.14] (1-121) -*Homo sapiens* IGHG1*03, G1m3 (CH1 (122-219), bisagra (220-234), CH2 (235-344), CH3 (345-449), CHS (450-451)) (122-451)], (224-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizado (*Homo sapiens* IGKV1-9*01 (82.20%) -IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dímero (230-230":233-233")-bisdisulfuro |

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLQQSGSE LKKPGASVKV SCKASGYTFT NYGMNWVKQA PGQGLKWMGW  50
INTYTGEPTY TDDFKGRFAF SLDTSVSTAY LQISSLKADD TAVYFCARGG 100
FGSSYWYFDV WGQGSLVTVS SASTKGPSVF PLAPSSKSTS GGTAALGCLV 150
KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSSVV TVPSSSLGTQ 200
TYICNVNHKP SNTKVDKRVE PKSCDKTHTC PPCPAPELLG GPSVFLFPPK 250
PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY 300
NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALPAPIEKTI SKAKGQPREP 350
QVYTLPPSRE EMTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP 400
VLDSDGSFFL YSKLTVDKSR WQQGNVFSCS VMHEALHNHY TQKSLSLSPG 450
K                                                       451
```

Light chain / Chaîne légère / Cadena ligera

```
DIQLTQSPSS LSASVGDRVS ITCKASQDVS IAVAWYQQKP GKAPKLLIYS  50
ASYRYTGVPD RFSGSGSGTD FTLTISSLQP EDFAVYYCQQ HYITPLTFGA 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 148-204 265-325 371-429
22"-96" 148"-204" 265"-325" 371'-429"
Intra-L (C23-C104) 23'-88' 134'-194'
23'"-88'" 134'"-194'"
Inter-H-L (h 5-CL 126) 224-214' 224"-214'"
Inter-H-H (h 11, h 14) 230-230" 233-233"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
301, 301"
Fucosylated complex bi-antennary Sp2/0-type glycans / glycanes de type Sp2/0 bi-antennaires complexes fucosylés / glicanos de tipo Sp2/0 biantenarios complejos fucosilados

**satoreotidum**

satoreotide

$S^2$,$S^7$-cyclo{4-chloro-L-phenylalanyl-D-cysteinyl-4-[(4*S*)-2,6-dioxo-1,3-diazinane-4-carboxamido]-L-phenylalanyl-4-(carbamoylamino)-D-phenylalanyl-L-lysyl-L-threonyl-L-cysteinyl-D-tyrosinamide}

satoréotide

$S^2$,$S^7$-cyclo{4-chloro-L-phénylalanyl-D-cystéinyl-4-[(4*S*)-2,6-dioxo-1,3-diazinane-4-carboxamido]-L-phénylalanyl-4-(carbamoylamino)-D-phénylalanyl-L-lysyl-L-thréonyl-L-cystéinyl-D-tyrosinamide}

satoreotida

$S^2$,$S^7$-ciclo{4-cloro-L-fenilalanil-D-cisteinil-4-[(4*S*)-2,6-dioxo-1,3-diazinano-4-carboxamido]-L-fenilalanil-4-(carbamoilamino)-D-fenilalanil-L-lisil-L-treonil-L-cisteinil-D-tirosinamida}

$C_{58}H_{72}ClN_{15}O_{14}S_2$




**seladelparum**

seladelpar

[4-({(2*R*)-2-ethoxy-3-[4-(trifluoromethyl)phenoxy]propyl}sulfanyl)-2-methylphenoxy]acetic acid

séladelpar — acide [4-({(2*R*)-2-éthoxy-3-[4-(trifluorométhyl)phénoxy]propyl}sulfanyl)-2-méthylphénoxy]acétique

seladelpar — ácido [4-({(2*R*)-2-etoxi-3-[4-(trifluorometil)fenoxi]propil}sulfanil)-2-metilfenoxi]acético

$C_{21}H_{23}F_3O_5S$



**seltorexantum**

seltorexant — [(3a*R*,6a*S*)-5-(4,6-dimethylpyrimidin-2-yl)hexahydropyrrolo[3,4-*c*]pyrrol-2(1*H*)-yl][2-fluoro-6-(2*H*-1,2,3-triazol-2-yl)phenyl]methanone

seltorexant — [(3a*R*,6a*S*)-5-(4,6-diméthylpyrimidin-2-yl)hexahydropyrrolo[3,4-*c*]pyrrol-2(1*H*)-yl][2-fluoro-6-(2*H*-1,2,3-triazol-2-yl)phényl]méthanone

seltorexant — [(3a*R*,6a*S*)-5-(4,6-dimetilpirimidin-2-il)hexahidropirrolo[3,4-*c*]pirrol-2(1*H*)-il][2-fluoro-6-(2*H*-1,2,3-triazol-2-il)fenil]metanona

$C_{21}H_{22}FN_7O$



**serabelisibum**

serabelisib — [6-(2-amino-1,3-benzoxazol-5-yl)imidazo[1,2-*a*]pyridin-3-yl](morpholin-4-yl)methanone

sérabélisib — [6-(2-amino-1,3-benzoxazol-5-yl)imidazo[1,2-*a*]pyridin-3-yl](morpholin-4-yl)méthanone

serabelisib — [6-(2-amino-1,3-benzoxazol-5-il)imidazo[1,2-*a*]piridin-3-il](morfolin-4-il)metanona

$C_{19}H_{17}N_5O_3$



**sofpironii bromidum**

sofpironium bromide — 1-*ambo*-(3*R*)-3-{[(*R*)-(cyclopentyl)hydroxy(phenyl) acetyl]oxy}-1-(2-ethoxy-2-oxoethyl)-1-methylpyrrolidinium bromide

bromure de sofpironium — bromure de 1-*ambo*-(3*R*)-3-{[(*R*)-(cyclopentyl)hydroxyl (phényl)acétyl]oxy}-1-(2-éthoxy-2-oxoéthyl)-1-méthylpyrrolidinium

bromuro de sofpironio — bromuro de 1-*ambo*-(3*R*)-3-{[(*R*)-(ciclopentil)hidroxi (fenil)acetil]oxi}-1-(2-etoxi-2-oxoetil)-1-metilpirrolidinio

$C_{22}H_{32}BrNO_5$



and epimer at $N^+$
et l'épimère en $N^+$
y el epímero al $N^+$

**somatrogonum #**

somatrogon — fusion protein of human choriogonadotropin subunit β (CG-β)-(118-145)-peptide (1-28) with human somatotropin (growth hormone, GH) (29-219) and two tandem copies of human choriogonadotropin subunit β (CG-β)-(118-145)-peptide (220-247, 248-275), *O*-glycosylated on 12-18 serines, produced in Chinese hamster ovary (CHO) cells

somatrogon — sous-unité bêta de la choriogonadotrophine humaine (CG-β)-(118-145)-peptide (1-28) protéine de fusion avec la somatropine humaine (hormone de croissance, GH) (29-219) protéine de fusion avec deux copies de la sous-unité bêta de la choriogonadotrophine humaine (CG-β)-(118-145)-peptide (1-28), 12-18 sérines sont *O*-glycosylées, produite par des cellules ovariennes de hamster chinois (CHO)

somatrogón — subunidad beta de la coriogonadotropina humana (CG-β)-(118-145)-péptido (1-28) proteína de fusión con la somatropina humana (hormona de crecimiento, GH) (29-219) proteína de fusión con ambas copias de la subunidad beta de la coriogonadotropina humana (CG-β)-(118-145)-péptido (1-28), 12-18 serinas *O*-glicosiladas, producidas por las células de ovario de hamster chino (CHO)

Sequence / Séquence / Secuencia

```
SSSSKAPPPS LPSPSRLPGP SDTPILPQFP TIPLSRLFDN AMLRAHRLHQ 50
LAFDTYQEFE EAYIPKEQKY SFLQNPQTSL CFSESIPTPS NREETQQKSN 100
LELLRISLLL IQSWLEPVQF LRSVFANSLV YGASDSNVYD LLKDLEEGIQ 150
TLMGRLEDGS PRTGQIFKQT YSKFDTNSHN DDALLKNYGL LYCFRKDMDK 200
VETFLRIVQC RSVEGSCGFS SSSKAPPPSL PSPSRLPGPS DTPILPQSSS 250
SKAPPPSLPS PSRLPGPSDT PILPQ                            275
```

Disulfide bridges location / Position des ponts disulfures / Posiciones de los puentes disulfuro
81-193 210-217

Potential glycosylation sites / Sites potentiels de glycosylation / Sitios potenciales de glicosilación

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| Ser-1* | Ser-2* | Ser-3* | Ser-4* | **Ser-10** | **Ser-13** | **Ser-15** | **Ser-21** |
| Ser-220* | Ser-221* | Ser-222* | Ser-223* | **Ser-229** | **Ser-232** | **Ser-234** | **Ser-240** |
| Ser-248* | Ser-249* | Ser-250* | Ser-251* | **Ser-257** | **Ser-260** | **Ser-262** | **Ser-268** |

* when two serines are linked together, only one can be glycosylated.
quand deux sérines sont liées l'une à l'autre, une seule peut être glycosylée.
cuando dos serinas están ligadas una al otra, una sola puede ser glicosilada .

**suptavumabum #**

| | |
|---|---|
| suptavumab | immunoglobulin G1-kappa, anti-[human respiratory syncytial virus (RSV) fusion glycoprotein F], *Homo sapiens* monoclonal antibody;<br>gamma1 heavy chain (1-453) [*Homo sapiens* VH (IGHV3-9*01 (87.90%) -(IGHD) -IGHJ6*01) [8.8.16](1-123) -IGHG1*01, G1m17,1 (CH1 (124-221), hinge (222-236), CH2 (237-346), CH3 (347-451), CHS (452-453))(124-453)], (226-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-15*01 (94.70%) -IGKJ4*01) [6.3.9] (1'-107')-IGKC*01, Km3 (108'-214')];<br>dimer (232-232":235-235")-bisdisulfide |
| suptavumab | immunoglobuline G1-kappa, anti-[glycoprotéine de fusion F du virus respiratoire syncytial (VRS) humain], *Homo sapiens* anticorps monoclonal;<br>chaîne lourde gamma1 (1-453) [*Homo sapiens* VH (IGHV3-9*01 (87.90%) -(IGHD) -IGHJ6*01) [8.8.16] (1-123) -IGHG1*01, G1m17,1 (CH1 (124-221), charnière (222-236), CH2 (237-346), CH3 (347-451), CHS (452-453))(124-453)], (226-214')-disulfure avec la chaîne légère kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-15*01 (94.70%) -IGKJ4*01) [6.3.9] (1'-107') -IGKC*01, Km3 (108'-214')]; dimère (232-232":235-235")-bisdisulfure |
| suptavumab | inmunoglobulina G1-kappa, anti-[glicoproteína de fusión F del virus respiratorio sincitial (VRS) humano], *Homo sapiens* anticuerpo monoclonal;<br>cadena pesada gamma1 (1-453) [*Homo sapiens* VH (IGHV3-9*01 (87.90%) -(IGHD) -IGHJ6*01) [8.8.16] (1-123) -IGHG1*01, G1m17,1 (CH1 (124-221), bisagra (222-236), CH2 (237-346), CH3 (347-451), CHS (452-453))(124-453)], (226-214')-disulfuro con la cadena ligera kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-15*01 (94.70%) -IGKJ4*01) [6.3.9] (1'-107') -IGKC*01, Km3 (108'-214')]; dímero (232-232":235-235")-bisdisulfuro |

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGD LVQPGRSLRL SCVASGFTFD DYAMHWVRQA PGKGLEWVSG  50
VSWSGSTVGY ADSVKGRFTV SRDNAQKSLY LQMNSLRAED TALYYCVKDA 100
YKFNYYYYGL DVWGQGTTVT VSSASTKGPS VFPLAPSSKS TSGGTAALGC 150
LVKDYFPEPV TVSWNSGALT SGVHTFPAVL QSSGLYSLSS VVTVPSSSLG 200
TQTYICNVNH KPSNTKVDKK VEPKSCDKTH TCPPCPAPEL LGGPSVFLFP 250
PKPKDTLMIS RTPEVTCVVV DVSHEDPEVK FNWYVDGVEV HNAKTKPREE 300
QYNSTYRVVS VLTVLHQDWL NGKEYKCKVS NKALPAPIEK TISKAKGQPR 350
EPQVYTLPPS RDELTKNQVS LTCLVKGFYP SDIAVEWESN GQPENNYKTT 400
PPVLDSDGSF FLYSKLTVDK SRWQQGNVFS CSVMHEALHN HYTQKSLSLS 450
PGK                                                     453
```

Light chain / Chaîne légère / Cadena ligera

```
EIVMTQSPAT LSVSPGERAT LSCRASQTIL SNLAWYLQKP GQAPRLLIYG  50
ASTRATGLPA RFSGSGSGTE FTLTISSLQS EDFAVYYCQQ YNNWPLTFGG 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                         214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 150-206 267-327 373-431
22"-96" 150"-206" 267"-327" 373"-431"
Intra-L (C23-C104) 23'-88' 134'-194'
23'"-88'" 134'"-194'"
Inter-H-L (h 5-CL 126) 226-214' 226"-214"
Inter-H-H (h 11, h 14) 232-232" 235-235"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
303, 303"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

**telisotuzumabum #**

telisotuzumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* MET (met proto-oncogene, hepatocyte growth factor (HGF) receptor, HGFR, scatter factor (SF) receptor, HGF/SF receptor, receptor tyrosine-protein kinase c-met, papillary renal cell carcinoma 2, RCCP2)], humanized monoclonal antibody; gamma1 heavy chain (1-445) [humanized VH (*Homo sapiens* IGHV1-2*02 (92.90%) -(IGHD)-IGHJ4*01) [8.8.11] (1-118) -*Homo sapiens* IGHG1*03, G1m3 (CH1 (119-216), hinge K7>del, T8>C (223), T10>del (217-229), CH2 (230-339), CH3 (340-444), CHS K>del (445)) (119-445)], (221-218')-disulfide with kappa light chain (1'-218') [humanized V-KAPPA (*Homo sapiens* IGKV4-1*01 (85.10%) -IGKJ4*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01, Km3 (112'-218')]; dimer (223-223":225-225":228:228")-trisdisulfide

télisotuzumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* MET (proto-oncogène met, récepteur du facteur de croissance hépatocytaire, HGFR, récepteur du facteur de dispersion, récepteur de l'HGF/SF, récepteur protéine-tyrosine kinase c-Met, carcinome papillaire à cellules rénales 2, RCCP2)], anticorps monoclonal humanisé;
chaîne lourde gamma1 (1-445) [VH humanisé (*Homo sapiens* IGHV1-2*02 (92.90%) -(IGHD)-IGHJ4*01) [8.8.11] (1-118) -*Homo sapiens* IGHG1*03, G1m3 (CH1 (119-216),charnière K7>del, T8>C (223), T10>del (217-229), CH2 (230-339), CH3 (340-444), CHS K>del (445)) (119-445)], (221-218')-disulfure avec la chaîne légère kappa (1'-218') [V-KAPPA humanisé (*Homo sapiens* IGKV4-1*01 (85.10%) -IGKJ4*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01, Km3 (112'-218')]; dimère (223-223":225-225":228:228")-trisdisulfure

telisotuzumab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* MET (proto-oncogen met, receptor del factor de crecimiento de hepatocitos, HGFR, receptor del factor de dispersión, receptor del HGF/SF, receptor proteína-tirosina kinasa c-Met, carcinoma papilar de células renales 2, RCCP2)], anticuerpo monoclonal humanizado;
cadena pesada gamma1 (1-445) [VH humanizado (*Homo sapiens* IGHV1-2*02 (92.90%) -(IGHD)-IGHJ4*01) [8.8.11] (1-118) -*Homo sapiens* IGHG1*03, G1m3 (CH1 (119-216),bisagra K7>del, T8>C (223), T10>del (217-229), CH2 (230-339), CH3 (340-444), CHS K>del (445)) (119-445)], (221-218')-disulfuro con la cadena ligera kappa (1'-218') [V-KAPPA humanizado (*Homo sapiens* IGKV4-1*01 (85.10%) -IGKJ4*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01, Km3 (112'-218')]; dímero (223-223":225-225":228:228")-trisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VKKPGASVKV SCKASGYIFT AYTMHWVRQA PGQGLEWMGW  50
IKPNNGLANY AQKFQGRVTM TRDTSISTAY MELSRLRSDD TAVYYCARSE 100
ITTEFDYWGQ GTLVTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY 150
FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI 200
CNVNHKPSNT KVDKRVEPKS CDCHCPPCPA PELLGGPSVF LFPPKPKDTL 250
MISRTPEVTC VVVDVSHEDP EVKFNWYVDG VEVHNAKTKP REEQYNSTYR 300
VVSVLTVLHQ DWLNGKEYKC KVSNKALPAP IEKTISKAKG QPREPQVYTL 350
PPSREEMTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD 400
GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA LHNHYTQKSL SLSPG      445
```

Light chain / Chaîne légère / Cadena ligera

```
DIVMTQSPDS LAVSLGERAT INCKSSESVD SYANSFLHWY QQKPGQPPKL  50
LIYRASTRES GVPDRFSGSG SGTDFTLTIS SLQAEDVAVY YCQQSKEDPL 100
TFGGGTKVEI KRTVAAPSVF IFPPSDEQLK SGTASVVCLL NNFYPREAKV 150
QWKVDNALQS GNSQESVTEQ DSKDSTYSLS STLTLSKADY EKHKVYACEV 200
THQGLSSPVT KSFNRGEC                                    218
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

| | | | | |
|---|---|---|---|---|
| Intra-H (C23-C104) | 22-96 | 145-201 | 260-320 | 366-424 |
| | 22"-96" | 145"-201" | 260"-320" | 366"-424" |
| Intra-L (C23-C104) | 23'-92' | 138'-198' | | |
| | 23'"-92'" | 138'"-198'" | | |
| Inter-H-L (h 5-CL 126) | 221-218' | 221"-218'" | | |
| Inter-H-H (h 11, h 14) | 225-225" | 228-228" | (h 8>C) | 223-223" |

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
296, 296"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

**telisotuzumabum vedotinum #**
telisotuzumab vedotin

immunoglobulin G1-kappa, anti-[*Homo sapiens* MET (met proto-oncogene, hepatocyte growth factor (HGF) receptor, HGFR, scatter factor (SF) receptor, HGF/SF receptor, receptor tyrosine-protein kinase c-met, papillary renal cell carcinoma 2, RCCP2)], humanized monoclonal antibody conjugated to auristatin E;
gamma1 heavy chain (1-445) [humanized VH (*Homo sapiens* IGHV1-2*02 (92.90%) -(IGHD)-IGHJ4*01) [8.8.11] (1-118) -*Homo sapiens* IGHG1*03, G1m3 (CH1 (119-216), hinge K7>del, T8>C (223), T10>del (217-229), CH2 (230-339), CH3 (340-444), CHS K>del (445)) (119-445)], (221-218')-disulfide with kappa light chain (1'-218') [humanized V-KAPPA (*Homo sapiens* IGKV4-1*01 (85.10%) -IGKJ4*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01, Km3 (112'-218')]; dimer (223-223":225-225":228:228")-trisdisulfide; conjugated, on an average of 3 cysteinyl, to

| | |
|---|---|
| | monomethylauristatin E (MMAE), via a cleavable maleimidocaproyl-valyl-citrullinyl-*p*-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker<br>For the *vedotin* part, please refer to the document *"INN for pharmaceutical substances: Names for radicals, groups and others"*.* |
| télisotuzumab védotine | immunoglobuline G1-kappa, anti-[*Homo sapiens* MET (proto-oncogène met, récepteur du facteur de croissance hépatocytaire, HGFR, récepteur du facteur de dispersion, récepteur de l'HGF/SF, récepteur protéine-tyrosine kinase c-Met, carcinome papillaire à cellules rénales 2, RCCP2)], anticorps monoclonal humanisé conjugué à l'auristatine E; chaîne lourde gamma1 (1-445) [VH humanisé (*Homo sapiens* IGHV1-2*02 (92.90%) -(IGHD)-IGHJ4*01) [8.8.11] (1-118) -*Homo sapiens* IGHG1*03, G1m3 (CH1 (119-216),charnière K7>del, T8>C (223), T10>del (217-229), CH2 (230-339), CH3 (340-444), CHS K>del (445)) (119-445)], (221-218')-disulfure avec la chaîne légère kappa (1'-218') [V-KAPPA humanisé (*Homo sapiens* IGKV4-1*01 (85.10%) -IGKJ4*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01, Km3 (112'-218')]; dimère (223-223":225-225":228:228")-trisdisulfure; conjugué, sur 3 cystéinyl en moyenne, au monométhylauristatine E (MMAE), via un linker clivable de type maléimidocaproyl-valyl-citrullinyl-*p*-aminobenzyloxycarbonyl (mc-val-cit-PABC)<br>Pour la partie *védotine*, veuillez-vous référer au document *"INN for pharmaceutical substances: Names for radicals, groups and others"*.* |
| telisotuzumab vedotina | inmunoglobulina G1-kappa, anti-[*Homo sapiens* MET (protooncogén met, receptor del factor de crecimiento de los hepatocitos, HGFR, receptor del factor de dispersión, receptor del HGF/SF, receptor proteína-tirosina kinasa c-Met, carcinoma papilar de las células renales 2, RCCP2)], anticuerpo monoclonal humanizado conjugado con la auristatina E;<br>cadena pesada gamma1 (1-445) [VH humanizado (*Homo sapiens* IGHV1-2*02 (92.90%) -(IGHD)-IGHJ4*01) [8.8.11] (1-118) -*Homo sapiens* IGHG1*03, G1m3 (CH1 (119-216),bisagra K7>del, T8>C (223), T10>del (217-229), CH2 (230-339), CH3 (340-444), CHS K>del (445)) (119-445)], (221-218')-disulfuro con la cadena ligera kappa (1'-218') [V-KAPPA humanizado (*Homo sapiens* IGKV4-1*01 (85.10%) -IGKJ4*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01, Km3 (112'-218')]; dímero (223-223":225-225":228:228")-trisdisulfuro; conjugado, sobre una media de 3 cisteinil, a la monometilauristatina E (MMAE), mediante un enlace escindible de tipo maleimidocaproil-valil-citrulinil-*p*-aminobenciloxicarbonil (mc-val-cit-PABC)<br>Para la fracción *vedotina* se pueden referir al documento *"INN for pharmaceutical substances: Names for radicals, groups and others"*.* |

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VKKPGASVKV SCKASGYIFT AYTMHWVRQA PGQGLEWMGW  50
IKPNNGLANY AQKFQGRVTM TRDTSISTAY MELSRLRSDD TAVYYCARSE 100
ITTEFDYWGQ GTLVTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY 150
FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI 200
CNVNHKPSNT KVDKRVEPKS CDCHCPPCPA PELLGGPSVF LFPPKPKDTL 250
MISRTPEVTC VVVDVSHEDP EVKFNWYVDG VEVHNAKTKP REEQYNSTYR 300
VVSVLTVLHQ DWLNGKEYKC KVSNKALPAP IEKTISKAKG QPREPQVYTL 350
PPSREEMTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD 400
GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA LHNHYTQKSL SLSPG      445
```

Light chain / Chaîne légère / Cadena ligera

```
DIVMTQSPDS LAVSLGERAT INCKSSESVD SYANSFLHWY QQKPGQPPKL  50
LIYRASTRES GVPDRFSGSG SGTDFTLTIS SLQAEDVAVY YCQQSKEDPL 100
TFGGGTKVEI KRTVAAPSVF IFPPSDEQLK SGTASVVCLL NNFYPREAKV 150
QWKVDNALQS GNSQESVTEQ DSKDSTYSLS STLTLSKADY EKHKVYACEV 200
THQGLSSPVT KSFNRGEC                                    218
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 145-201 260-320 366-424
22"-96" 145"-201" 260"-320" 366"-424"
Intra-L (C23-C104) 23'-92' 138'-198'
23'"-92'" 138'"-198'"
Inter-H-L (h 5-CL 126)* 221-218' 221"-218"
Inter-H-H (h 11, h 14)* 225-225" 228-228" (h 8>C) 223-223"

*Two or three of the inter-chain disulfide bridges are not present, an average of 3 cysteinyl being conjugated each via a thioether bond to a drug linker.

*Deux ou trois des ponts disulfures inter-chaînes ne sont pas présents, 3 cystéinyl en moyenne étant chacun conjugué via une liaison thioéther à un linker-principe actif.

*Faltan dos o tres puentes disulfuro inter-catenarios, una media de 3 cisteinil está conjugada a conectores de principio activo.

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
296, 296"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

**tenofovirum exalidexum**

tenofovir exalidex — 3-(hexadecyloxy)propyl hydrogen ({[(2*R*)-1-(6-amino-9*H*-purin-9-yl)propan-2-yl]oxy}methyl)phosphonate

ténofovir exalidex — ({[(2*R*)-1-(6-amino-9*H*-purin-9-yl)propan-2-yl]oxy}méthyl)hydrogénophosphonate de 3-(hexadécyloxy)propyle

tenofovir exalidex — ({[(2*R*)-1-(6-amino-9*H*-purin-9-il)propan-2-il]oxi}metil)hidrogenofosfonato de 3-(hexadeciloxi)propilo

$C_{28}H_{52}N_5O_5P$



**tirabrutinibum**

tirabrutinib — 6-amino-9-[(3*R*)-1-(but-2-ynoyl)pyrrolidin-3-yl]-7-(4-phenoxyphenyl)-7,9-dihydro-8*H*-purin-8-one

tirabrutinib — 6-amino-9-[(3*R*)-1-(but-2-ynoyl)pyrrolidin-3-yl]-7-(4-phénoxyphényl)-7,9-dihydro-8*H*-purin-8-one

tirabrutinib — 6-amino-9-[(3*R*)-1-(but-2-inoil)pirrolidin-3-il]-7-(4-fenoxifenil)-7,9-dihidro-8*H*-purin-8-ona




**tonabacasum #**

tonabacase — *Staphylococcus aureus* phage 1 (SAP-1)-derived soluble endolysin (*Staphylococcus aureus* phage lysin-1, bacteriolysin SAL-1), produced in *Escherichia coli*

tonabacase — endolysine soluble dérivée du phage 1 de *Staphylococcus aureus* (lysine du phage 1 de *Staphylococcus aureus*, bactériolysine SAL-1), produite par *Escherichia coli*

tonabacasa — endolisina soluble derivada del fago 1 de *Staphylococcus aureus* (lisina del fago 1 de *Staphylococcus aureus*, bacteriolisina SAL-1), producida por *Escherichia coli*

Sequence / Séquence / Secuencia

```
AKTQAEINKR LDAYAKGTVD SPYRIKKATS YDPSFGVMEA GAIDADGYYH 50
AQCQDLITDY VLWLTDNKVR TWGNAKDQIK QSYGTGFKIH ENKPSTVPKK 100
GWIAVFTSGS YQQWGHIGIV YDGGNTSTFT ILEQNWNGYA NKKPTKRVDN 150
YYGLTHFIEI PVKAGTTVKK ETAKKSASKT PAPKKKATLK VSKNHINYTM 200
DKRGKKPEGM VIHNDAGRSS GQQYENSLAN AGYARYANGI AHYYGSEGYV 250
WEAIDAKNQI AWHTGDGTGA NSGNFRFAGI EVCQSMSASD AQFLKNEQAV 300
FQFTAEKFKE WGLTPNRKTV RLHMEFVPTA CPHRSMVLHT GFNPVTQGRP 350
SQAIMNKLKD YFIKQIKNYM DKGTSSSTVV KDGKTSSAST PATRPVTGSW 400
KKNQYGTWYK PENATFVNGN QPIVTRIGSP FLNAPVGGNL PAGATIVYDE 450
VCIQAGHIWI GYNAYNGNRV YCPVRTCQGV PPNHIPGVAW GVFK       494
```

**tonogenconcelum #**

tonogenconcel — Allogeneic primary human chondrocytes transduced with a retroviral vector expressing human transforming growth factor-beta1 (TGF-β1). A master cell bank of primary human chondrocytes, grown from cartilage tissue obtained from the surgical excision of a polydactyly finger from a three-year-old female donor, was prepared. After transduction of cells from the master cell bank, a single clonal population was selected using limiting dilution and submitted to irradiation.
Cells express TGF-β1, Type I and Type II collagen as well as Type I and Type II TGF-β1 receptors; they lack expression of gag and pol genes.

tonogenconcel — Chondrocytes humains primaires allogéniques transduits par un vecteur rétroviral exprimant le facteur de croissance transformant-bêta1 (TGF-β1). Une banque de cellules primaires a été préparée à partir de tissu cartilagineux obtenu par excision chirurgicale d'un doigt surnuméraire d'un donneur âgé de 3 ans et de sexe féminin. Après transduction des cellules de la banque de cellules primaires, un seul clone a été sélectionné en utilisant une dilution limitative et en le soumettant à une irradiation.
Les cellules expriment le TGF- β1, du collagène de type I et II ainsi que les récepteurs de type I et II du TGF- β1; elles sont dépourvues d'expression de gènes gag et pol.

tonogenconcel

Condrocitos humanos primarios alogénicos transducidos por un vector retroviral que expresa el factor de crecimiento transformador-bêta1 (TGF-β1). Un banco de células primarias preparado a partir de tejido cartilaginoso obtenido por escisión quirúrgica de un dedo adicional de un donante de 3 años de edad y de sexo femenino. Después de la transducción de las células del banco de células primarias, se selecciona un único clon utilizando una dilución limitante y se somete a radiación.
Las células que expresan el TGF- β1, del colágeno de tipo I y II así como los receptes de tipo I y II del TGF- β1; ellas carecen de la expresión de los genes gag y pol.

**tozuleristidum**
tozuleristide

$N^{6.27}$-[6-(2-{(1*E*,2*E*,4*E*,6*E*)-7-[1,1-dimethyl-3-(4-sulfonatobutyl)-1*H*-benzo[*e*]indol-3-ium-2-yl]hepta-2,4,6-trien-1-ylidene}-1,1-dimethyl-1,2-dihydro-3*H*-benzo[*e*]indol-3-yl)hexanoyl]-[$Lys^{15}$>Arg,$Lys^{23}$>Arg]chlorotoxin (*Leiurus quinquestriatus quinquestriatus*) (Egyptian scorpion)

tozuléristide

$N^{6.27}$-[6-(2-{(1*E*,2*E*,4*E*,6*E*)-7-[1,1-diméthyl-3-(4-sulfonatobutyl)-1*H*-benzo[*e*]indol-3-ium-2-yl]hepta-2,4,6-trién-1-ylidène}-1,1-diméthyl-1,2-dihydro-3*H*-benzo[*e*]indol-3-yl)hexanoyl]-[$Lys^{15}$>Arg,$Lys^{23}$>Arg]chlorotoxine de *Leiurus quinquestriatus quinquestriatus* (scorpion égyptien)

tozuleristida

$N^{6.27}$-[6-(2-{(1*E*,2*E*,4*E*,6*E*)-7-[1,1-dimetil-3-(4-sulfonatobutil)-1*H*-benzo[*e*]indol-3-ium-2-il]hepta-2,4,6-trien-1-ilideno}-1,1-dimetil-1,2-dihidro-3*H*-benzo[*e*]indol-3-il)hexanoil]-[$Lys^{15}$>Arg,$Lys^{23}$>Arg]clorotoxina de *Leiurus quinquestriatus quinquestriatus* (escorpión egipcio)
$C_{203}H_{296}N_{58}O_{52}S_{12}$

Sequence / Sequence / Secuencia
MCMPCFTTDH QMARRCDDCC GGRGRGKCYG PQCLCR 36

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
2-19 5-28 16-33 20-35

Modified residue / Résidu modifié / Resto modificado




**trastuzumabum duocarmazinum #**
trastuzumab duocarmazine

immunoglobulin G1-kappa, anti-[*Homo sapiens* ERBB2 (epidermal growth factor receptor 2, receptor tyrosine-protein kinase erbB-2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340)], humanized monoclonal antibody conjugated to the pro-drug *seco*-duocarmycin-hydroxybenzamide-azaindole (*seco*-DUBA);

| | |
|---|---|
| | gamma1 heavy chain (1-449) [humanized VH (*Homo sapiens* (IGHV3-66-*01 (81.60%) -(IGHD)-IGHJ6*01) [8.8.13] (1-120) -*Homo sapiens* IGHG1*01, G1m17, nG1m1 (CH1 (121-218), hinge (219-233),CH2 (234-343), CH3 D12>E (359), L14>M (361) (344-448), CHS K>del (449)) (121-449)], (223-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens* IGKV1-39*01 (86.30%) -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimer (229-229":232-232")-bisdisulfide, conjugated on an average of 2 or 4 cysteines, to *seco*-DUBA via the cleavable linker *N*-[2-(2-maleimidoethoxy)ethoxycarbonyl]-L-valyl-L-citrullinyl-*p*-aminobenzyloxycarbonyl-*N*-[2-(2-hydroxyethoxy)ethyl]-*N*-[2-(methylamino)ethyl]carbamoyl |
| trastuzumab duocarmazine | immunoglobuline G1-kappa, anti-[*Homo sapiens* ERBB2 (récepteur 2 du facteur de croissance épidermique, récepteur tyrosine-protéine kinase erbB-2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340)], anticorps monoclonal humanisé conjugué à la pro-drogue *seco*-duocarmycine-hydroxybenzamide-azaindole (*seco*-DUBA); chaîne lourde gamma1 (1-449) [VH humanisé (*Homo sapiens* (IGHV3-66-*01 (81.60%) -(IGHD)-IGHJ6*01) [8.8.13] (1-120) -*Homo sapiens* IGHG1*01, G1m17, nG1m1 (CH1 (121-218), charnière (219-233),CH2 (234-343), CH3 D12>E (359), L14>M (361) (344-448), CHS K>del (449)) (121-449)], (223-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (*Homo sapiens* IGKV1-39*01 (86.30%) -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimère (229-229":232-232")-bisdisulfure, conjugué sur une moyenne de 2 ou 4 cystéines au *séco*-DUBA via le linker clivable *N*-[2-(2-maléimidoéthoxy)éthoxycarbonyl]-L-valyl-L-citrullinyl-*p*-aminobenzyloxycarbonyl-*N*-[2-(2-hydroxyéthoxy)éthyl]-*N*-[2-(méthylamino)éthyl]carbamoyle |
| trastuzumab duocarmazina | inmunoglobulina G1-kappa, anti-[*Homo sapiens* ERBB2 (receptor 2 del factor de crecimiento epidérmico, receptor tirosina-proteína kinasa erbB-2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340)], anticuerpo monoclonal humanizado conjugado con el profármaco *seco*-duocarmicina-hidroxibenzamida-azaindol (*seco*-DUBA); cadena pesada gamma1 (1-449) [VH humanizado (*Homo sapiens* (IGHV3-66-*01 (81.60%) -(IGHD)-IGHJ6*01) [8.8.13] (1-120) -*Homo sapiens* IGHG1*01, G1m17, nG1m1 (CH1 (121-218), bisagra (219-233),CH2 (234-343), CH3 D12>E (359), L14>M (361) (344-448), CHS K>del (449)) (121-449)], (223-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizado (*Homo sapiens* IGKV1-39*01 (86.30%) -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dímero (229-229":232-232")-bisdisulfuro; conjugado en 2 o 4 cisteínas, por término medio con *seco*-DUBA mediante el enlace escin-dible *N*-[2-(2-maleimidoetoxi)etoxicarbonil]-L-valil-L-citrulinil-*p*-aminobenciloxicarbonil-*N*-[2-(2-hidroxietoxi)etil]-*N*-[2-(metilamino)etil]carbamoilo |

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG LVQPGGSLRL SCAASGFNIK DTYIHWVRQA PGKGLEWVAR  50
IYPTNGYTRY ADSVKGRFTI SADTSKNTAY LQMNSLRAED TAVYYCSRWG 100
GDGFYAMDYW GQGTLVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK 150
DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT 200
YICNVNHKPS NTKVDKKVEP KSCDKTHTCP PCPAPELLGG PSVFLFPPKP 250
KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN 300
STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ 350
VYTLPPSREE MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV 400
LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPG  449
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVT ITCRASQDVN TAVAWYQQKP GKAPKLLIYS  50
ASFLYSGVPS RFSGSRSGTD FTLTISSLQP EDFATYYCQQ HYTTPPTFGQ 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                        214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

| | | | | |
|---|---|---|---|---|
| Intra-H (C23-C104) | 22-96 | 147-203 | 264-324 | 370-428 |
| | 22"-96" | 147"-203" | 264"-324" | 370"-428" |
| Intra-L (C23-C104) | 23'-88' | 134'-194' | | |
| | 23'"-88'" | 134'"-194'" | | |
| Inter-H-L (h 5-CL 126)* | 223-214' | 223"-214'" | | |
| Inter-H-H (h 11, h 14)* | 229-229" | 232-232" | | |

*Two or three of the inter-chain disulfide bridges are not present, on average 2 or 4 cysteinyl being conjugated each via a thioether bond to a drug linker.

*Deux ou trois des ponts disulfures inter-chaînes ne sont pas présents, 2 or 4 cystéinyl en moyenne étant chacun conjugué via une liaison thioéther à un linker-principe actif.

*Faltan dos o tres puentes disulfuro inter-catenarios, una media de 2 o 4 cisteinil está conjugada a conectores de principio activo.

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
300, 300"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

Potential modified residues / résidus modifiés potentiels / restos modificados potenciales

C*
214', 214'", 223, 223",
229, 229", 232, 232"



**tucidinostatum**

tucidinostat — *N*-(2-amino-4-fluorophenyl)-4-{[(2*E*)-3-(pyridin-3-yl)prop-2-enamido]methyl}benzamide

tucidinostat — *N*-(2-amino-4-fluorophényl)-4-{[(2*E*)-3-(pyridin-3-yl)prop-2-énamido]méthyl}benzamide

tucidinostat — *N*-(2-amino-4-fluorofenil)-4-{[(2*E*)-3-(piridin-3-il)prop-2-enamido]metil}benzamida

$C_{22}H_{19}FN_4O_2$



**upadacitinibum**

upadacitinib — (3*S*,4*R*)-3-ethyl-4-(3*H*-imidazo[1,2-*a*]pyrrolo[2,3-*e*]pyrazin-8-yl)-*N*-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide

upadacitinib

(3*S*,4*R*)-3-éthyl-4-(3*H*-imidazo[1,2-*a*]pyrrolo[2,3-*e*]pyrazin-8-yl)-*N*-(2,2,2-trifluoroéthyl)pyrrolidine-1-carboxamide

upadacitinib

(3*S*,4*R*)-3-etil-4-(3*H*-imidazo[1,2-*a*]pirrolo[2,3-*e*]pirazin-8-il)-*N*-(2,2,2-trifluoroetil)pirrolidina-1-carboxamida




**uprifosbuvirum**

uprifosbuvir

propan-2-yl *N*-[(*R*)-{[(2*R*,3*R*,4*R*,5*R*)-4-chloro-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2*H*)-yl)-3-hydroxy-4-methyloxolan-2-yl]methoxy}phenoxyphosphoryl]-D-alaninate

uprifosbuvir

*N*-[(*R*)-{[(2*R*,3*R*,4*R*,5*R*)-4-chloro-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2*H*)-yl)-3-hydroxy-4-méthyloxolan-2-yl]méthoxy}phénoxyphosphoryl]-D-alaninate de propan-2-yle

uprifosbuvir

*N*-[(*R*)-{[(2*R*,3*R*,4*R*,5*R*)-4-cloro-5-(2,4-dioxo-3,4-dihidropirimidin-1(2*H*)-il)-3-hidroxi-4-metiloxolan-2-il]metoxi}fenoxifosforil]-D-alaninato de propan-2-ilo




**utomilumabum #**

utomilumab

immunoglobulin G2-lambda, anti-[*Homo sapiens* TNFRSF9 (tumor necrosis factor receptor (TNFR) superfamily member 9, 4-1BB, T cell antigen ILA, CD137)], *Homo sapiens* monoclonal antibody;
gamma2 heavy chain (1-442) [*Homo sapiens* VH (IGHV5-10-1*04 (94.90%) -(IGHD)-IGHJ4*01) [8.8.9] (1-116) -IGHG2*01, G2m.. (CH1 (117-214), hinge (215-226), CH2 (227-335), CH3 (336-440), CHS (441-442)) (117-442)], (130-213')-disulfide with lambda light chain (1'-214') [*Homo sapiens* V-LAMBDA (IGLV3-1*01 (90.00%) -IGLJ7*01) [6.3.11] (1'-108') -IGLC2*01 (109'-214')]; dimer (218-218":219-219":222-222":225-225")-tetrakisdisulfide

utomilumab

immunoglobuline G2-lambda, anti-[*Homo sapiens* TNFRSF9 (membre 9 de la superfamille des récepteurs du facteur de nécrose tumorale, 4-1BB, antigène ILA de lymphocyte T, CD137)], *Homo sapiens* anticorps monoclonal;

| | |
|---|---|
| | chaîne lourde gamma2 (1-442) [*Homo sapiens* VH (IGHV5-10-1*04 (94.90%) -(IGHD)-IGHJ4*01) [8.8.9] (1-116) -IGHG2*01, G2m.. (CH1 (117-214), charnière (215-226), CH2 (227-335), CH3 (336-440), CHS (441-442)) (117-442)], (130-213')-disulfure avec la chaîne légère lambda (1'-214') [*Homo sapiens* V-LAMBDA (IGLV3-1*01 (90.00%) -IGLJ7*01) [6.3.11] (1'-108') -IGLC2*01 (109'-214')]; dimère (218-218'':219-219'':222-222'':225-225'')-tétrakisdisulfure |
| utomilumab | inmunoglobulina G2-lambda, anti-[*Homo sapiens* TNFRSF9 (miembro 9 de la superfamilia de los receptores del factor de necrosis tumoral, 4-1BB, antígeno ILA de linfocito T, CD137)], *Homo sapiens* anticuerpo monoclonal; cadena pesada gamma2 (1-442) [*Homo sapiens* VH (IGHV5-10-1*04 (94.90%) -(IGHD)-IGHJ4*01) [8.8.9] (1-116) -IGHG2*01, G2m.. (CH1 (117-214), bisagra (215-226), CH2 (227-335), CH3 (336-440), CHS (441-442)) (117-442)], (130-213')-disulfuro con la cadena ligera lambda (1'-214') [*Homo sapiens* V-LAMBDA (IGLV3-1*01 (90.00%) -IGLJ7*01) [6.3.11] (1'-108') -IGLC2*01 (109'-214')]; dímero (218-218'':219-219'':222-222'':225-225'')-tetrakisdisulfuro |

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVQSGAE VKKPGESLRI SCKGSGYSFS TYWISWVRQM PGKGLEWMGK  50
IYPGDSYTNY SPSFQGQVTI SADKSISTAY LQWSSLKASD TAMYYCARGY 100
GIFDYWGQGT LVTVSSASTK GPSVFPLAPC SRSTSESTAA LGCLVKDYFP 150
EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS LSSVVTVPSS NFGTQTYTCN 200
VDHKPSNTKV DKTVERKCCV ECPPCPAPPV AGPSVFLFPP KPKDTLMISR 250
TPEVTCVVVD VSHEDPEVQF NWYVDGVEVH NAKTKPREEQ FNSTFRVVSV 300
LTVVHQDWLN GKEYKCKVSN KGLPAPIEKT ISKTKGQPRE PQVYTLPPSR 350
EEMTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTP PMLDSDGSFF 400
LYSKLTVDKS RWQQGNVFSC SVMHEALHNH YTQKSLSLSP GK         442
```

Light chain / Chaîne légère / Cadena ligera

```
SYELTQPPSV SVSPGQTASI TCSGDNIGDQ YAHWYQQKPG QSPVLVIYQD  50
KNRPSGIPER FSGSNSGNTA TLTISGTQAM DEADYYCATY TGFGSLAVFG 100
GGTKLTVLGQ PKAAPSVTLF PPSSEELQAN KATLVCLISD FYPGAVTVAW 150
KADSSPVKAG VETTTPSKQS NNKYAASSYL SLTPEQWKSH RSYSCQVTHE 200
GSTVEKTVAP TECS                                        214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

| | | | | |
|---|---|---|---|---|
| Intra-H (C23-C104) | 22-96 | 143-199 | 256-316 | 362-420 |
| | 22''-96'' | 143''-199'' | 256''-316'' | 362''-420'' |
| Intra-L (C23-C104) | 22'-87' | 136'-195' | | |
| | 22'''-87''' | 136'''-195''' | | |
| Inter-H-L (CH1 10-CL 126) | 130-213' | 130''-213''' | | |
| Inter-H-H (h 4, h 5, h 8, h 11) | 218-218'' | 219-219'' | 222-222'' | 225-225'' |

*In addition to the isoform A, isoform A/B characterized by an inter-H-H (h 4 - CH1 10) 218-130'' and an inter-H-L (h 4-CL 126) 218''-213'', instead of the inter-H-H (h 4 - h 4) 218-218'' and of one of the two inter-H-L (CH1 10-CL 126) 130''-213'', isoform B characterized by an inter-H-H (h 5 - CH1 10) 219-130 and an inter-H-L (h 5- CL 126) 219''-213', instead of the inter-H-H (h 5 - h 5) 219-219'' and of the inter-H-L (CH1 10-CL 126) 130-213'.

*En plus de l'isoforme A, isoforme A/B caractérisée par un inter-H-H (h 4 - CH1 10) 218-130'' et un inter-H-L (h 4- CL 126) 218''-213'', au lieu de l'inter-H-H (h 4 - h 4) 218-218'' et de l'un des deux inter-H-L (CH1 10-CL 126) 130''-213'', isoforme B caractérisée par un inter-H-H (h 5 - CH1 10) 219-130 et un inter-H-L (h 5- CL 126) 219''-213', au lieu de l'inter-H-H (h 5 - h 5) 219-219'' et de l'inter-H-L (CH1 10-CL 126) 130-213'.

*Además de la isoforma A, isoforma A/B caracterizado por un inter-H-H (h4 - CH1 10) 218-130'' y un inter-H-L (h 4- CL 126) 218''-213'', en lugar del inter-H-H (h 4 - h 4) 218-218'' y uno de los dos inter-H-L (CH1 10-CL 126) 130''-213'', isoforma B caracterizado por un inter-H-H (h 5 - CH1 10) 219-130 y un inter-H-L (h 5- CL 126) 219''-213', en lugar del inter-H-H (h 5 - h 5) 219-219'' y del inter-H-L (CH1 10-CL 126) 130-213'.

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H VH N66:
59, 59'' (partially occupied, with up to two sialic acids)
H CH2 N84.4:
292, 292'' (fully occupied)
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados.

Other post-translational modifications / Autres modifications post-traductionnelles / Otras modificaciones post-traduccionales
H CHS K2 C-terminal lysine clipping:
442, 442''

**valnivudinum**

valnivudine — {(2*R*,3*S*,5*R*)-3-hydroxy-5-[2-oxo-6-(4-pentylphenyl)furo[2,3-*d*]pyrimidin-3(2*H*)-yl]oxolan-2-yl}methyl L-valinate

valnivudine — L-valinate de {(2*R*,3*S*,5*R*)-3-hydroxy-5-[2-oxo-6-(4-pentylphényl)furo[2,3-*d*]pyrimidin-3(2*H*)-yl]oxolan-2-yl}methyl

valnivudina — L-valinato de {(2*R*,3*S*,5*R*)-3-hidroxi-5-[2-oxo-6-(4-pentilfenil)furo[2,3-*d*]pirimidin-3(2*H*)-il]oxolan-2-il}metilo

$C_{27}H_{35}N_3O_6$



**vamorolonum**

vamorolone — 17,21-dihydroxy-16α-methylpregna-1,4,9(11)-triene-3,20-dione

vamorolone — 17,21-dihydroxy-16α-méthylprègna-1,4,9(11)-triène-3,20-dione

vamorolona — 17,21-dihidroxi-16α-metilpregna-1,4,9(11)-trieno-3,20-diona

$C_{22}H_{28}O_4$



**vandefitemcelum**

vandefitemcel — human differentiation-restricted descendents (DRCs) of bone-marrow-derived adherent stromal cells (MASCs) isolated from adult donor. To obtain DRCs, MASCs were transiently transfected with a DNA plasmid encoding human Notch-1 intracellular domain (NICD) and expanded in growth media. The transfection does not result in permanent incorporation of the gene into the cells, but does result in changes in a number of proteins and in the methylation pattern of the DNA (there is complete loss of recombinant NICD protein and of the plasmid in the final cell population). The transfection changes the nature of the cells such that they no longer readily differentiate into bone, cartilage or adipose cells, and also results in cells altered in their ability to secrete trophic and chemotactic factors, and extracellular matrix proteins to support damaged neural cells.

| | |
|---|---|
| | Cells are positive for mesenchymal stem cell (MSC) markers (CD29, CD90, CD105) and negative for hematopoietic markers (CD31, CD34, CD45). |
| vandéfitemcel | descendants à différenciation restreinte (DRCs) humains de cellules stromales adhérentes dérivées de la moelle osseuse (MASCs) isolées d'un donneur adulte. Pour obtenir les DRCs, les MASCs ont été transitoirement transfectées avec un plasmide dont l'ADN code pour le domaine intracellulaire de Notch-1 humain (NICD) et ont été expansées par des moyens de croissance. La transfection ne résulte pas d'une incorporation permanente du gène dans les cellules, mais de changements dans un nombre de protéines et dans les méthylations de l'ADN (il y a une perte complète de la protéine recombinante NICD et du plasmide dans la population finale). La transfection change la nature des cellules de telle sorte qu'elles ne se différencient plus en cellules osseuses, cartilagineuses ou adipeuses et il en résulte aussi des cellules modifiées dans leur capacité à secréter des facteurs trophiques et chimiotactiques, et des protéines de la matrice extracellulaire qui supportent les cellules neuronales endommagées.<br>Les cellules sont positives pour les marqueurs des cellules souches mésenchymateuses (CD29, CD90, CD105) et négatives pour les marqueurs hématopoïétiques (CD31, CD34, CD45). |
| vandefitemcel | descendientes humanos de la diferenciación restrictiva (DRCs) de células estromales adherentes derivadas de la médula ósea (MASCs) aisladas de un donante adulto. Para obtener los DRCs, las MASCs se transfectan transitoriamente con un plásmido de ADN que codifica para el dominio intracelular Notch-1 humano (NICD) y se expanden en un medio de crecimiento. La transfección no resulta en una incorporación permanente del gen dentro de las células, pero sí en cambios en el número de proteínas y en el patrón de metilación del DNA (hay una pérdida completa de proteína recombinante NICD y del plásmido en la población final celular).<br>La transfección cambia la naturaleza de las células de tal modo que no se diferencian con más facilidad en células óseas, cartilaginosas o adiposas y también resulta en células modificadas bajo la capacidad de secretar factores tróficos y quimiotácticos, y las proteínas de la matriz extracelular que soportan las células neuronales dañadas. Las células son positivas para los marcadores de las células madres mesenquimales (CD29, CD90, CD105) y negativas para los marcadores hematopoyéticos (CD31, CD34, CD45). |
| **velagliflozinum** | |
| velagliflozin | 2-[(4-cyclopropylphenyl)methyl]-4-β-D-glucopyranosylbenzonitrile |
| vélagliflozine | 2-[(4-cyclopropylphényl)méthyl]-4-β-D-glucopyranosylbenzonitrile |

velagliflozina

2-[(4-ciclopropilfenil)metil]-4-β-D-glucopiranosilbenzonitrilo

$C_{23}H_{25}NO_5$




**vestronidasum alfa #**

vestronidase alfa

human β-glucuronidase, natural Leu$^{627}$>Pro variant, homotetramer, produced in Chinese hamster ovary cells (CHO), glycoform alfa

vestronidase alfa

β-glucuronidase humaine, variant naturel Leu$^{627}$>Pro, homotétramère, produit dans des cellules ovariennes de hamsters chinois (CHO), glycoforme alfa

vestronidasa alfa

β-glucuronidasa humana, variante natural Leu$^{627}$>Pro, homotetrámero, producido en células de ovario de hamster chino (CHO), glicoforma alfa

Monomer /Monomère / Monómero

```
LQGGMLYPQE SPSRECKELD GLWSFRADFS DNRRRGFEEQ WYRRPLWESG 50
PTVDMPVPSS FNDISQDWRL RHFVGWVWYE REVILPERWT QDLRTRVVLR 100
IGSAHSYAIV WVNGVDTLEH EGGYLPFEAD ISNLVQVGPL PSRLRITIAI 150
NNTLTPTTLP PGTIQYLTDT SKYPKGYFVQ NTYFDFFNYA GLQRSVLLYT 200
TPTTYIDDIT VTTSVEQDSG LVNYQISVKG SNLFKLEVRL LDAENKVVAN 250
GTGTQGQLKV PGVSLWWPYL MHERPAYLYS LEVQLTAQTS LGPVSDFYTL 300
PVGIRTVAVT KSQFLINGKP FYFHGVNKHE DADIRGKGFD WPLLVKDFNL 350
LRWLGANAFR TSHYPYAEEV MQMCDRYGIV VIDECPGVGL ALPQFFNNVS 400
LHHHMQVMEE VVRRDKNHPA VVMWSVANEP ASHLESAGYY LKMVIAHTKS 450
LDPSRPVTFV SNSNYAADKG APYVDVICLN SYYSWYHDYG HLELIQLQLA 500
TQFENWYKKY QKPIIQSEYG AETIAGFHQD PPLMFTEEYQ KSLLEQYHLG 550
LDQKRRKYVV GELIWNFADF MTEQSPTRVL GNKKGIFTRQ RQPKSAAFLL 600
RERYWKIANE TRYPHSVAKS QCLENSPFT                        629
```

Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)
Asn-151 Asn-250 Asn-398 Asn-609

Disulfide bridges (**C**)
inter-chain 622-622' 622''-622'''
intra-chain not determined

**voretigenum neparvovecum #**

voretigene neparvovec

recombinant adeno-associated serotype 2 (rAAV-2) virus vector that carries the RPE65 gene, encoding a retinal pigment (RPE)-specific human retinoid isomerohydrolase, containing a modified Kozak sequence at the translation start site and under the control of the cytomegalovirus (CMV) immediate early enhancer and the chicken beta-actin (CBA) promoter.

voretigène néparvovec

vecteur viral adéno-associé de type 2 (rAAV-2) recombinant, contenant le gène RPE65 codant pour l'isomérohydrolase des rétinoïdes, humaine, spécifique de l'épithélium pigmentaire de la rétine, contenant une séquence de Kozak au site de démarrage de la traduction et sous le contrôle de l'activateur immédiat-précoce du cytomégalovirus et du promoteur de l'actine bêta du poulet (ABP, CBA).

voretigén neparvovec

vector viral adeno-associado de tipo 2 (rAAV-2) recombinante, que contiene el gen RPE65 que codifica para la retinoide isomerohidrolasa, humana, especifica del epitelium pigmentario de la retina, que contiene una secuencia de Kozak al sitio del comienzo de la traducción y bajo el control del activador inmediato precoz del citomegalovirus (CMV) y del promotor de la actina beta del pollo (CBA).

**vorolanibum**

vorolanib

*N*-[(3*S*)-1-(dimethylcarbamoyl)pyrrolidin-3-yl]-5-[(*Z*)-(5-fluoro-2-oxo-1,2-dihydro-3*H*-indol-3-ylidene)methyl]-2,4-dimethyl-1*H*-pyrrole-3-carboxamide

vorolanib

*N*-[(3*S*)-1-(diméthylcarbamoyl)pyrrolidin-3-yl]-5-[(*Z*)-(5-fluoro-2-oxo-1,2-dihydro-3*H*-indol-3-ylidène)méthyl]-2,4-diméthyl-1*H*-pyrrole-3-carboxamide

vorolanib

*N*-[(3*S*)-1-(dimetilcarbamoil)pirrolidin-3-il]-5-[(*Z*)-(5-fluoro-2-oxo-1,2-dihidro-3*H*-indol-3-ilideno)metil]-2,4-dimetil-1*H*-pirrolo-3-carboxamida

$C_{23}H_{26}FN_5O_3$



**vunakizumabum #**

vunakizumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* IL17A (interleukin 17A, IL-17A)], humanized monoclonal antibody;
gamma1 heavy chain (1-453) [humanized VH (*Homo sapiens* IGHV1-2*02 (82.70%) -(IGHD)-IGHJ4*01) [8.8.16] (1-123) -*Homo sapiens* IGHG1*01, G1m17, nG1m1 (CH1 (124-221), hinge (222-236),CH2 (237-346), CH3 D12>E (362), L14>M (364) (347-451), CHS (452-453)) (124-453)], (226-213')-disulfide with kappa light chain (1'-213') [humanized V-KAPPA (*Homo sapiens* IGKV6-21*01 (80.00%) -IGKJ1*01) [5.3.9] (1'-106') -*Homo sapiens* IGKC*01, Km3 (107'-213')]; dimer (232-232":235-235")-bisdisulfide

vunakizumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* IL17A (interleukine 17A, IL-17A)], anticorps monoclonal humanisé;
chaîne lourde gamma1 (1-453) [VH humanisé (*Homo sapiens* IGHV1-2*02 (82.70%) -(IGHD)-IGHJ4*01) [8.8.16] (1-123) -*Homo sapiens* IGHG1*01, G1m17, nG1m1 (CH1 (124-221), charnière (222-236),CH2 (237-346), CH3 D12>E (362), L14>M (364) (347-451), CHS (452-453)) (124-453)], (226-213')-disulfure avec la chaîne légère

kappa (1'-213') [V-KAPPA humanisé (*Homo sapiens* IGKV6-21*01 (80.00%) -IGKJ1*01) [5.3.9] (1'-106') -*Homo sapiens* IGKC*01, Km3 (107'-213')]; dimère (232-232":235-235")-bisdisulfure

vunakizumab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* IL17A (interleukina 17A, IL-17A)], anticuerpo monoclonal humanizado;
cadena pesada gamma1 (1-453) [VH humanizado (*Homo sapiens* IGHV1-2*02 (82.70%) -(IGHD)-IGHJ4*01) [8.8.16] (1-123) -*Homo sapiens* IGHG1*01, G1m17, nG1m1 (CH1 (124-221), bisagra (222-236),CH2 (237-346), CH3 D12>E (362), L14>M (364) (347-451), CHS (452-453)) (124-453)], (226-213')-disulfuro con la cadena ligera kappa (1'-213') [V-KAPPA humanizado (*Homo sapiens* IGKV6-21*01 (80.00%) -IGKJ1*01) [5.3.9] (1'-106') -*Homo sapiens* IGKC*01, Km3 (107'-213')]; dímero (232-232":235-235")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVQSGAE VKKPGASVKV SCKASGYTFT DYEVHWVRQA PGQGLEWMGV  50
IDPGTGGVAY NQKFEGRVTM TADTSTSTAY MELRSLRSDD TAVYYCTRYS 100
LFYGSSPYAM DYWGQGTLVT VSSASTKGPS VFPLAPSSKS TSGGTAALGC 150
LVKDYFPEPV TVSWNSGALT SGVHTFPAVL QSSGLYSLSS VVTVPSSSLG 200
TQTYICNVNH KPSNTKVDKK VEPKSCDKTH TCPPCPAPEL LGGPSVFLFP 250
PKPKDTLMIS RTPEVTCVVV DVSHEDPEVK FNWYVDGVEV HNAKTKPREE 300
QYNSTYRVVS VLTVLHQDWL NGKEYKCKVS NKALPAPIEK TISKAKGQPR 350
EPQVYTLPPS REEMTKNQVS LTCLVKGFYP SDIAVEWESN GQPENNYKTT 400
PPVLDSDGSF FLYSKLTVDK SRWQQGNVFS CSVMHEALHN HYTQKSLSLS 450
PGK                                                     453
```

Light chain / Chaîne légère / Cadena ligera

```
EIVLTQSPDF QSVTPKEKVT ITCSASSSVN YMHWFQQKPD QSPKLWIYRT  50
SNLASGVPSR FSGSGSGTDY TLTINSLEAE DAATYYCQQR SSYPWTFGQG 100
TKLEIKRTVA APSVFIFPPS DEQLKSGTAS VVCLLNNFYP REAKVQWKVD 150
NALQSGNSQE SVTEQDSKDS TYSLSSTLTL SKADYEKHKV YACEVTHQGL 200
SSPVTKSFNR GEC                                          213
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

| | | | | |
|---|---|---|---|---|
| Intra-H (C23-C104) | 22-96 | 150-206 | 267-327 | 373-431 |
| | 22"-96" | 150"-206" | 267"-327" | 373"-431" |
| Intra-L (C23-C104) | 23'-87' | 133'-193' | | |
| | 23'"-87'" | 133'"-193'" | | |
| Inter-H-L (h 5-CL 126) | 226-213' | 226"-213'" | | |
| Inter-H-H (h 11, h 14) | 232-232" | 235-235" | | |

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
303, 303"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

Other post-translational modifications / Autres modifications post-traductionnelles / Otras modificaciones post-traduccionales
H CHS K2 C-terminal lysine clipping:
453, 453"

# Electronic structure available on Mednet: http://mednet.who.int/
# Structure électronique disponible sur Mednet: http://mednet.who.int/
# Estructura electrónica disponible en Mednet: http://mednet.who.int/
* http://www.who.int/medicines/services/inn/publication/en/

## AMENDMENTS TO PREVIOUS LISTS
## MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
## MODIFICACIONES A LAS LISTAS ANTERIORES

**Recommended International Nonproprietary Names (Rec. INN): List 32**
**Dénominations communes internationales recommandées (DCI Rec.): Liste 32**
**Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 32**
***(WHO Drug Information, Vol. 6, No. 3, 1992)***

| | | |
|---|---|---|
| p. 9 | *suprimáse*<br>tacrolimus | *insertese*<br>tacrólimus |

**Recommended International Nonproprietary Names (Rec. INN): List 34**
**Dénominations communes internationales recommandées (DCI Rec.): Liste 34**
**Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 34**
***(WHO Drug Information, Vol. 8, No. 3, 1994)***

| | | |
|---|---|---|
| p. 19 | *suprimáse*<br>sirolimus | *insertese*<br>sirólimus |

**Recommended International Nonproprietary Names (Rec. INN): List 43**
**Dénominations communes internationales recommandées (DCI Rec.): Liste 43**
**Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 43**
***(WHO Drug Information, Vol. 14, No. 1, 2000)***

| | | |
|---|---|---|
| p. 64 | *suprimáse*<br>pimecrolimús | *insertese*<br>pimecrólimus |

**Recommended International Nonproprietary Names (Rec. INN): List 44**
**Dénominations communes internationales recommandées (DCI Rec.): Liste 44**
**Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 44**
***(WHO Drug Information, Vol. 14, No. 3, 2000)***

| | | |
|---|---|---|
| p. 194 | *suprimáse*<br>everolimus | *insertese*<br>everólimus |

**Recommended International Nonproprietary Names (Rec. INN): List 54**
**Dénominations communes internationales recommandées (DCI Rec.): Liste 54**
**Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 54**
***(WHO Drug Information, Vol. 19, No. 3, 2005)***

| | | |
|---|---|---|
| p. 266 | *suprimáse*<br>temsirolimus | *insertese*<br>temsirólimus |

**Recommended International Nonproprietary Names (Rec. INN): List 56**
**Dénominations communes internationales recommandées (DCI Rec.): Liste 56**
**Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 56**
***(WHO Drug Information, Vol. 20, No. 3, 2006)***

| | | |
|---|---|---|
| p. 233 | *suprimáse*<br>zotarolimus | *insertese*<br>zotarólimus |

**Recommended International Nonproprietary Names (Rec. INN): List 65**
**Dénominations communes internationales recommandées (DCI Rec.): Liste 65**
**Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 65**
***(WHO Drug Information, Vol. 25, No. 1, 2011)***

| p. 91 | *suprimáse* | *insertese* |
|---|---|---|
| | umirolimús | umirólimus |

**Recommended International Nonproprietary Names (Rec. INN): List 67**
**Dénominations communes internationales recommandées (DCI Rec.): Liste 67**
**Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 67**
***(WHO Drug Information, Vol. 26, No. 1, 2012)***

| p. 77 | *suprimáse* | *insertese* |
|---|---|---|
| | olcorolimús | olcorólimus |

**Recommended International Nonproprietary Names (Rec. INN): List 69**
**Dénominations communes internationales recommandées (DCI Rec.): Liste 69**
**Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 69**
***(WHO Drug Information, Vol. 27, No. 1, 2013)***

p. 44 **antithrombinum gamma #**

antithrombin gamma
antithrombine gamma
antitrombina gamma

*replace the structure by the following one*
*remplacer la structure par la suivante*
*sustitúyase la estructura por la siguiente*

```
HGSPVDICTA KPRDIPMNPM CIYRSPEKKA TEDEGSEQKI PEATNRRVWE 50
LSKANSRFAT TFYQHLADSK NDNDNIFLSP LSISTAFAMT KLGACNDTLQ 100
QLMEVFKFDT ISEKTSDQIH FFFAKLNCRL YRKANKSSKL VSANRLFGDK 150
SLTFNETYQD ISELVYGAKL QPLDFKENAE QSRAAINKWV SNKTEGRITD 200
VIPSEAINEL TVLVLVNTIY FKGLWKSKFS PENTRKELFY KADGESCSAS 250
MMYQEGKFRY RRVAEGTQVL ELPFKGDDIT MVLILPKPEK SLAKVEKELT 300
PEVLQEWLDE LEEMMLVVHM PRFRIEDGFS LKEQLQDMGL VDLFSPEKSK 350
LPGIVAEGRD DLYVSDAFHK AFLEVNEEGS EAAASTAVVI AGRSLNPNRV 400
TFKANRPFLV FIREVPLNTI IFMGRVANPC VK                    432
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
8-128 21-95 247-430

Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)
Asn-96 Asn-135 Asn-155 Asn-192

α-Sia→3-β-Gal→3-β-Gl-*N*→2-α-Man→6-
β-Man→4-β-Gl-*N*→4-β-Gl-*N*→N
α-Sia→3-β-Gal→3-β-Gl-*N*→2-α-Man→3-

**Recommended International Nonproprietary Names (Rec. INN): List 69**
**Dénominations communes internationales recommandées (DCI Rec.): Liste 69**
**Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 69**
***(WHO Drug Information, Vol. 27, No. 1, 2013)***

| p. 90 | *suprimáse* | *insertese* |
|---|---|---|
| | ridaforolimus | ridaforólimus |

**Recommended International Nonproprietary Names (Rec. INN): List 76**
**Dénominations communes internationales recommandées (DCI Rec.): Liste 76**
**Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 76**
***(WHO Drug Information, Vol. 30, No. 3, 2016)***

p. 496 **enoblituzumabum #**

enoblituzumab *replace the structure by the following one*
énoblituzumab *remplacer la structure par la suivante*
enoblituzumab *sustitúyase la estructura por la siguiente*

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG LVQPGGSLRL SCAASGFTFS SFGMHWVRQA PGKGLEWVAY  50
ISSDSSAIYY ADTVKGRFTI SRDNAKNSLY LQMNSLRDED TAVYYCGRGR 100
ENIYYGSRLD YWGQGTTVTV SSASTKGPSV FPLAPSSKST SGGTAALGCL 150
VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV VTVPSSSLGT 200
QTYICNVNHK PSNTKVDKRV EPKSCDKTHT CPPCPAPELV GGPSVFLLPP 250
KPKDTLMISR TPEVTCVVVD VSHEDPEVKF NWYVDGVEVH NAKTKPPEEQ 300
YNSTLRVVSV LTVLHQDWLN GKEYKCKVSN KALPAPIEKT ISKAKGQPRE 350
PQVYTLPPSR EEMTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTP 400
LVLDSDGSFF LYSKLTVDKS RWQQGNVFSC SVMHEALHNH YTQKSLSLSP 450
GK                                                      452
```

Light chain / Chaîne légère / Cadena ligera

```
DIQLTQSPSF LSASVGDRVT ITCKASQNVD TNVAWYQQKP GKAPKALIYS  50
ASYRYSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ YNNYPFTFGQ 100
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC                                         214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

| | | | | |
|---|---|---|---|---|
| Intra-H (C23-C104) | 22-96 | 149-205 | 266-326 | 372-430 |
| | 22"-96" | 149"-205" | 266"-326" | 372"-430" |
| Intra-L (C23-C104) | 23'-88' | 134'-194' | | |
| | 23'"-88'" | 134'"-194'" | | |
| Inter-H-L (h 5-CL 126) | 225-214' | 225"-214'" | | |
| Inter-H-H (h 11, h 14) | 231-231" | 234-234" | | |

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
302, 302"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

p. 511 **leniolisibum**

leniolisib *replace the chemical name by the following one*
léniolisib *remplacer le nom chimique par le suivant*
leniolisib *sustitúyase el nombre químico por el siguiente*

1-[(3*S*)-3-({6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-5,6,7,8-tetrahydropyrido[4,3-*d*]pyrimidin-4-yl}amino)pyrrolidin-1-yl]propan-1-one

1-[(3*S*)-3-({6-[6-méthoxy-5-(trifluorométhyl)pyridin-3-yl]-5,6,7,8-tétrahydropyrido[4,3-*d*]pyrimidin-4-yl}amino)pyrrolidin-1-yl]propan-1-one

1-[(3*S*)-3-({6-[6-metoxi-5-(trifluorometil)piridin-3-il]-5,6,7,8-tetrahidropirido[4,3-*d*]pirimidin-4-il}amino)pirrolidin-1-il]propan-1-ona

**Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales**

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will be reproduced in proposed INN lists only.

Les textes de la *Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les substances pharmaceutiques* et des *Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques* seront publiés seulement dans les listes des DCI proposées.

El texto de los *Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas* y de los *Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas* aparece solamente en las listas de DCI propuestas.